var title_f24_32_25088="MRI of early breast cancer";
var content_f24_32_25088=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F59469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F59469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI of early breast cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 399px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left breast MRI demonstrates a mass with lobulated margins and heterogeneous enhancement. There was rapid wash-in of intravenous gadolinium with a rapid washout on the delayed phase (suspicious enhancement curve).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Pierre J Sasson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_32_25088=[""].join("\n");
var outline_f24_32_25088=null;
var title_f24_32_25089="Hirschsprung diagnosis";
var content_f24_32_25089=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51156&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51156&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 611px\">",
"   <div class=\"ttl\">",
"    Assessment for Hirschsprung disease in infants and children 0 to 3 years old",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 591px; height: 629px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The \"squirt sign\" is a forceful expulsion of stool as the finger is withdrawn from the anus after the digital rectal examination, particularly in infants.",
"     <br>",
"      &Delta; In our practice, we generally perform a barium enema rather than suction biopsy as the initial diagnostic procedure; if a clear transition zone is seen the study is virtually pathognomonic of Hirschsprung disease and helps the surgeon plan the level of resection preoperatively. We always confirm the diagnosis by biopsy even when the barium enema shows typical features of Hirschsprung disease. If a transition zone is not seen, Hirschsprung disease cannot be entirely excluded. The barium enema may have false-negative results if performed within 24 hours of a digital rectal examination.",
"      <br>",
"       <span class=\"lozenge\">",
"        &loz;",
"       </span>",
"       Some providers proceed to an anorectal manometry and/or rectal suction biopsy without a barium enema. If ganglia are seen in an appropriately performed suction biopsy, Hirschsprung disease is excluded. Lack of ganglia on the suction biopsy is suspicious for Hirschsprung disease, but the diagnosis may have to be confirmed by a full-thickness rectal biopsy if the pathologist considers the suction biopsy to be an inadequate sample. Similarly, normal results of anorectal manometry can exclude Hirschsprung disease, but abnormal results should be confirmed by biopsy. Anorectal manometry is less accurate in infants under one month of age.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_32_25089=[""].join("\n");
var outline_f24_32_25089=null;
var title_f24_32_25090="MRI ganglion cyst";
var content_f24_32_25090=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F69811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F69811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI ganglion cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 439px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRI of intraneural ganglion cyst involving the posterior tibial nerve. The cyst is both supra- and infrapatellar. A) Sagittal T1 image of the knee showing an extensive intraneural ganglion cyst (bracket) of the posterior tibial nerve (arrows). The signal is higher than expected for simple fluid, likely from elevated protein content. B) With gadolinium administration, there is extensive enhancement of the tumor (bracket) suprapatellar and less extensive below the knee. C) Axial image showing gadolinium enhancement of the ganglion cyst with neural elements surrounding it.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James M Gilchrist, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_32_25090=[""].join("\n");
var outline_f24_32_25090=null;
var title_f24_32_25091="RTT after 10 years of age";
var content_f24_32_25091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rett syndrome, wasting of lower extremities",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After 10 years of age, quadriparesis, scoliosis, and staring may be features of RTT. In contrast to figure 3, this child now shows wasting of lower extremities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Glaze DG, Schultz RJ. Rett syndrome: Meeting the challenge of this gender-specific neurodevelopmental disorder. Medscape Women's Health 1997; 2. Copyright &copy; 1997 Medscape.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_32_25091=[""].join("\n");
var outline_f24_32_25091=null;
var title_f24_32_25092="Arsenic trioxide: Patient drug information";
var content_f24_32_25092=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Arsenic trioxide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     see \"Arsenic trioxide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/1/24598?source=see_link\">",
"     see \"Arsenic trioxide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F136731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Trisenox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700233",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       An unsafe fast heartbeat may happen. Tell your doctor if you have a history of fast heartbeats, kidney failure, low potassium or magnesium levels, or lung failure. Check all drugs with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause a health problem called retinoic-acid-APL syndrome. Very bad problems may happen in some patients who have this health problem. Call your doctor right away if you have fever, trouble breathing, or weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat some types of leukemias and bone marrow problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701547",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to arsenic trioxide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698275",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. You may need drugs to lower this side effect. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698137",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high blood sugar like confusion, feeling sleepy, more thirst, more hungry, passing urine more often, flushing, fast breathing, or breath that smells like fruit.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11564 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-C88E1676B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_32_25092=[""].join("\n");
var outline_f24_32_25092=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136731\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018542\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018544\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018543\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018548\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018549\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018551\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018546\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018553\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=related_link\">",
"      Arsenic trioxide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/1/24598?source=related_link\">",
"      Arsenic trioxide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_32_25093="Glucagon: Drug information";
var content_f24_32_25093=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Glucagon: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/48/16131?source=see_link\">",
"    see \"Glucagon: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"    see \"Glucagon: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      GlucaGen&reg;;",
"     </li>",
"     <li>",
"      GlucaGen&reg; Diagnostic Kit;",
"     </li>",
"     <li>",
"      GlucaGen&reg; HypoKit&reg;;",
"     </li>",
"     <li>",
"      Glucagon Emergency Kit",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14733086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      GlucaGen&reg;;",
"     </li>",
"     <li>",
"      GlucaGen&reg; HypoKit&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F176511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote;",
"     </li>",
"     <li>",
"      Antidote, Hypoglycemia;",
"     </li>",
"     <li>",
"      Diagnostic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F176481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypoglycemia:",
"     </b>",
"     I.M., I.V., SubQ: 1 mg; may repeat in 20 minutes as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     I.V. dextrose should be administered as soon as it is available; if patient fails to respond to glucagon, I.V. dextrose must be given.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Beta-blocker- or calcium channel blocker-induced myocardial depression (with or without hypotension) unresponsive to standard measures (unlabeled use):",
"     </b>",
"     I.V.: 3-10 mg (or 0.05-0.15 mg/kg) bolus followed by an infusion of 3-5 mg/hour (or 0.05-0.1 mg/kg/hour); titrate infusion rate to achieve adequate hemodynamic response (ACLS, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Diagnostic aid:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 1-2 mg 10 minutes prior to gastrointestinal procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 0.25-2 mg 10 minutes prior to gastrointestinal procedure",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F176497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"      see \"Glucagon: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypoglycemia:",
"     </b>",
"     I.M., I.V., SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;20 kg: 0.5 mg or 20-30 mcg/kg/dose; repeated in 20 minutes as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;20 kg: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     I.V. dextrose should be administered as soon as it is available; if patient fails to respond to glucagon, I.V. dextrose must be given.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Beta-blocker- or calcium channel blocker-induced myocardial depression (with or without hypotension) unresponsive to standard measures (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Initial bolus of 30-150 mcg/kg followed by an infusion of 70 mcg/kg/hour (maximum: 5 mg/hour) (Hegenbarth, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: Initial: 5-10 mg over several minutes followed by infusion of 1-5 mg/hour (Hegenbarth, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F176482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15896360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F176459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glucagon Emergency Kit: 1 mg [contains glycerin (in diluent), lactose 49 mg; equivalent to 1 unit]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GlucaGen&reg;: 1 mg [contains lactose 107 mg; equivalent to 1 unit]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GlucaGen&reg; Diagnostic Kit: 1 mg [contains lactose 107 mg; equivalent to 1 unit]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GlucaGen&reg; HypoKit&reg;: 1 mg [contains lactose 107 mg; equivalent to 1 unit]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F176444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F176462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Bolus may be associated with nausea and vomiting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-blocker/calcium channel blocker toxicity: Administer bolus over 3-5 minutes; continuous infusions may be used. Ensure adequate supply available to continue therapy.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14472642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     4 mg in 50 mL (concentration: 0.08 mg/mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F176460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of hypoglycemia; diagnostic aid in radiologic examinations to temporarily inhibit GI tract movement",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F176508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Beta-blocker- or calcium channel blocker-induced myocardial depression (with or without hypotension) unresponsive to standard measures; suspected or documented hypoglycemia secondary to insulin or sulfonylurea overdose (as adjunct to dextrose)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F176509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension (up to 2 hours after GI procedures), hypertension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting (high incidence with rapid administration of high doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions, anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F176465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to glucagon or any component of the formulation; insulinoma; pheochromocytoma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F176448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency; levels of glucose stores in liver may be decreased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic hypoglycemia: Use with caution in patients with chronic hypoglycemia; levels of glucose stores in liver may be decreased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Insulinoma: Exogenous glucagon may cause an initial rise in blood glucose followed by rebound hypoglycemia. The use of glucagon is contraindicated in patients with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma: Exogenous glucagon may cause the release of catecholamines, resulting in an increase in blood pressure. The use of glucagon is contraindicated in patients with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Starvation/fasting: Use caution with prolonged fasting and/or starvation; levels of glucose stores in liver may be decreased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose: May contain lactose; avoid administration in hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Insulin or sulfonylurea overdose: Patients with hypoglycemia should immediately be treated with dextrose. If I.V. access cannot be established or if dextrose is not available, glucagon may be considered as alternative acute treatment until dextrose can be administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring: Monitor blood glucose levels closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary hypoglycemia: Supplemental carbohydrates should be given to patients who respond to glucagon for severe hypoglycemia to prevent secondary hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F176453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Glucagon may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F176477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Glucagon depletes glycogen stores.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F176455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13882222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F176486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13882223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Glucagon is not absorbed from the GI tract and therefore, it is unlikely adverse effects would occur in a breast-feeding infant.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F176468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer carbohydrates to patient as soon as possible after response to treatment.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Glucagon Emergency Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (1): $166.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (GlucaGen HypoKit Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (1): $166.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (GlucaGen Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (1): $132.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F176457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, blood glucose, ECG, heart rate, mentation",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F176469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Garcon (KP);",
"     </li>",
"     <li>",
"      Glucagen (AR, BE, BR, CH, CN, CO, DE, DK, FR, GR, HK, IE, IN, IT, MY, PL, PY, TH, UY, ZA);",
"     </li>",
"     <li>",
"      GlucaGen (AT, AU, FI, GB, HR, HU, IE, IL, LU, NL, PT, SG);",
"     </li>",
"     <li>",
"      Glucagen Novo (HK);",
"     </li>",
"     <li>",
"      Glucagon Novo Nordisk (SE);",
"     </li>",
"     <li>",
"      R-Glucagon Lilly (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F176447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates adenylate cyclase to produce increased cyclic AMP, which promotes hepatic glycogenolysis and gluconeogenesis, causing a raise in blood glucose levels",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F176464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: Blood glucose levels: Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 5-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ: 30-45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Glucose elevation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ: 60-90 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic; some inactivation occurring renally and in plasma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination, plasma: 8-18 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bailey B, &ldquo;Glucagon in Beta-Blocker and Calcium Channel Blocker Overdoses: A Systematic Review,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2003, 41(5):595-602.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/32/25093/abstract-text/14514004/pubmed\" id=\"14514004\" target=\"_blank\">",
"        14514004",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, \"Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/32/25093/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, \"Preparing for Pediatric Emergencies: Drugs to Consider,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/32/25093/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holger JS, Engebretsen KM, Obetz CL, et al, \"A Comparison of Vasopressin and Glucagon in Beta-Blocker Induced Toxicity,\"",
"      <i>",
"       Clin Toxicol (Phila)",
"      </i>",
"      , 2006, 44(1):45-51.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/32/25093/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Love JN, Sachdeva DK, Bessman ES, et al, \"A Potential Role for Glucagon in the Treatment of Drug-Induced Symptomatic Bradycardia,\"",
"      <i>",
"       Chest",
"      </i>",
"      , 1998, 114(1):323-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/32/25093/abstract-text/9674488/pubmed\" id=\"9674488\" target=\"_blank\">",
"        9674488",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lvoff R and Wilcken D, &ldquo;Glucagon in Heart Failure and in Cardiogenic Shock - Experience in 50 Patients,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1972, 45(3):534-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/32/25093/abstract-text/4401050/pubmed\" id=\"4401050\" target=\"_blank\">",
"        4401050",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/32/25093/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olson KR, ed,",
"      <i>",
"       Poisoning and Drug Overdose",
"      </i>",
"      , 5th ed, New York, NY: McGraw Hill/Lange Medical Books, 2007",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pollack CV Jr, &ldquo;Utility of Glucagon in the Emergency Department,&rdquo;",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 1993, 11(2):195-205.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/32/25093/abstract-text/8099364/pubmed\" id=\"8099364\" target=\"_blank\">",
"        8099364",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thoma ME and Glauser JM, &ldquo;Use of Glucagon for Removal of an Orogastric Lavage Tube,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1995, 13(2):219-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/32/25093/abstract-text/7893313/pubmed\" id=\"7893313\" target=\"_blank\">",
"        7893313",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trujillo MH, Guerrero J, Fragachan C, et al, \"Pharmacologic Antidotes in Critical Care Medicine: A Practical Guide for Drug Administration,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1998, 26 (2): 377-391.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vanden Hoek TL, Morrison LJ, Shuster M, et al, \"Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):829-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/32/25093/abstract-text/20956228/pubmed\" id=\"20956228\" target=\"_blank\">",
"        20956228",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wax PM, Erdman AR, Chyka PA, et al, &ldquo;Beta-Blocker Ingestion: An Evidence-Based Consensus Guideline for Out-of-Hospital Management,&rdquo;",
"      <i>",
"       Clin Toxicol (Phila)",
"      </i>",
"      , 2005, 43(3):131-46.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      White CM, &ldquo;A Review of Potential Cardiovascular Uses of Intravenous Glucagon Administration,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1999, 39:442-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/32/25093/abstract-text/10234590/pubmed\" id=\"10234590\" target=\"_blank\">",
"        10234590",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8493 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-FC54B750F8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_32_25093=[""].join("\n");
var outline_f24_32_25093=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176479\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14733086\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176511\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176481\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176497\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176482\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896360\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896361\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176459\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176444\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176462\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472642\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176460\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176508\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176509\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176465\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176448\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299406\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176453\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176477\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176455\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13882222\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176486\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13882223\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176468\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524623\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176457\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176469\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176447\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176464\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8493\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8493|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/48/16131?source=related_link\">",
"      Glucagon: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=related_link\">",
"      Glucagon: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_32_25094="Fibrin sealant";
var content_f24_32_25094=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fibrin sealant",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/32/25094/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/32/25094/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/32/25094/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/32/25094/contributors\">",
"     Steven Kleinman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/32/25094/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/32/25094/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/32/25094/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrin sealant, or fibrin \"glue,\" is a unique surgical",
"    <span class=\"nowrap\">",
"     hemostatic/adhesive",
"    </span>",
"    material that is being utilized with increasing frequency in a variety of surgical situations. In practice, it is a two-component system in which a solution of concentrated fibrinogen and factor XIII are combined with a solution of thrombin and calcium in order to form a coagulum, simulating the final stage of the clotting cascade. Once the",
"    <span class=\"nowrap\">",
"     thrombin/calcium",
"    </span>",
"    is combined with the",
"    <span class=\"nowrap\">",
"     fibrinogen/factor",
"    </span>",
"    XIII, a fibrin clot forms in seconds, or somewhat slower if a more dilute form of thrombin is used. In some preparations, or in selected indications, an antifibrinolytic agent is included, presumably to prevent lysis of the clot [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Commercially prepared fibrin sealants, Tisseel (Immuno, Vienna, Austria), Beriplast (Behringwerke AG,",
"    <span class=\"nowrap\">",
"     Marburg/Lahn,",
"    </span>",
"    FRG), and Biocol (CRTS, Lille, France) have been used extensively in Europe for almost 15 years. During this time, these products were not available in the United States due to the reluctance of the Food and Drug Administration (FDA) to license fibrinogen prepared from pooled human plasma, given the previously demonstrated increased risk of hepatitis transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/3\">",
"     3",
"    </a>",
"    ]. Instead, cryoprecipitate, prepared from a single (autologous of allogeneic) donor, most often served as the fibrinogen source in the non FDA-approved used in the United States. However, in 1998, the FDA approved the first commercial fibrin sealant, Tisseel.",
"   </p>",
"   <p>",
"    The use of fibrin sealant will be discussed here. Reviews of agents used for the purpose of reducing bleeding by causing blood to clot, sealing vessels, or gluing tissues are available for the interested reader [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL APPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The search for the perfect operative sealant began in the first decade of the 20th century. By the 1940s, fibrinogen and thrombin were combined in operative settings. When Cohn fractionation led to the ability to generate highly concentrated fibrinogen preparations (in the 1960s), fibrin sealants were used to promote wound healing, skin grafting, and dural sealing; to provide hemostasis in microvascular surgery and parenchymal injury; and to serve as a matrix for bony chips and fragments in the repair of bone defects [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Much of the literature generated during the past 20 years has come from Europe, but some have been performed in the United States. Although most studies are either anecdotal or lacking a reasonable control group, it appears that fibrin sealant systems are efficacious in controlling slowly bleeding foci, diffuse oozing, bleeding from needle puncture sites, lymphatic leaks, serous fluid collections, and diffuse parenchymal organ hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Virtually every surgical discipline has found an application for fibrin sealant, primarily cardiovascular and neurologic surgery. Depending upon the nature of the surgery, sealant is utilized primarily for either its hemostatic properties or its adhesive properties:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemostatic uses &mdash; Cardiovascular and thoracic surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/9\">",
"       9",
"      </a>",
"      ]; trauma, including liver and spleen lacerations [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/10\">",
"       10",
"      </a>",
"      ]; dental extractions in hemophiliacs [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/11\">",
"       11",
"      </a>",
"      ]; hemostasis at cannulation sites in ECMO (extracorporeal circulating membrane oxygenation); application on gastric ulcers; or on vascular grafts; and replacement for nasal packing in endonasal operations [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adhesive uses &mdash; Sealing of dural leaks [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/13\">",
"       13",
"      </a>",
"      ]; promoting union of middle ear bones [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/14\">",
"       14",
"      </a>",
"      ]; skin grafting after burn injuries [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/15\">",
"       15",
"      </a>",
"      ]; reconstructive urologic surgery; sealing of bronchopleural fistulas; as an alternative to sutures in plastic surgery; and to provide a matrix for the repair of bony defects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Experimental applications of fibrin sealant technology include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of lyophilized components of fibrin sealant impregnated onto a bandage which can then be applied either directly onto a wound or into a body cavity to stop internal bleeding.",
"     </li>",
"     <li>",
"      Fibrin sealant impregnated with antibiotics may be able to concentrate them at the site of an infection and promote wound healing [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It is possible that fibrin sealant could also be used for the local delivery of chemotherapeutic agents [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fibrin sealant may be used in combination with cytokines capable of promoting endothelialization of vascular grafts in vivo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMPONENTS OF COMMERCIAL AND ALTERNATIVE PREPARATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrin sealant preparations contain fibrinogen, factor XIII, thrombin, ionized calcium, fibronectin and often, but not always, an antifibrinolytic agent.",
"   </p>",
"   <p>",
"    Solvent (tri(n-butyl)) phosphate (TNBP) detergent (Tween 80) treatment of fibrin sealant prepared from large batches of pooled plasma can result in a sealant with predictable and measurable",
"    <span class=\"nowrap\">",
"     hemostatic/adhesive",
"    </span>",
"    qualities and minimal infectious disease risk [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/18\">",
"     18",
"    </a>",
"    ]. When licensed, this may become the sealant preparation of choice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fibrinogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrinogen is the most important component. It gives the system both its adhesive and its hemostatic capabilities. In addition, the tensile or adhesive strength of the sealant correlates directly with the fibrinogen content. Thus, the commercial systems mentioned above have one major advantage over most locally (operating room or blood bank) prepared sealants: a more uniform and highly concentrated fibrinogen component. As an example, Tisseel has a fibrinogen concentration of 70 to 100",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    compared with 2.5 to 25",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    in cryoprecipitate (unmanipulated). Other published methods for producing sealant generate fibrinogen levels intermediate between the cryoprecipitated and lyophilized methods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Thrombin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second most critical component of fibrin sealant preparations is thrombin. The rapidity of the clot formation, and the tensile strength of the fibrin seal are a function of the concentration of thrombin used to initiate the process.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When rapid clot formation (5 to 10 seconds) is desired, thrombin concentrations of 500 to 1000 NIH units should be used.",
"     </li>",
"     <li>",
"      If slower clot formation is desirable (eg, in plastic surgery procedures when close approximation of tissues is sought) thrombin concentrations of 4 to 10 NIH units should be used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Source of thrombin",
"    </span>",
"    &nbsp;&mdash;&nbsp;While virtually all earlier fibrin sealant preparations utilized",
"    <strong>",
"     bovine",
"    </strong>",
"    thrombin, this has largely been supplanted by",
"    <strong>",
"     human",
"    </strong>",
"    thrombin in currently available preparations. In addition to other benefits, use of human thrombin should eliminate the factor V deficiency (and concomitant bleeding diathesis) that occasionally result when patients make antibodies to bovine factor V (a common contaminant of bovine thrombin) which cross reacted with endogenous factor V to produce a functional deficiency of that clotting factor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link&amp;anchor=H21#H21\">",
"     \"Acquired inhibitors of coagulation\", section on 'Thrombin inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link&amp;anchor=H22#H22\">",
"     \"Acquired inhibitors of coagulation\", section on 'Factor V inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, in a prospective study of 151 patients undergoing cardiac surgery, 95 and 51 percent of those with prior exposure to bovine thrombin demonstrated a seropositive response to bovine and human coagulant proteins, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/23\">",
"     23",
"    </a>",
"    ]. The adjusted odds ratio for development of an adverse postoperative outcome was 5.4 when multiple antibodies to bovine coagulant proteins were present preoperatively. Such antibodies may persist for years following the initial exposure to bovine thrombin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A recombinant human thrombin preparation has been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/25\">",
"     25",
"    </a>",
"    ]. Results from eight clinical trials have indicated that this preparation is well tolerated in numerous surgical settings when used as a topical adjunct to hemostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/26\">",
"     26",
"    </a>",
"    ]. Less than 1 percent of the patients developed antibodies to human recombinant thrombin; these antibodies did not neutralize native human thrombin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other coagulation factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The contributions of the other components are important, although in some cases controversial. Ionized calcium is critical to the action of thrombin. Factor XIII, or fibrin stabilizing factor, is felt by some to be important in the fibrin crosslinking that determines the sealant's breaking strength, or mechanical properties [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/6,27,28\">",
"     6,27,28",
"    </a>",
"    ]. Fortunately, most methods of preparation that isolate fibrinogen also generate adequate amounts of factor XIII.",
"   </p>",
"   <p>",
"    Antifibrinolytic agents may or may not be necessary. In fact, in certain sites, such as the middle ear, rapid lysis of the sealant is considered essential; antifibrinolytic agents, which can promote a seal lasting three to four weeks rather than several days, would therefore be contraindicated. On the other hand, in surgical procedures on tissues with high levels of fibrinolysins (such as kidney, prostate, lung, or uterus), antifibrinolytic agents may be a valuable adjunct. Additional studies or accumulating clinical data may clarify the ultimate role of antifibrinolytic agents in fibrin sealant preparations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cryoprecipitate preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgeons in the United States wishing to use a fibrin sealant have relied on a variety of alternative preparations, most often cryoprecipitate-based. Cryoprecipitate, despite its low (and variable) fibrinogen content, is readily available in most communities, needs little handling after preparation, and has the low infectious disease risk of a single-donor component. It is currently the most widely used source of fibrinogen in United States operating rooms where fibrin sealant is employed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11895?source=see_link&amp;anchor=H16#H16\">",
"     \"Preparation of blood components\", section on 'Cryoprecipitate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When time for planning is available, autologous cryoprecipitate can be prepared, virtually eliminating any infectious disease risk [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/29\">",
"     29",
"    </a>",
"    ]. Preparation of sealant from platelet-rich or platelet-poor plasma harvested in the operating room at the start of surgery has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In institutions with special interest in fibrin sealant, alternative preparations include twice-precipitated, or twice centrifuged, or chemically modified (ammonium sulfate or polyethylene glycol [PEG] precipitated) cryoprecipitate to enhance the fibrinogen concentration of the final product. Also, an alternative product dubbed \"French\" glue, containing a gelatin-resorcinol- formaldehyde-glutaraldehyde mixture, has been shown (in an animal model) to have excellent adhesive qualities [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Platelet derived products",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of platelets or platelet-derived products for accelerating the healing of wounds, either alone or along with fibrin sealant preparations, is an area of active research interest [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other hemostatic preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of hemostatic devices have been used by the United States military to control external bleeding in the combat setting, and additional ones are being evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. The effectiveness of, and the indications for, these devices are not fully known at this time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link&amp;anchor=H18#H18\">",
"     \"Initial evaluation and management of shock in adult trauma\", section on 'Hemostatic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     HemCon bandage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HemCon&reg; bandage (HemCon Medical Technologies, Inc., Portland, OR) is a dressing composed of lyophilized chitosan, a biodegradable complex carbohydrate derived from chitin. Its hemostatic function is attributed to the strong adhesive properties of chitosan, which attaches firmly to wet tissues and seals bleeding vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/36\">",
"     36",
"    </a>",
"    ]. Successful use of this bandage as a hemostatic agent for pre-hospital combat casualties has been reported when standard methods were unsuccessful [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This bandage has also been employed in a civilian emergency medical services system when conventional treatment (ie, pressure and gauze dressings) failed to control external bleeding wounds, or for obvious arterial bleeding. Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The bandage controlled hemorrhage in 27 of 34 cases (79 percent), most often within 3 minutes of application.",
"     </li>",
"     <li>",
"      The bandage effectively controlled bleeding in 19 of the 25 cases in which direct pressure had initially failed.",
"     </li>",
"     <li>",
"      No adverse events or complications were reported. Proper training in the use of this bandage was considered essential, as user error was a contributing factor in most of the documented failures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Chitoflex",
"    </span>",
"    &nbsp;&mdash;&nbsp;ChitoFlex&trade; (North American Rescue, Inc., Greer, SC) is a rolled version of chitosan in a different formulation than the HemCon bandage. It is very pliable and is designed to be packed into a wound tract [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     QuikClot granules",
"    </span>",
"    &nbsp;&mdash;&nbsp;QuikClot is a zeolite-based granule with 1 percent moisture that, when placed on a bleeding wound, absorbs water and concentrates red cells, platelets, and clotting proteins at the injury site, thereby promoting rapid coagulation and arresting hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/36\">",
"     36",
"    </a>",
"    ]. The reaction releases significant amounts of heat, causing thermal injury in some tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TECHNICAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrin sealant is applied very much like epoxy glue, utilizing a two-syringe technique. Application devices are commercially available which contain all the essential components (side by side syringes, Y-connector and tubing, needle-tip or spray applicator).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the operating room, the",
"      <span class=\"nowrap\">",
"       fibrinogen/factor",
"      </span>",
"      XIII source (eg, cryoprecipitate) is thawed, if necessary, and drawn into one syringe, and the",
"      <span class=\"nowrap\">",
"       thrombin/calcium",
"      </span>",
"      drawn into the other.",
"     </li>",
"     <li>",
"      Depending upon the clinical application (eg, suture line stabilization versus achieving hemostasis of a diffusely oozing surface), one would select either the needle-tip or the spray applicator.",
"     </li>",
"     <li>",
"      At the appropriate time, the contents of the syringes are simultaneously expressed and allowed to mix (in a 1:1 ratio) in either a concentrated or aerosol form, proceed to fibrin generation, and achieve hemostasis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ADVERSE REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite a very good safety record, there are both documented and theoretical problems associated with the use of fibrin sealant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bleeding diathesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, a bleeding diathesis is one of the most important complications. The bleeding diathesis has been reported in patients who develop factor V deficiency because they make an anti-bovine factor V antibody (bovine factor V is a contaminant of bovine thrombin preparations) which crossreacts with endogenous factor V. Use of human thrombin should prevent this complication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of profound hypotension in some individuals after direct parenchymal injection of sealant is also believed to be related to highly concentrated bovine thrombin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/10\">",
"     10",
"    </a>",
"    ]. The hypotension, which lasts approximately 30 seconds, responds to epinephrine; in addition, this complication can be avoided by reducing the dose of bovine thrombin and by compressing the injection sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An anaphylactic reaction to plasma proteins is a rare complication of fibrin sealant [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/40\">",
"     40",
"    </a>",
"    ]. A history of prior anaphylactic reactions to plasma products or of IgA deficiency would contraindicate the use of sealant prepared from plasma or cryoprecipitate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Transmission of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complication, common to all blood components, is the potential transmission of an infectious disease, even from screened and tested blood. To date, there has been one reported case of HIV transmission from fibrin sealant [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/41\">",
"     41",
"    </a>",
"    ]. In addition to the patient, health care workers in the operating room may theoretically be exposed to an infectious disease risk when sealant is applied in an aerosolized form. Furthermore, aerosolized sealant was responsible for the development of multiple intraabdominal abscesses when it was used in a patient during a contaminated intraabdominal procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38247?source=see_link\">",
"     \"Pathogen inactivation of blood products\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Interference with tissue repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excess application of sealant may impede tissue repair, both in neural tissue (if sealant material interposes between opposed nerve bundles) and in bone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25094/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;While widespread use of fibrin sealant in the United States was initially hampered by the lack of a commercial product, numerous \"home brew\" glues have been used by surgeons in a variety of settings with largely positive, although also largely anecdotal, results. This has changed with the licensure of several commercial sealants over the past decade. Fibrin sealants appear to be effective hemostatic and",
"    <span class=\"nowrap\">",
"     /or",
"    </span>",
"    adhesive agents capable, in some settings, of contributing to a decrease in allogeneic blood exposure.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/1\">",
"      Kram HB, Nathan RC, Mackabee JR, et al. Clinical use of nonautologous fibrin glue. Am Surg 1988; 54:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/2\">",
"      Harris DM, Siedentop KH, Ham KR, Sanchez B. Autologous fibrin tissue adhesive biodegration and systemic effects. Laryngoscope 1987; 97:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/3\">",
"      Bove JR. Fibrinogen--is the benefit worth the risk? Transfusion 1978; 18:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/4\">",
"      Spotnitz WD, Burks S. Hemostats, sealants, and adhesives: components of the surgical toolbox. Transfusion 2008; 48:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/5\">",
"      Achneck HE, Sileshi B, Jamiolkowski RM, et al. A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. Ann Surg 2010; 251:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/6\">",
"      Alving BM, Weinstein MJ, Finlayson JS, et al. Fibrin sealant: summary of a conference on characteristics and clinical uses. Transfusion 1995; 35:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/7\">",
"      Gibble JW, Ness PM. Fibrin glue: the perfect operative sealant? Transfusion 1990; 30:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/8\">",
"      Radosevich M, Goubran HI, Burnouf T. Fibrin sealant: scientific rationale, production methods, properties, and current clinical use. Vox Sang 1997; 72:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/9\">",
"      Matthew TL, Spotnitz WD, Kron IL, et al. Four years' experience with fibrin sealant in thoracic and cardiovascular surgery. Ann Thorac Surg 1990; 50:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/10\">",
"      Ochsner MG, Maniscalco-Theberge ME, Champion HR. Fibrin glue as a hemostatic agent in hepatic and splenic trauma. J Trauma 1990; 30:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/11\">",
"      Rakocz M, Mazar A, Varon D, et al. Dental extractions in patients with bleeding disorders. The use of fibrin glue. Oral Surg Oral Med Oral Pathol 1993; 75:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/12\">",
"      Vaiman M, Eviatar E, Segal S. Effectiveness of second-generation fibrin glue in endonasal operations. Otolaryngol Head Neck Surg 2002; 126:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/13\">",
"      Cain JE Jr, Dryer RF, Barton BR. Evaluation of dural closure techniques. Suture methods, fibrin adhesive sealant, and cyanoacrylate polymer. Spine (Phila Pa 1976) 1988; 13:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/14\">",
"      Silberstein LE, Williams LJ, Hughlett MA, et al. An autologous fibrinogen-based adhesive for use in otologic surgery. Transfusion 1988; 28:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/15\">",
"      Stuart JD, Kenney JG, Lettieri J, et al. Application of single-donor fibrin glue to burns. J Burn Care Rehabil 1988; 9:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/16\">",
"      Kram HB, Bansal M, Timberlake O, Shoemaker WC. Antibacterial effects of fibrin glue-antibiotic mixtures. J Surg Res 1991; 50:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/17\">",
"      Kawasaki H, Shimizu T, Takakura K, Umezawa Y. [Pharmacodynamic study of mitomycin C mixed with fibrin glue for treatment of malignant brain tumors]. No Shinkei Geka 1994; 22:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/18\">",
"      Burnouf-Radosevich M, Burnouf T, Huart JJ. Biochemical and physical properties of a solvent-detergent-treated fibrin glue. Vox Sang 1990; 58:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/19\">",
"      B&auml;nninger H, Hardegger T, Tobler A, et al. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol 1993; 85:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/20\">",
"      Zehnder JL, Leung LL. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990; 76:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/21\">",
"      Streiff MB, Ness PM. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 2002; 42:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/22\">",
"      Lundblad RL, Bradshaw RA, Gabriel D, et al. A review of the therapeutic uses of thrombin. Thromb Haemost 2004; 91:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/23\">",
"      Ortel TL, Mercer MC, Thames EH, et al. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001; 233:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/24\">",
"      Randleman CD Jr, Singla NK, Renkens KL, et al. Persistence of antibodies to the topical hemostat bovine thrombin. J Am Coll Surg 2010; 211:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/25\">",
"      Chapman WC, Lockstadt H, Singla N, et al. Phase 2, randomized, double-blind, placebo-controlled, multicenter clinical evaluation of recombinant human thrombin in multiple surgical indications. J Thromb Haemost 2006; 4:2083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/26\">",
"      Ballard JL, Weaver FA, Singla NK, et al. Safety and immunogenicity observations pooled from eight clinical trials of recombinant human thrombin. J Am Coll Surg 2010; 210:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/27\">",
"      Hoffman M, Jenner P. Variability in the fibrinogen and von Willebrand factor content of cryoprecipitate. Implications for reducing donor exposure. Am J Clin Pathol 1990; 93:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/28\">",
"      Tamaki T, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor. J Biol Chem 1982; 257:14767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/29\">",
"      Reiss RF, Oz MC. Autologous fibrin glue: production and clinical use. Transfus Med Rev 1996; 10:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/30\">",
"      Oz MC, Jeevanandam V, Smith CR, et al. Autologous fibrin glue from intraoperatively collected platelet-rich plasma. Ann Thorac Surg 1992; 53:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/31\">",
"      Quigley RL, Perkins JA, Gottner RJ, et al. Intraoperative procurement of autologous fibrin glue. Ann Thorac Surg 1993; 56:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/32\">",
"      Basu S, Marini CP, Bauman FG, et al. Comparative study of biological glues: cryoprecipitate glue, two-component fibrin sealant, and \"French\" glue. Ann Thorac Surg 1995; 60:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/33\">",
"      Soffer E, Ouhayoun JP, Anagnostou F. Fibrin sealants and platelet preparations in bone and periodontal healing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/34\">",
"      Liu L, Hartwig D, Harloff S, et al. Corneal epitheliotrophic capacity of three different blood-derived preparations. Invest Ophthalmol Vis Sci 2006; 47:2438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/35\">",
"      Sum R, Hager S, Pietramaggiori G, et al. Wound-healing properties of trehalose-stabilized freeze-dried outdated platelets. Transfusion 2007; 47:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/36\">",
"      Kheirabadi BS, Edens JW, Terrazas IB, et al. Comparison of new hemostatic granules/powders with currently deployed hemostatic products in a lethal model of extremity arterial hemorrhage in swine. J Trauma 2009; 66:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/37\">",
"      Cox ED, Schreiber MA, McManus J, et al. New hemostatic agents in the combat setting. Transfusion 2009; 49 Suppl 5:248S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/38\">",
"      Wedmore I, McManus JG, Pusateri AE, Holcomb JB. A special report on the chitosan-based hemostatic dressing: experience in current combat operations. J Trauma 2006; 60:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/39\">",
"      Brown MA, Daya MR, Worley JA. Experience with chitosan dressings in a civilian EMS system. J Emerg Med 2009; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/40\">",
"      Milde LN. An anaphylactic reaction to fibrin glue. Anesth Analg 1989; 69:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/41\">",
"      Wilson SM, Pell P, Donegan EA. HIV-1 transmission following the use of cryoprecipitated fibrinogen as gel/adhesive (abstract). Transfusion 1991; 31:51S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/42\">",
"      Dubrow T, Schwartz RJ, McKissock J, Wilson SE. Effect of aerosolized fibrin solution on intraperitoneal contamination. Arch Surg 1991; 126:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25094/abstract/43\">",
"      Narakas A. The use of fibrin glue in repair of peripheral nerves. Orthop Clin North Am 1988; 19:187.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7938 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-652B83C886-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_32_25094=[""].join("\n");
var outline_f24_32_25094=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL APPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMPONENTS OF COMMERCIAL AND ALTERNATIVE PREPARATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fibrinogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Thrombin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Source of thrombin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other coagulation factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cryoprecipitate preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Platelet derived products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other hemostatic preparations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - HemCon bandage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Chitoflex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - QuikClot granules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TECHNICAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ADVERSE REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hypotension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Transmission of disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Interference with tissue repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=related_link\">",
"      Acquired inhibitors of coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38247?source=related_link\">",
"      Pathogen inactivation of blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11895?source=related_link\">",
"      Preparation of blood components",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_32_25095="Management of rotator cuff tears";
var content_f24_32_25095=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of rotator cuff tears",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/32/25095/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/32/25095/contributors\">",
"     Scott David Martin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/32/25095/contributors\">",
"     Tamara L Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/32/25095/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/32/25095/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/32/25095/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/32/25095/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/32/25095/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glenohumeral joint allows for tremendous mobility but is highly susceptible to injury. What is commonly described as the rotator cuff (RC) is a composite of muscles arising from the scapula and inserting onto the humerus. The rotator cuff is crucial to the function and stability of the glenohumeral joint [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Records of rotator cuff problems extend to the third century BC, when Hippocrates described the relationship of the tendons around the shoulder and noted the injuries associated with these tendons and the variability in their healing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/4\">",
"     4",
"    </a>",
"    ]. Rotator cuff disease remains a common cause of shoulder pain, accounting for over 4.5 million physician visits per year in the United States alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/5\">",
"     5",
"    </a>",
"    ]. While the radiographic imaging, physical therapy, and surgical techniques used to diagnose and manage rotator cuff tears have improved, the indications for surgery remain controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of rotator cuff tears will be reviewed here. The diagnosis of rotator cuff tears, diagnosis and management of rotator cuff tendinopathy, and the diagnostic approach to shoulder pain are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6887?source=see_link\">",
"     \"Presentation and diagnosis of rotator cuff tears\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS AND EVIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of rotator cuff tears depends upon several factors, including the duration of symptoms, shoulder dominance, the type of tear (partial versus full thickness), and patient factors such as age, comorbidities, and activity level [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/5,7-11\">",
"     5,7-11",
"    </a>",
"    ]. Treatment options include surgical repair and nonoperative management. To date, very few randomized trials have been performed that directly compare surgical and nonsurgical management of rotator cuff tears [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. Well-controlled, prospective trials are needed to determine the relative risks and benefits of each approach.",
"   </p>",
"   <p>",
"    Two systematic reviews of studies evaluating common interventions for the treatment of rotator cuff tears, including studies comparing different surgical approaches and others comparing surgery with physical therapy, found there was insufficient evidence to support one intervention over another and found the quality of many studies to be poor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/7,12\">",
"     7,12",
"    </a>",
"    ]. Therefore, our approach to the management of rotator cuff tears, summarized in the accompanying algorithm, is necessarily based upon observational data, animal studies, evidence extrapolated from successful treatment of non-rotator cuff tendon tears, and our clinical experience (",
"    <a class=\"graphic graphic_algorithm graphicRef78386 \" href=\"UTD.htm?18/46/19170\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/8,13-17\">",
"     8,13-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SURGICAL INDICATIONS FOR ROTATOR CUFF TEARS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appropriate indications for surgery to treat rotator cuff tears remain a source of debate among orthopedic surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/6\">",
"     6",
"    </a>",
"    ]. In most cases, surgery is considered only when conservative measures fail. One important exception to this principle is an acute, full thickness traumatic tear of an otherwise normal rotator cuff in a healthy individual. Such an injury is usually treated with immediate surgery, since delay can lead to significant muscle atrophy, tendon retraction, and poorer surgical results. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Acute rotator cuff tears'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For all other rotator cuff tears, a trial of conservative treatment, consisting primarily of physical therapy, is indicated. Should conservative therapy fail to relieve pain or improve function, surgery may be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NONOPERATIVE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonoperative management of rotator cuff tears consists primarily of physical therapy. Few recent studies have assessed the effectiveness of nonsurgical management, and those that have been performed are limited in scope and methodology, making it difficult to draw specific conclusions about which patients are most amenable to physical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/11,18,19\">",
"     11,18,19",
"    </a>",
"    ]. Reported success rates range from 33 to 92 percent, reflecting the limitations of existing studies. Nonoperative treatment is likely to be more successful in younger patients (less than 60 years) with incomplete tears [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conservative treatment consists primarily of physical therapy emphasizing activity modification; stretching of the shoulder capsule to restore flexibility and maintain motion; and strengthening of the periscapular, rotator cuff, and deltoid muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/19,21-23\">",
"     19,21-23",
"    </a>",
"    ]. Programs are individually tailored to patient needs and expectations, but do not differ substantially for those with partial or complete tears.",
"   </p>",
"   <p>",
"    For patients without ready access to physical therapists, home therapy programs are an important form of conservative management. Early on, activity modifications, especially limiting overhead and reaching activities, can help to control symptoms.",
"   </p>",
"   <p>",
"    Physical therapy progresses through three phases of recovery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial phase emphasizes shoulder mobility. The goal is to recover a full range of motion equal and symmetrical with the contralateral shoulder (assuming the contralateral shoulder is uninjured). Stretching of the posterior and anterior joint capsule is emphasized.",
"     </li>",
"     <li>",
"      The second phase emphasizes strength. Exercises with elastic bands and light weights are performed below shoulder height to increase the strength and endurance of the muscles involved in shoulder motion and stabilization.",
"     </li>",
"     <li>",
"      The third phase emphasizes shoulder function. Exercises that stimulate joint reactivation, such as shoulder plyometrics, are performed to improve shoulder proprioception and coordination among the scapular stabilizers and glenohumeral structures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many facets of the recovery program are adjusted according to the size and age of the rotator cuff tear, the amount of tendon retraction, the degree of muscle atrophy, and the patient's functional needs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/19,22\">",
"     19,22",
"    </a>",
"    ]. As an example, the program for a young athlete with a small acute tear who plans a return to competition will differ significantly from one for an elderly patient with a chronic tear who hopes to perform basic activities of daily living.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Glucocorticoid injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of small studies of varying quality suggest that subacromial glucocorticoid injections provide some short term benefit in controlling pain from rotator cuff tears, but the effects tend to be short lived [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Frequently, glucocorticoid injections are reserved for patients with severe pain from rotator cuff tears or tendinopathy, although other options, such as nonsteroidal antiinflammatory drugs, may be equally effective at controlling pain [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucocorticoid injections may have deleterious effects upon healthy tendons and repeat injections should be discouraged, except in cases where surgery is not possible because of poor patient health or severe, chronic rotator cuff tears [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/24,27\">",
"     24,27",
"    </a>",
"    ]. The use of more than four injections is associated with decreased durability in surgically repaired tendons [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subacromial injection techniques vary according to physician experience and preference, and include anterior, lateral, and posterior approaches. Clinicians using the anterior approach must avoid injecting the biceps tendon, which may result in biceps tendon tear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other nonsurgical treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of other treatment modalities as they pertain to rotator cuff tears, such as ultrasound, topical agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , glucocorticoid iontophoresis, massage, acupuncture, shock-wave therapy, and viscosupplement injections, are yet unclear and require further study. The use of these treatments for rotator cuff tendinopathy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=see_link&amp;anchor=H17#H17\">",
"     \"Rotator cuff tendinopathy\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PARTIAL THICKNESS ROTATOR CUFF TEARS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most rotator cuff tears start as partial undersurface (ie, on the articular side) tears of the supraspinatus tendon. They may result from secondary impingement syndrome. Secondary impingement of the rotator cuff on the acromion occurs when a deficient rotator cuff fails to center the humeral head on the glenoid during active abduction and forward flexion of the shoulder. Degeneration of muscles and tendons, overload of the muscle tendon unit, and weakness of the periscapular muscles may also contribute to rotator cuff tears. Partial cuff tears can progress to full thickness tears. The pathophysiology and diagnosis of rotator cuff tears is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6887?source=see_link\">",
"     \"Presentation and diagnosis of rotator cuff tears\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32280?source=see_link\">",
"     \"Shoulder impingement syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Partial thickness rotator cuff tears are often difficult to detect. They may cause pain with little or no loss of function. In partial thickness tears a portion of the tendon remains intact preventing the tendon from retracting and allowing the muscle tendon unit to function, thereby preventing muscle atrophy. When partial tears cause pain or weakness, the initial treatment consists of analgesics, physical therapy that emphasizes improving range of motion and strength, and avoidance of activities that exacerbate symptoms, such as those involving overhead and reaching motions.",
"   </p>",
"   <p>",
"    Surgical repair may be needed to control pain and preserve function in patients with chronic partial tears that are recalcitrant to conservative treatment. Recalcitrant cases are generally defined by a failure to respond to up to twelve weeks of properly performed physical therapy and one or two glucocorticoid injections. Older patients may need longer treatment.",
"   </p>",
"   <p>",
"    In cases needing operative repair, the partial tear is evaluated during surgery. If the tear comprises less than 50 percent of the tendon's thickness, surgery consists of light debridement with or without a subacromial decompression. If the tear involves more than 50 percent of the rotator cuff's insertion site or is over 2 cm in diameter, arthroscopic repair is often performed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Surgical approaches'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ACUTE ROTATOR CUFF TEARS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend immediate surgical repair in cases of acute, full thickness rotator cuff tears in otherwise healthy individuals (",
"    <a class=\"graphic graphic_algorithm graphicRef78386 \" href=\"UTD.htm?18/46/19170\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/14,15,17,31-36\">",
"     14,15,17,31-36",
"    </a>",
"    ]. Delayed repair of such tears can result in significant muscle atrophy with tendon degeneration and retraction, and compromised surgical results [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/9,15,16,34-36\">",
"     9,15,16,34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fatty infiltration of muscle tissue develops over a period of months to years following a rotator cuff tear; the older the patient the more quickly fatty infiltration occurs, and resulting declines in function may be irreversible [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/37\">",
"     37",
"    </a>",
"    ]. More extensive infiltration is associated with worse surgical outcomes.",
"   </p>",
"   <p>",
"    We suggest that surgical repair be performed within six weeks of the injury. Early repair is supported by several observational studies, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 74 patients with rotator cuff tears treated operatively, surgeons noted that signs of irreversible muscle damage (eg, fatty degeneration) associated with delays between injury and repair correlated with greater difficulty performing surgery and poorer functional outcomes (eg, decreased motion and strength) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Excellent or good outcomes, using the UCLA shoulder function scale, were achieved in 24 of 26 patients who sustained an acute full thickness rotator cuff tear and were treated with operative repair within three weeks of symptom onset [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above, complete tendon tears can lead to irreversible muscle degeneration. Therefore, expeditious surgery may also be helpful in cases of acute-on-chronic rotator cuff tears where the patient suddenly loses the ability to actively abduct or flex the shoulder. This condition is referred to as pseudoparalysis and presumably results from exacerbation of the preexisting tear.",
"   </p>",
"   <p>",
"    Nonoperative management is preferred for the initial treatment of acute rotator cuff tears in elderly patients, patients with major comorbidities that increase the risk of surgery, and noncompliant patients. Patients with limited functional demands often tolerate rotator cuff tears without major problems. Even patients with moderately symptomatic massive cuff tears have been found to maintain satisfactory function for at least four years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pushing, pulling, and lifting with the elbows kept close to the side is usually well tolerated even with significant tears, allowing most patients to perform basic activities and to transfer, for example, from sitting to standing, comfortably. Adequate pain control can usually be achieved with nonsteroidal antiinflammatory medications,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , cryotherapy, and glucocorticoid injections, when indicated. Care should be taken not to exceed a total of four injections in patients who may require surgery. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Glucocorticoid injection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Surgery may be necessary in patients whose symptoms and function fail to improve despite at least six weeks of appropriate physical therapy and two glucocorticoid injections. Patients who refuse surgery should be counseled that significant pathologic changes may occur in the musculotendinous unit that may become irreversible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CHRONIC, SYMPTOMATIC ROTATOR CUFF TEARS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial management of patients with chronic, symptomatic rotator cuff tears is nonoperative (",
"    <a class=\"graphic graphic_algorithm graphicRef78386 \" href=\"UTD.htm?18/46/19170\">",
"     algorithm 1",
"    </a>",
"    ). Conservative treatment for such tears generally consists of a minimum of six weeks of physical therapy and may include one or two glucocorticoid injections. A rigorous attempt at conservative management should be completed before surgery is considered.",
"   </p>",
"   <p>",
"    Surgical outcomes depend upon a number of factors including age (better results are reported in patients under 60), the age of the tear, the size of the tear (larger tears have higher reinjury rates), and the degree of muscle atrophy and tendon retraction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/9,14-17,31-33,39,40\">",
"     9,14-17,31-33,39,40",
"    </a>",
"    ]. The surgeon should discuss these factors and the likelihood of an acceptable outcome with the patient. With chronic tears, surgery involving an attempt at rotator cuff repair and possible subacromial decompression may reduce pain but fail to improve function, especially in cases with moderate to severe muscle atrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SURGICAL APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical repair of the rotator cuff can be performed arthroscopically or open. Open procedures involve either a standard or a \"mini-open\" technique. Studies assessing these three approaches are limited in size and methodology and provide little guidance for determining the best method [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/7\">",
"     7",
"    </a>",
"    ]. Furthermore, improvements in arthroscopic technique developed subsequent to the majority of these studies make many of their conclusions obsolete [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. We believe that in experienced hands arthroscopic repair is preferable because of decreased morbidity and comparable functional outcomes. The advantages of arthroscopic repair can be lost if a technically difficult repair is performed by an inexperienced arthroscopist.",
"   </p>",
"   <p>",
"    Arthroscopic rotator cuff repair has steadily gained popularity. Its advantages include the ability to see the entire joint including the rotator cuff, decreased loss of motion, preservation of the deltoid muscle, lower infection rates, less postoperative pain, shorter delays until physical therapy, and shorter hospital stays (most arthroscopies are performed as day surgeries) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/7,45\">",
"     7,45",
"    </a>",
"    ]. Although morbidity is low, disadvantages do exist. These include increased cost, especially when implants such as suture anchors are used, and increased operative times with novice arthroscopists.",
"   </p>",
"   <p>",
"    So-called \"mini-open\" rotator cuff repair became popular in the 1990s and remains an acceptable approach for surgeons who are unfamiliar or uncomfortable with arthroscopic surgical techniques. This approach involves a substantially smaller incision and exposure than that of a standard open approach. The results achieved using mini-open cuff repair with arthroscopic subacromial decompression appear equal to those of open reconstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/46\">",
"     46",
"    </a>",
"    ]. Disadvantages include difficulty with surgical exposure, increased risk of axillary nerve injury, and increased postoperative pain.",
"   </p>",
"   <p>",
"    Formal open surgical repair of the rotator cuff is an acceptable surgical procedure but is rarely employed due to the availability of the less invasive surgical techniques described above. Disadvantages include violation of the deltoid muscle (which in a rotator cuff-deficient shoulder may be the glenohumeral joint's only abductor and forward flexor), and difficulty achieving exposure of the entire rotator cuff, biceps attachment, and subscapularis tendon. Complications can include deltoid detachment, higher infection rates, axillary nerve injury, glenohumeral joint stiffness, and increased postoperative pain.",
"   </p>",
"   <p>",
"    With all three techniques, rerupture of the rotator cuff can occur. The risk of rerupture is related to the size and age of the tear, age of the patient, quality of the repair, degree of muscle and tendon atrophy, and nicotine use [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/47\">",
"     47",
"    </a>",
"    ]. Regardless of the surgical technique performed, the basic tenets of rotator cuff repair remain unchanged: provide a secure repair of the rotator cuff tendon over a large tendon-bone contact area at the original cuff attachment site on the humerus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE AND RETURN TO WORK OR SPORTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative rehabilitation protocols vary depending upon the surgeon's preference, the extent of the repair, and the quality of the tissue. Most patients are instructed to use an abduction brace for six weeks to relieve stress on the repair and to reduce the chances of damaging it, for example, should the patient fall.",
"   </p>",
"   <p>",
"    Immediate use of the elbow, wrist, and hand when sitting may be allowed for simple daily activities, such as holding a phone, using eating utensils, showering, and perhaps driving a car. The patient MUST keep the elbow on the side of the affected shoulder against his or her side at all times when the abduction brace is not in place.",
"   </p>",
"   <p>",
"    At three months, most patients are allowed to use the shoulder for light activities above shoulder height. At six months, more vigorous activities are permitted. Patients should be warned that an extended period of time may be needed to regain strength and stamina in the affected shoulder [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25095/abstract/13,16\">",
"     13,16",
"    </a>",
"    ]. Patients may continue to improve their shoulder strength for up to two years postoperatively.",
"   </p>",
"   <p>",
"    Return to work is contingent upon the patient's job activities and can range from one week in sedentary work to six months for jobs involving heavy overhead lifting or strenuous overhead sports. Physical therapy programs often incorporate activities that simulate the patient's work for those whose work places heavy demands upon the shoulder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/53/29522?source=see_link\">",
"       \"Patient information: Rotator cuff injury (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/49/24341?source=see_link\">",
"       \"Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Partial thickness rotator cuff tears are often difficult to detect. They may cause pain with little or no loss of function. For symptomatic partial tears, we suggest that the initial treatment consist of activity modification, analgesics, and physical therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Surgical repair may be needed in patients with chronic partial tears that do not improve with nonoperative treatment. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Partial thickness rotator cuff tears'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of acute rotator cuff tears varies with the clinical scenario (",
"      <a class=\"graphic graphic_algorithm graphicRef78386 \" href=\"UTD.htm?18/46/19170\">",
"       algorithm 1",
"      </a>",
"      ). We recommend immediate surgical repair for acute, full thickness rotator cuff tears in otherwise healthy individuals (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Expeditious surgery may also be helpful in cases of acute-on-chronic rotator cuff tears where the patient suddenly loses the ability to actively abduct or flex the shoulder. We suggest that such patients be urgently referred to an orthopedic surgeon. We suggest nonoperative management for the initial treatment of acute rotator cuff tears in elderly patients, patients with major comorbidities, and noncompliant patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Acute rotator cuff tears'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that the initial care of symptomatic chronic rotator cuff tears be nonoperative (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Such care generally consists of a minimum of six weeks of physical therapy and may include one or two glucocorticoid injections. A rigorous attempt at conservative management should be completed before surgery is considered. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Chronic, symptomatic rotator cuff tears'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conservative treatment consists primarily of physical therapy emphasizing activity modification; stretching of the shoulder capsule to restore flexibility and maintain motion; and strengthening of the periscapular, rotator cuff, and deltoid muscles. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Physical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subacromial glucocorticoid injections may provide some short term benefit in controlling pain from rotator cuff tears. However, effects tend to be short lived and glucocorticoids may have deleterious effects upon healthy tendons. One or two injections are acceptable in patients with severe pain that is refractory to oral medications. We suggest that repeated injections of glucocorticoids be avoided, except in cases where surgery is not possible (eg, patient with severe comorbidities precluding surgery) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Glucocorticoid injection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Matsen, FA, III, Arntz, CT. Rotator cuff failure. In: The Shoulder, Vol. 2, Rockwood, CA Jr, Matsen, FA III (Eds), WB Saunders, Philadelphia 1990. p.647.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/2\">",
"      Clark JM, Harryman DT 2nd. Tendons, ligaments, and capsule of the rotator cuff. Gross and microscopic anatomy. J Bone Joint Surg Am 1992; 74:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/3\">",
"      Harryman DT 2nd, Sidles JA, Clark JM, et al. Translation of the humeral head on the glenoid with passive glenohumeral motion. J Bone Joint Surg Am 1990; 72:1334.",
"     </a>",
"    </li>",
"    <li>",
"     Hippocrates. Hippocrates writings. Trans. Francis Adam. In: The Great Books of the Western World Series, Vol. 10, Adler, MJ (Eds), Encyclopedia Britannica, Chicago 1952. p.197.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/5\">",
"      Oh LS, Wolf BR, Hall MP, et al. Indications for rotator cuff repair: a systematic review. Clin Orthop Relat Res 2007; 455:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/6\">",
"      Dunn WR, Schackman BR, Walsh C, et al. Variation in orthopaedic surgeons' perceptions about the indications for rotator cuff surgery. J Bone Joint Surg Am 2005; 87:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/7\">",
"      Coghlan JA, Buchbinder R, Green S, et al. Surgery for rotator cuff disease. Cochrane Database Syst Rev 2008; :CD005619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/8\">",
"      Sperling JW, Cofield RH, Schleck C. Rotator cuff repair in patients fifty years of age and younger. J Bone Joint Surg Am 2004; 86-A:2212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/9\">",
"      Galatz LM, Ball CM, Teefey SA, et al. The outcome and repair integrity of completely arthroscopically repaired large and massive rotator cuff tears. J Bone Joint Surg Am 2004; 86-A:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/10\">",
"      Yamaguchi K, Ditsios K, Middleton WD, et al. The demographic and morphological features of rotator cuff disease. A comparison of asymptomatic and symptomatic shoulders. J Bone Joint Surg Am 2006; 88:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/11\">",
"      Wolfgang GL. Surgical repair of tears of the rotator cuff of the shoulder. Factors influencing the result. J Bone Joint Surg Am 1974; 56:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/12\">",
"      Seida JC, LeBlanc C, Schouten JR, et al. Systematic review: nonoperative and operative treatments for rotator cuff tears. Ann Intern Med 2010; 153:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/13\">",
"      Wolf BR, Dunn WR, Wright RW. Indications for repair of full-thickness rotator cuff tears. Am J Sports Med 2007; 35:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/14\">",
"      Gerber C, Fuchs B, Hodler J. The results of repair of massive tears of the rotator cuff. J Bone Joint Surg Am 2000; 82:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/15\">",
"      Gerber C, Meyer DC, Schneeberger AG, et al. Effect of tendon release and delayed repair on the structure of the muscles of the rotator cuff: an experimental study in sheep. J Bone Joint Surg Am 2004; 86-A:1973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/16\">",
"      Cofield RH, Parvizi J, Hoffmeyer PJ, et al. Surgical repair of chronic rotator cuff tears. A prospective long-term study. J Bone Joint Surg Am 2001; 83-A:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/17\">",
"      Goutallier D, Postel JM, Gleyze P, et al. Influence of cuff muscle fatty degeneration on anatomic and functional outcomes after simple suture of full-thickness tears. J Shoulder Elbow Surg 2003; 12:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/18\">",
"      BROWN JT. Early assessment of supraspinatus tears; procaine infiltration as a guide to treatment. J Bone Joint Surg Br 1949; 31B:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/19\">",
"      Ainsworth R, Lewis JS. Exercise therapy for the conservative management of full thickness tears of the rotator cuff: a systematic review. Br J Sports Med 2007; 41:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/20\">",
"      Maman E, Harris C, White L, et al. Outcome of nonoperative treatment of symptomatic rotator cuff tears monitored by magnetic resonance imaging. J Bone Joint Surg Am 2009; 91:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/21\">",
"      Takagishi, N. Conservative treatment of ruptures of the rotator cuff. J Japanese Orthopedic Association 1978; 52:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/22\">",
"      Jobe FW, Moynes DR. Delineation of diagnostic criteria and a rehabilitation program for rotator cuff injuries. Am J Sports Med 1982; 10:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/23\">",
"      Krabak BJ, Sugar R, McFarland EG. Practical nonoperative management of rotator cuff injuries. Clin J Sport Med 2003; 13:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/24\">",
"      Buchbinder R, Green S, Youd JM. Corticosteroid injections for shoulder pain. Cochrane Database Syst Rev 2003; :CD004016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/25\">",
"      Blair B, Rokito AS, Cuomo F, et al. Efficacy of injections of corticosteroids for subacromial impingement syndrome. J Bone Joint Surg Am 1996; 78:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/26\">",
"      Alvarez CM, Litchfield R, Jackowski D, et al. A prospective, double-blind, randomized clinical trial comparing subacromial injection of betamethasone and xylocaine to xylocaine alone in chronic rotator cuff tendinosis. Am J Sports Med 2005; 33:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/27\">",
"      Wei AS, Callaci JJ, Juknelis D, et al. The effect of corticosteroid on collagen expression in injured rotator cuff tendon. J Bone Joint Surg Am 2006; 88:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/28\">",
"      Wiggins ME, Fadale PD, Ehrlich MG, Walsh WR. Effects of local injection of corticosteroids on the healing of ligaments. A follow-up report. J Bone Joint Surg Am 1995; 77:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/29\">",
"      Budoff JE, Nirschl RP, Guidi EJ. D&eacute;bridement of partial-thickness tears of the rotator cuff without acromioplasty. Long-term follow-up and review of the literature. J Bone Joint Surg Am 1998; 80:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/30\">",
"      Fukuda H. The management of partial-thickness tears of the rotator cuff. J Bone Joint Surg Br 2003; 85:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/31\">",
"      Gladstone JN, Bishop JY, Lo IK, Flatow EL. Fatty infiltration and atrophy of the rotator cuff do not improve after rotator cuff repair and correlate with poor functional outcome. Am J Sports Med 2007; 35:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/32\">",
"      Safran O, Derwin KA, Powell K, Iannotti JP. Changes in rotator cuff muscle volume, fat content, and passive mechanics after chronic detachment in a canine model. J Bone Joint Surg Am 2005; 87:2662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/33\">",
"      Coleman SH, Fealy S, Ehteshami JR, et al. Chronic rotator cuff injury and repair model in sheep. J Bone Joint Surg Am 2003; 85-A:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/34\">",
"      Goutallier D, Postel JM, Bernageau J, et al. Fatty muscle degeneration in cuff ruptures. Pre- and postoperative evaluation by CT scan. Clin Orthop Relat Res 1994; :78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/35\">",
"      Goutallier D, Postel JM, Lavau L, Bernageau J. [Impact of fatty degeneration of the suparspinatus and infraspinatus msucles on the prognosis of surgical repair of the rotator cuff]. Rev Chir Orthop Reparatrice Appar Mot 1999; 85:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/36\">",
"      L&auml;hteenm&auml;ki HE, Virolainen P, Hiltunen A, et al. Results of early operative treatment of rotator cuff tears with acute symptoms. J Shoulder Elbow Surg 2006; 15:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/37\">",
"      Melis B, DeFranco MJ, Chuinard C, Walch G. Natural history of fatty infiltration and atrophy of the supraspinatus muscle in rotator cuff tears. Clin Orthop Relat Res 2010; 468:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/38\">",
"      Zingg PO, Jost B, Sukthankar A, et al. Clinical and structural outcomes of nonoperative management of massive rotator cuff tears. J Bone Joint Surg Am 2007; 89:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/39\">",
"      Martin SD, Baumgarten TE, Andrews JR. Arthroscopic resection of the distal aspect of the clavicle with concomitant subacromial decompression. J Bone Joint Surg Am 2001; 83-A:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/40\">",
"      Ozaki J, Fujimoto S, Nakagawa Y, et al. Tears of the rotator cuff of the shoulder associated with pathological changes in the acromion. A study in cadavera. J Bone Joint Surg Am 1988; 70:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/41\">",
"      Busfield BT, Glousman RE, McGarry MH, et al. A biomechanical comparison of 2 technical variations of double-row rotator cuff fixation: the importance of medial row knots. Am J Sports Med 2008; 36:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/42\">",
"      Frank JB, ElAttrache NS, Dines JS, et al. Repair site integrity after arthroscopic transosseous-equivalent suture-bridge rotator cuff repair. Am J Sports Med 2008; 36:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/43\">",
"      Park JY, Lhee SH, Choi JH, et al. Comparison of the clinical outcomes of single- and double-row repairs in rotator cuff tears. Am J Sports Med 2008; 36:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/44\">",
"      Kim SH, Ha KI, Park JH, et al. Arthroscopic versus mini-open salvage repair of the rotator cuff tear: outcome analysis at 2 to 6 years' follow-up. Arthroscopy 2003; 19:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/45\">",
"      Gartsman GM, Khan M, Hammerman SM. Arthroscopic repair of full-thickness tears of the rotator cuff. J Bone Joint Surg Am 1998; 80:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/46\">",
"      Mohtadi NG, Hollinshead RM, Sasyniuk TM, et al. A randomized clinical trial comparing open to arthroscopic acromioplasty with mini-open rotator cuff repair for full-thickness rotator cuff tears: disease-specific quality of life outcome at an average 2-year follow-up. Am J Sports Med 2008; 36:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25095/abstract/47\">",
"      Galatz LM, Silva MJ, Rothermich SY, et al. Nicotine delays tendon-to-bone healing in a rat shoulder model. J Bone Joint Surg Am 2006; 88:2027.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 235 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-1201EFFE29-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_32_25095=[""].join("\n");
var outline_f24_32_25095=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT OPTIONS AND EVIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SURGICAL INDICATIONS FOR ROTATOR CUFF TEARS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NONOPERATIVE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Glucocorticoid injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other nonsurgical treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PARTIAL THICKNESS ROTATOR CUFF TEARS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ACUTE ROTATOR CUFF TEARS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CHRONIC, SYMPTOMATIC ROTATOR CUFF TEARS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SURGICAL APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      POSTOPERATIVE CARE AND RETURN TO WORK OR SPORTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/235\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/235|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?18/46/19170\" title=\"algorithm 1\">",
"      Algorithm for management of rotator cuff tear",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=related_link\">",
"      Evaluation of the patient with shoulder complaints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/53/29522?source=related_link\">",
"      Patient information: Rotator cuff injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/49/24341?source=related_link\">",
"      Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6887?source=related_link\">",
"      Presentation and diagnosis of rotator cuff tears",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=related_link\">",
"      Rotator cuff tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32280?source=related_link\">",
"      Shoulder impingement syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_32_25096="Indications for corrective surgery in severe chronic primary mitral regurgitation";
var content_f24_32_25096=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Indications for corrective surgery in severe chronic primary mitral regurgitation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/32/25096/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/32/25096/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/32/25096/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/32/25096/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/32/25096/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/32/25096/contributors\">",
"     Edward Verrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/32/25096/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/32/25096/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/32/25096/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modern management of patients with chronic mitral regurgitation (MR) requires an understanding of multiple factors. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The pathophysiology and natural history of the disease",
"     </li>",
"     <li>",
"      The severity of the valvular lesion",
"     </li>",
"     <li>",
"      The presence or absence of atrial fibrillation",
"     </li>",
"     <li>",
"      The indications for mitral valve repair and mitral valve replacement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The only effective treatment is surgical valve repair or valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations for treatment of severe chronic primary MR differ from those for severe functional (also known as secondary) MR [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/2\">",
"     2",
"    </a>",
"    ]. The indications for corrective surgery in severe chronic primary MR will be reviewed here. The types of procedures that are available, the factors that determine the choice of procedure, an overview of the natural history and management of chronic MR, and issues related to mitral valve prolapse, ischemic MR, functional MR, and MR in elderly patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36697?source=see_link\">",
"     \"Surgical procedures for severe chronic mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=see_link\">",
"     \"Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=see_link\">",
"     \"Overview of the management of chronic mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=see_link\">",
"     \"Ischemic mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=see_link\">",
"     \"Functional mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34377?source=see_link\">",
"     \"Valvular heart disease in elderly adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DETERMINANTS OF THE TIMING OF SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon a variety of hemodynamic and echocardiographic studies and natural history and outcome data, it is possible to develop a rational management strategy for patients with severe chronic MR, and recommendations for valve surgery.",
"   </p>",
"   <p>",
"    In patients with flail or partial flail mitral leaflet and severe chronic MR, indications for corrective surgery are similar to those for severe MR generally.",
"   </p>",
"   <p>",
"    The following discussion is generally in accord with the recommendations from the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    and the 2012 European Society of Cardiology (ESC) guidelines on the management of valvular heart disease in adults with primary MR and in adolescents or young adults with congenital MR (",
"    <a class=\"graphic graphic_table graphicRef51845 graphicRef71650 graphicRef86954 \" href=\"UTD.htm?28/1/28702\">",
"     table 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal timing of corrective surgery is determined by a number of factors, including (",
"    <a class=\"graphic graphic_algorithm graphicRef58148 graphicRef81099 \" href=\"UTD.htm?0/47/753\">",
"     algorithm 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The severity of the MR",
"     </li>",
"     <li>",
"      The presence or absence of symptoms",
"     </li>",
"     <li>",
"      The functional state of the left ventricle",
"     </li>",
"     <li>",
"      The feasibility of valve repair",
"     </li>",
"     <li>",
"      The presence of AF",
"     </li>",
"     <li>",
"      The presence of pulmonary hypertension at rest or with exercise",
"     </li>",
"     <li>",
"      The preference and expectations of the patient",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEFINITION OF SEVERE MR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corrective surgery is indicated only in selected patients with severe chronic MR, which is usually defined by Doppler echocardiography. Based upon the 2003 American Society of Echocardiography and the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/1,4\">",
"     1,4",
"    </a>",
"    ], the following findings, in order of priority, are consistent with severe MR (",
"    <a class=\"graphic graphic_movie graphicRef63107 \" href=\"UTD.htm?8/37/8784\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef75955 \" href=\"UTD.htm?16/31/16884\">",
"     movie 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A vena contracta width &ge;7 mm",
"     </li>",
"     <li>",
"      A regurgitant orifice area &ge;0.40 cm2",
"     </li>",
"     <li>",
"      A regurgitant volume &ge;60 mL",
"     </li>",
"     <li>",
"      A regurgitant fraction &ge;50 percent",
"     </li>",
"     <li>",
"      A jet area &gt;40 percent of left atrial area, but this is not so reproducible",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These values are based on an average adult size and may need to be adjusted for body size in small or large patients; however, there is no specific formula for making this adjustment.",
"   </p>",
"   <p>",
"    The effective regurgitant orifice (ERO) is applicable to patients with isolated primary MR, not to mixed valve lesions or ischemic or functional MR. A major limitation to the use of ERO in isolated primary MR is that quantitation of ERO is technically difficult and should only be performed in an experienced echocardiography laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/5\">",
"     5",
"    </a>",
"    ]. Another key issue is that ERO does not account for the duration of regurgitation (mid-late systolic versus holosystolic), which likely explains why regurgitant volume rather than ERO predicted outcomes in one large series [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/6\">",
"     6",
"    </a>",
"    ]. These issues are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=see_link&amp;anchor=H8#H8\">",
"     \"Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet\", section on 'Clinical outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since echocardiographic grading of the severity of MR is not absolute, the potential risk of misclassifying moderate MR as severe or severe MR as moderate should be considered. Assessment of the overall severity of MR should also take into account the cause and acuteness of the lesion, left ventricular size and systolic function, and pulmonary artery pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9705?source=see_link&amp;anchor=H14#H14\">",
"     \"Etiology, clinical features, and evaluation of chronic mitral regurgitation\", section on 'Cause of mitral regurgitation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of echo-Doppler grading, severe chronic MR does",
"    <strong>",
"     NOT",
"    </strong>",
"    exist (with rare exceptions) without clear evidence of left atrial or left ventricular enlargement. If the left ventricular end-diastolic dimension (by echocardiography) is less than 60 mm (approximately 35",
"    <span class=\"nowrap\">",
"     mm/m2),",
"    </span>",
"    the diagnosis of severe chronic MR should be seriously questioned. Left atrial size may reflect the \"history\" (severity and duration) of chronic MR [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36901?source=see_link\">",
"     \"Pathophysiology and stages of chronic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     THE ASYMPTOMATIC PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of symptoms, management decisions and the indications for surgery rest largely upon the echocardiographic assessment of LV size and function as well as careful confirmation of the severity of MR [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Some degree of LV and left atrial enlargement are to be expected in severe chronic MR; thus, chamber enlargement alone is generally not an indication for surgery in patients with severe chronic MR (",
"    <a class=\"graphic graphic_table graphicRef51845 \" href=\"UTD.htm?34/19/35132\">",
"     table 1A",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef71650 \" href=\"UTD.htm?30/34/31275\">",
"     table 1B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Some consideration of body size should be included in any estimation of LV dimension, since smaller women are less likely to reach the above criteria, which were largely established in men [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/2\">",
"     2",
"    </a>",
"    ]. However, simply normalizing for body surface area can lead to misleading conclusions, especially in obese patients. In general, somewhat lower values should be used in very small patients and somewhat higher values in very large patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Normal left ventricular function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic patients with severe chronic MR and normal LV systolic function (defined as LV ejection fraction [LVEF] &ge;60 percent and LV end-systolic dimension &lt;40 mm) are usually followed and managed conservatively. Such patients should be seen every 6 to 12 months or sooner if symptoms occur; repeat transthoracic echocardiography should be obtained at these visits [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the management of chronic mitral regurgitation\", section on 'Serial monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An occasional patient with a borderline LVEF or a technically limited study will require radionuclide, contrast angiography, or cardiovascular magnetic resonance imaging to assess LV function and regurgitant fraction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=see_link\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exercise stress testing may add objective evidence about symptoms and a change in exercise tolerance; it may be particularly useful if a good history of exercise capacity is difficult to obtain. Measurement of MR severity and pulmonary artery pressure during exercise may also be helpful.",
"   </p>",
"   <p>",
"    Mitral valve surgery is reasonable in some asymptomatic patients with severe chronic MR and preserved LV systolic function, defined as an LVEF &gt;60 percent and an LV end-systolic dimension &lt;40 mm",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    or &lt;45 mm (ESC). The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines concluded that the weight of evidence or opinion was in favor of the efficacy of mitral valve surgery in such patients who have one or more of the following (",
"    <a class=\"graphic graphic_table graphicRef51845 \" href=\"UTD.htm?34/19/35132\">",
"     table 1A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      New onset AF, which can represent documented new onset if the patient is followed prospectively or AF being present when the diagnosis of severe MR is first made.",
"     </li>",
"     <li>",
"      Pulmonary hypertension, defined as pulmonary artery systolic pressure &gt;50 mmHg at rest or &gt;60 mmHg with exercise.",
"     </li>",
"     <li>",
"      At experienced centers with more than a 90 percent likelihood of successful mitral valve repair without residual MR. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36697?source=see_link&amp;anchor=H5#H5\">",
"       \"Surgical procedures for severe chronic mitral regurgitation\", section on 'Valve repair'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2012 ESC guidelines reached similar conclusions, the main difference being that an exercise pulmonary artery systolic pressure &gt;60 mmHg with exercise (or left atrial dilatation &ge;60",
"    <span class=\"nowrap\">",
"     Ml/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    with sinus rhythm) is considered a weaker indication for consideration of mitral valve repair (",
"    <a class=\"graphic graphic_table graphicRef86954 \" href=\"UTD.htm?11/57/12189\">",
"     table 1C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/2\">",
"     2",
"    </a>",
"    ]. A somewhat higher threshold for surgery is used if valve replacement is required [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines noted that mitral valve surgery is NOT indicated for asymptomatic patients with MR and LVEF &gt;60 percent and end-systolic dimension &lt;40 mm in whom significant doubt about the feasibility of repair exists.",
"   </p>",
"   <p>",
"    In addition to the above indications, it has been suggested that the effective regurgitant orifice (ERO) and functional capacity may identify asymptomatic patients with isolated severe chronic MR who would benefit from surgery before they develop LV systolic dysfunction, AF,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Effective regurgitant orifice",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible importance of effective regurgitant orifice (ERO) was suggested in a prospective observational study of 465 patients with isolated primary MR (80 percent mitral valve prolapse), a normal LVEF (mean 70 percent), absence of pulmonary hypertension, and, in all but 9 percent, absence of AF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/8\">",
"     8",
"    </a>",
"    ]. An ERO &ge;40 mm2, which was present in 43 percent of cases, was associated with a significant increase in regurgitant volume (101 versus 29",
"    <span class=\"nowrap\">",
"     mL/beat",
"    </span>",
"    with an ERO &lt;20 mm2) and was a powerful predictor of an adverse outcome, including all-cause mortality, cardiac events, and undergoing cardiac surgery.",
"   </p>",
"   <p>",
"    As noted, ERO use is subject to technical limitations and the ERO does not account for the duration of regurgitation (mid-late systolic versus holosystolic) while this is accounted for by the regurgitant volume. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Definition of severe MR'",
"    </a>",
"    above.)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23030411\">",
"    <span class=\"h3\">",
"     Left atrial size",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognostic significance of left atrial volume indexed to body surface area (LA index) was suggested by a prospective observational study of 492 patients with isolated primary MR (81 percent mitral valve prolapse) in sinus rhythm at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/10\">",
"     10",
"    </a>",
"    ]. Five-year survival with medical management was 80 percent. LA index was an independent predictor of mortality and of cardiac events in patients receiving medical management. Patients with LA index &ge;60",
"    <span class=\"nowrap\">",
"     ml/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    had lower five-year survival (53 percent) than those with LA index of 40 to 59",
"    <span class=\"nowrap\">",
"     ml/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (84 percent) and those with LA index &lt;40",
"    <span class=\"nowrap\">",
"     ml/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (90 percent). LA index remained a significant predictor of mortality and cardiac events after adjustment by ERO.",
"    <br/>",
"   </p>",
"   <p>",
"    In this cohort, mitral surgery was associated with decreased mortality (HR 0.46, 95% CI, 0.26-0.84) and cardiac events (HR 0.38, 95% CI 0.23 to 0.62). Postoperative outcomes were not significantly different in patients with LA index &ge;60",
"    <span class=\"nowrap\">",
"     ml/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    as compared to those with LA index &lt;60",
"    <span class=\"nowrap\">",
"     ml/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (five-year mortality 9.1 versus 8.7 percent and cardiovascular events 20 versus 16.8 percent).",
"   </p>",
"   <p>",
"    These findings suggest that LA index may be a useful parameter for risk stratification of patients with MR although this study did not evaluate whether it provides predictive value beyond current monitored parameters such as pulmonary artery systolic pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Functional capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential value of quantitative assessment of functional capacity (FC) using cardiopulmonary exercise testing (CPET) with determination of gas exchange was assessed in 134 asymptomatic patients with MR (57 percent severe) who underwent CPET and echocardiographic quantitation of MR (including the ERO), as well as measurement of left ventricular systolic and diastolic function [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/11\">",
"     11",
"    </a>",
"    ]. At three years, clinical events and the combined end point of clinical events and surgery were significantly more common in the 25 percent of patients with markedly reduced FC. This is not surprising since decreased exercise intolerance is often the first symptom of severe MR and, as described below, symptomatic patients have worse outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Reduced left ventricular function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corrective surgery is indicated in asymptomatic patients with severe chronic MR if there is definite and reliable evidence of LV systolic dysfunction or significantly increased LV end-systolic dimension. Exercise echocardiography may be useful when there is a concern that symptoms may be occurring or there are borderline echocardiographic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of surgical repair before there is a significant impairment in left ventricular function or more than mild symptoms was illustrated in a report of 409 patients who underwent surgery for isolated, organic MR who were under age 75 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/13\">",
"     13",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ten-year survival was 72, 53, and 32 percent in patients with a preoperative LVEF of &ge;60 percent, 50 to 59 percent, and less than 50 percent, respectively. The hazard ratio for mortality compared to a LVEF &ge;60 percent was 1.81 for an LVEF of 50 to 59 percent and 2.79 for an LVEF less than 50 percent.",
"     </li>",
"     <li>",
"      Among patients with an LVEF &ge;60 percent, survival was higher in patients with NYHA class I or II compared to class III or IV (82 versus 59 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In two series published in 1979 and 1984, approximately 25 percent of patients had persistent postoperative LV enlargement and systolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. These patients could be identified by preoperative echocardiographic parameters of LV end-diastolic dimension &gt; 70 mm, LV end-systolic dimension &gt; 47 mm or a low-normal or depressed LVEF (",
"    <a class=\"graphic graphic_table graphicRef79918 \" href=\"UTD.htm?34/11/35003\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One or both of the following criteria for LV dysfunction is sufficient to warrant mitral valve surgery in the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines and the 2012 ESC guidelines (",
"    <a class=\"graphic graphic_table graphicRef51845 \" href=\"UTD.htm?34/19/35132\">",
"     table 1A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An LVEF &le;60 percent.",
"     </li>",
"     <li>",
"      An LV end-systolic dimension &ge;40 mm",
"      <span class=\"nowrap\">",
"       (ACC/AHA)",
"      </span>",
"      or &gt;45 mm (ESC).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A separate issue is surgery in patients with severe chronic MR and severe LV dysfunction (LVEF &lt;30 percent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    LV end-systolic dimension &gt;55 mm) in whom outcomes after surgery are poor. Such patients may have primary mitral valve disease with irreversible depression of ventricular contractility due to long-standing volume overload. Alternatively, the MR may be secondary to the left ventricular dysfunction (functional MR). In either case, LV systolic function often does not improve after mitral valve surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=see_link\">",
"     \"Functional mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines concluded that the weight of evidence or opinion was in favor of mitral valve surgery in such patients if the severe MR is due to a primary abnormality of the mitral apparatus (not functional MR) and mitral valve repair is highly likely (",
"    <a class=\"graphic graphic_table graphicRef51845 \" href=\"UTD.htm?34/19/35132\">",
"     table 1A",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/1\">",
"     1",
"    </a>",
"    ]. The weight of evidence or opinion was considered less well established for mitral valve repair in patients with severe LV dysfunction who have severe chronic functional MR and persistent NYHA class III-IV symptoms despite optimal therapy for heart failure, including biventricular pacing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Outcomes with watchful waiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The necessity of surgery is uncertain in patients with borderline LV function (LVEF 55 to 60 percent) or a borderline LV end-systolic dimension (40 to 45 mm), since some of these patients remain asymptomatic and stable for years. Thus, surgical decisions often depend upon other issues such as the presence or absence of atrial fibrillation (AF), evidence of pulmonary hypertension, the likelihood of successful mitral valve repair, and the preferences of the patient. Among those who are treated medically, any trend indicating a further decline in LVEF is an indication for surgery.",
"   </p>",
"   <p>",
"    The safety of watchful waiting in asymptomatic patients with severe chronic MR who do not meet guideline recommendations for mitral valve surgery was evaluated in two series. In the earlier report, 132 consecutive patients (mean age 55 years) with degenerative disease (mitral valve prolapse or flail leaflet) were followed prospectively for development of an indication for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/17\">",
"     17",
"    </a>",
"    ]. Criteria for surgery included symptoms, even if mild, LV end-systolic diameter &ge;45 mm or 26",
"    <span class=\"nowrap\">",
"     mm/m2",
"    </span>",
"    body surface area, LVEF &lt;60 percent or fractional shortening &lt;32 percent, systolic pulmonary artery pressure &gt;50 mmHg, or recurrent AF.",
"   </p>",
"   <p>",
"    At a mean follow-up of 5.2 years, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Criteria for surgery were met in 38 patients (29 percent). These included symptoms in 24, left ventricular criteria in 9, and pulmonary hypertension or AF in 5. Survival free of any indication for surgery was 92, 78, and 66 percent at two, four, and six years. Postoperative outcomes were good.",
"     </li>",
"     <li>",
"      Overall survival was not statistically different from expected in the overall group or in the patients with flail leaflet.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A limitation to these data is that there was no direct comparator group that underwent early surgery. This limitation was not present in a later prospective observational study in which outcomes with watchful waiting were compared to those following early surgery in 447 consecutive asymptomatic patients with severe degenerative MR, LVEF &ge;60 percent and LV end-systolic dimension &le;45 mm, and no other indication for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/9\">",
"     9",
"    </a>",
"    ]. Early surgery was performed in 161 patients. In the remaining 286 patients, a conventional treatment strategy was employed with referral for surgery for development of exertional dyspnea, LVEF &lt;60 percent, LV end-systolic dimension &gt;45 mm, Doppler-estimated pulmonary artery pressure &gt;50 mmHg, or atrial fibrillation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the early surgery group, mitral valve repair was performed successfully in 151 (94 percent) and 10 (6 percent) underwent mitral valve replacement.",
"     </li>",
"     <li>",
"      In the conventional treatment group, survival free of indications for surgery was 76 and 67 percent at five and seven years, similar to the rates noted in the previous study. Multivariate analysis identified baseline grade of pulmonary hypertension and effective regurgitant orifice (ERO) as independent predictors for development of an indication for surgery. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Effective regurgitant orifice'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During a median follow-up of 5.4 years, there were two repeat surgeries and no cardiac deaths or operative mortality in the early surgery group compared with 12 cardiac deaths, one repeat surgery, and 22 admissions for HF in the conventional treatment group.",
"     </li>",
"     <li>",
"      To control for potential bias, actuarial 7-year event-free survival was calculated for 127 propensity score-matched pairs and was significantly higher in the early surgery group compared to the conventional therapy group (99 versus 85 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results suggest that in a setting with high success rate of mitral valve repair with low operative mortality, a strategy of early surgery in patients with asymptomatic severe mitral regurgitation can produce favorable outcomes.",
"   </p>",
"   <p>",
"    Recommendations for asymptomatic patients and for watchful waiting are presented below. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Asymptomatic patients'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H17\">",
"     'Watchful waiting'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     THE SYMPTOMATIC PATIENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     The patient with mild symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyspnea and fatigue, even if mild (NYHA functional class II), (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 3",
"    </a>",
"    ), are an indication for corrective surgery in patients with severe chronic MR (",
"    <a class=\"graphic graphic_table graphicRef51845 \" href=\"UTD.htm?34/19/35132\">",
"     table 1A",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decision making is more difficult in patients with mild symptoms who have only moderate MR by quantitative echocardiographic evaluation. Because there is considerable variability in the accuracy of quantitative regurgitant severity, some of these patients may have hemodynamically severe disease. This issue is not directly addressed in the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines which note that isolated mitral valve surgery is not indicated for patients with mild or moderate mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with \"moderate\" mitral regurgitation and symptoms, careful evaluation for other causes of symptoms, including pulmonary disease, should be the first step. If no other cause of symptoms is present, other evidence for adverse hemodynamic consequences of mitral regurgitation (suggesting regurgitation is in fact severe) should be evaluated, including LV dilation or systolic dysfunction, the presence persistent or intermittent AF, or early pulmonary hypertension. When the likelihood of valve repair is high and the clinical evidence is consistent with symptoms due to mitral regurgitation, valve repair or replacement should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/18\">",
"     18",
"    </a>",
"    ]. Measurement of LV volumes, regurgitation fraction and ejection fraction by cardiovascular magnetic resonance (CMR) also may be helpful in these patients for more accurate quantitation of regurgitation severity, ventricular size and function. A conservative nonsurgical approach is suggested for the patient with no or mild symptoms and moderate MR with careful clinical follow-up. Echocardiographic assessment should be performed at 12 month intervals and sooner if symptoms change.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     The patient with moderate to severe symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient presents with serious symptoms (NYHA functional class III or IV), (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 3",
"    </a>",
"    ), surgery is almost always indicated unless there is severe left ventricular dysfunction (LVEF less than 30 percent or end-systolic dimension greater than 55 mm) (",
"    <a class=\"graphic graphic_table graphicRef51845 \" href=\"UTD.htm?34/19/35132\">",
"     table 1A",
"    </a>",
"    ). A valve repair procedure is preferable, regardless of the LVEF.",
"   </p>",
"   <p>",
"    Delaying surgery until moderate to severe symptoms occur is associated with increased perioperative and long-term mortality. The potential magnitude of this effect was illustrated in a retrospective study that compared the outcome after surgery in 199 patients in NYHA class",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    to 279 patients in class",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/19\">",
"     19",
"    </a>",
"    ]. Compared to those in class",
"    <span class=\"nowrap\">",
"     I/II,",
"    </span>",
"    patients in class",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    had a significantly higher surgical mortality (5.4 versus 0.5 percent) and a significantly lower 10-year survival (48 versus 76 percent). These differences were independent of all baseline characteristics, including LVEF (",
"    <a class=\"graphic graphic_figure graphicRef76172 \" href=\"UTD.htm?40/30/41453\">",
"     figure 1",
"    </a>",
"    ) and concomitant coronary artery bypass grafting (CABG) (",
"    <a class=\"graphic graphic_figure graphicRef50964 \" href=\"UTD.htm?40/5/41053\">",
"     figure 2",
"    </a>",
"    ), and were seen in patients undergoing valve replacement or repair, although the outcomes were better with valve repair (",
"    <a class=\"graphic graphic_figure graphicRef56177 \" href=\"UTD.htm?40/56/41869\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients with an LVEF below 30 percent are not likely to have an optimal result, especially if valve replacement is necessary. In such patients, medical management, including vasodilator therapy, may be preferable. In patients who do not respond to medical therapy, surgical intervention may be considered if the mitral annular&ndash;papillary muscle continuity can be maintained (which helps maintain LV systolic function) either by valve repair or replacement with perseveration of the chordal apparatus [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29109?source=see_link\">",
"     \"Vasodilator therapy in chronic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations illustrate the importance of careful monitoring to detect patients before such an advanced state is reached. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Outcomes with watchful waiting'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have not been performed comparing medical therapy to surgery in patients with severe chronic MR who meet the indications for corrective surgery. However, symptoms are clearly improved after surgery and a survival benefit has been suggested on multivariate analysis in observational studies in which some patients had undergone surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Indications for surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corrective surgery is indicated only in selected patients with severe chronic MR as usually determined by Doppler echocardiography. The echocardiographic criteria for severe MR are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9705?source=see_link&amp;anchor=H13#H13\">",
"     \"Etiology, clinical features, and evaluation of chronic mitral regurgitation\", section on 'Severity of mitral regurgitation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With better definition of the indication for corrective surgery and improved surgical techniques, outcomes for patients with severe chronic MR treated surgically have improved and the threshold for corrective surgery has declined. There is, however, some lack of agreement about the indications for surgery in an asymptomatic patient. As a result, the general guidelines presented in this review should be modified depending upon local experience and outcomes from surgery.",
"   </p>",
"   <p>",
"    The decision for surgery in patients with severe chronic MR (usually defined by Doppler echocardiography) is based largely upon the presence or absence of symptoms, LV function and size in both nonischemic MR and congenital MR (most often due to mitral valve prolapse), and whether or not valve repair can be performed. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Definition of severe MR'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following recommendations for surgery in patients with severe chronic nonischemic MR are generally consistent with those in the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    and 2012 ESC guidelines (",
"    <a class=\"graphic graphic_algorithm graphicRef58148 graphicRef81099 \" href=\"UTD.htm?0/47/753\">",
"     algorithm 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51845 \" href=\"UTD.htm?34/19/35132\">",
"     table 1A",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef71650 \" href=\"UTD.htm?30/34/31275\">",
"     table 1B",
"    </a>",
"    ) except where specified [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25096/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Recommendations for the management of ischemic MR and functional MR are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=see_link\">",
"     \"Ischemic mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=see_link\">",
"     \"Functional mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Symptomatic patients",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend mitral valve surgery in symptomatic patients with severe chronic MR if the LVEF is &ge;30 percent and the LV end-systolic dimension is &le;55 mm (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'The patient with mild symptoms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'The patient with moderate to severe symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If successful repair is highly likely, we suggest mitral valve surgery in patients with severe mitral regurgitation due to primary mitral valve disease (ie, not functional MR) who have NYHA class III-IV symptoms (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 3",
"      </a>",
"      ) and severe LV dysfunction (LVEF &lt;30 percent or LV end-systolic dimension &gt;55 mm) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Reduced left ventricular function'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'The patient with moderate to severe symptoms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Asymptomatic patients",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend mitral valve surgery in asymptomatic patients with severe chronic MR and an LVEF of 30 to 60 percent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an LV end-systolic dimension &ge;40 mm (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). However, watchful waiting is reasonable in selected patients with borderline values (LVEF 55 to 60 percent and LV end-systolic dimension 40 to 45 mm). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Reduced left ventricular function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest surgical mitral valve repair in asymptomatic patients with severe MR and an LVEF &gt;60 percent who have new onset AF or pulmonary hypertension (defined as a pulmonary artery systolic pressure &gt;50 mmHg at rest or &gt;60 mmHg with exercise) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). New onset AF can represent documented new onset if the patient is followed prospectively or AF being present when the diagnosis of severe MR is first made. A somewhat higher threshold for surgery is used if valve replacement is required. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Normal left ventricular function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest mitral valve repair in asymptomatic patients with severe MR and preserved LV function (LVEF &gt;60 percent and LV end-systolic diameter &lt;40 mm) if the likelihood of repair without residual MR is &gt;90 percent and surgical risk is low (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Possible findings favoring surgery in such patients are moderate left atrial enlargement (&gt;50 mm),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mild pulmonary hypertension (eg, pulmonary artery systolic pressure 30 to 50 mmHg). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Normal left ventricular function'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Watchful waiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Watchful waiting is indicated or reasonable in many patients with chronic severe MR. Such patients should undergo physical examination and echocardiography every 6 to 12 months or any time symptoms occur. The six month interval is preferred if stability has not been documented, there is evidence of progression, or measurements are close to the echocardiographic cutoff values. A decision about watchful waiting must consider patient preference, the presence or absence of other risk factors, and whether mitral valve repair, the preferred approach, can be performed. Surgery may be offered earlier in patients with borderline values in patients in whom access to such monitoring is limited. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Outcomes with watchful waiting'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend watchful waiting in asymptomatic patients with severe chronic MR who do not meet the criteria for mitral valve surgery (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Because there is variability in measurement of LVEF and end-systolic size, we suggest watchful waiting as an alternate strategy in asymptomatic patients with borderline values of LV function (LVEF 55 to 60 percent and LV end-systolic dimension 40 to 45 mm) on a single study. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These patients should have repeat studies at 6 months intervals to determine if there are consistent, reproducible changes in LV size or systolic function that would warrant intervention per the guidelines above.",
"     </li>",
"     <li>",
"      Because there is considerable variability in the accuracy of quantitation of regurgitation severity, some patients classified as having moderate MR may have hemodynamically severe disease. This issue is not directly addressed in the 2006",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      and 2012 ESC guidelines. If symptoms are present, alternate causes for symptoms should be sought. If no other cause is evident, we suggest watchful waiting in patients with mild symptoms (NYHA functional class II), (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 3",
"      </a>",
"      ) and moderate MR who have preserved LV function (LVEF &gt;60 percent and LV end-systolic dimension &lt;40 mm) and no other risk factors, such as early pulmonary hypertension (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25096/abstract/1\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25096/abstract/2\">",
"      Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33:2451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25096/abstract/3\">",
"      Gaasch WH, Meyer TE. Left ventricular response to mitral regurgitation: implications for management. Circulation 2008; 118:2298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25096/abstract/4\">",
"      Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25096/abstract/5\">",
"      Otto CM, Salerno CT. Timing of surgery in asymptomatic mitral regurgitation. N Engl J Med 2005; 352:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25096/abstract/6\">",
"      Topilsky Y, Michelena H, Bichara V, et al. Mitral valve prolapse with mid-late systolic mitral regurgitation: pitfalls of evaluation and clinical outcome compared with holosystolic regurgitation. Circulation 2012; 125:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25096/abstract/7\">",
"      Reed D, Abbott RD, Smucker ML, Kaul S. Prediction of outcome after mitral valve replacement in patients with symptomatic chronic mitral regurgitation. The importance of left atrial size. Circulation 1991; 84:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25096/abstract/8\">",
"      Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med 2005; 352:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25096/abstract/9\">",
"      Kang DH, Kim JH, Rim JH, et al. Comparison of early surgery versus conventional treatment in asymptomatic severe mitral regurgitation. Circulation 2009; 119:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25096/abstract/10\">",
"      Le Tourneau T, Messika-Zeitoun D, Russo A, et al. Impact of left atrial volume on clinical outcome in organic mitral regurgitation. J Am Coll Cardiol 2010; 56:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25096/abstract/11\">",
"      Messika-Zeitoun D, Johnson BD, Nkomo V, et al. Cardiopulmonary exercise testing determination of functional capacity in mitral regurgitation: physiologic and outcome implications. J Am Coll Cardiol 2006; 47:2521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25096/abstract/12\">",
"      Leung DY, Griffin BP, Stewart WJ, et al. Left ventricular function after valve repair for chronic mitral regurgitation: predictive value of preoperative assessment of contractile reserve by exercise echocardiography. J Am Coll Cardiol 1996; 28:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25096/abstract/13\">",
"      Enriquez-Sarano M, Tajik AJ, Schaff HV, et al. Echocardiographic prediction of survival after surgical correction of organic mitral regurgitation. Circulation 1994; 90:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25096/abstract/14\">",
"      Schuler G, Peterson KL, Johnson A, et al. Temporal response of left ventricular performance to mitral valve surgery. Circulation 1979; 59:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25096/abstract/15\">",
"      Zile MR, Gaasch WH, Carroll JD, Levine HJ. Chronic mitral regurgitation: predictive value of preoperative echocardiographic indexes of left ventricular function and wall stress. J Am Coll Cardiol 1984; 3:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25096/abstract/16\">",
"      Wisenbaugh T, Skudicky D, Sareli P. Prediction of outcome after valve replacement for rheumatic mitral regurgitation in the era of chordal preservation. Circulation 1994; 89:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25096/abstract/17\">",
"      Rosenhek R, Rader F, Klaar U, et al. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation 2006; 113:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25096/abstract/18\">",
"      Dalrymple-Hay MJ, Bryant M, Jones RA, et al. Degenerative mitral regurgitation: when should we operate? Ann Thorac Surg 1998; 66:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25096/abstract/19\">",
"      Tribouilloy CM, Enriquez-Sarano M, Schaff HV, et al. Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation: rationale for optimizing surgical indications. Circulation 1999; 99:400.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8149 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-593C6D74E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_32_25096=[""].join("\n");
var outline_f24_32_25096=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DETERMINANTS OF THE TIMING OF SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEFINITION OF SEVERE MR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      THE ASYMPTOMATIC PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Normal left ventricular function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Effective regurgitant orifice",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23030411\">",
"      - Left atrial size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Functional capacity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Reduced left ventricular function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Outcomes with watchful waiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      THE SYMPTOMATIC PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      The patient with mild symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      The patient with moderate to severe symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Indications for surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Watchful waiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8149\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8149|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?10/39/10879\" title=\"algorithm 1A\">",
"      Rx asymptomatic chron severe MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?13/36/13902\" title=\"algorithm 1B\">",
"      Rx symptomatic chron severe MR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8149|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/30/41453\" title=\"figure 1\">",
"      NYHA LVEF outcome MV surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/5/41053\" title=\"figure 2\">",
"      NYHA CABG outcome MV surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/56/41869\" title=\"figure 3\">",
"      NYHA repair vs replacement MV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8149|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?8/37/8784\" title=\"movie 1\">",
"      Echo four chamber severe MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?16/31/16884\" title=\"movie 2\">",
"      Echo 4-chamber view MR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8149|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/19/35132\" title=\"table 1A\">",
"      Valve surgery nonischemic MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/34/31275\" title=\"table 1B\">",
"      Valve surgery congenital MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/57/12189\" title=\"table 1C\">",
"      ESC surgery for primary MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/11/35003\" title=\"table 2\">",
"      Echo stages of chronic MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 3\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9705?source=related_link\">",
"      Etiology, clinical features, and evaluation of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=related_link\">",
"      Functional mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=related_link\">",
"      Ischemic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=related_link\">",
"      Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=related_link\">",
"      Noninvasive methods for measurement of left ventricular systolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=related_link\">",
"      Overview of the management of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36901?source=related_link\">",
"      Pathophysiology and stages of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36697?source=related_link\">",
"      Surgical procedures for severe chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34377?source=related_link\">",
"      Valvular heart disease in elderly adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29109?source=related_link\">",
"      Vasodilator therapy in chronic mitral regurgitation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_32_25097="Radiologic evaluation of the hip in infants, children, and adolescents";
var content_f24_32_25097=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Radiologic evaluation of the hip in infants, children, and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/32/25097/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/32/25097/contributors\">",
"     Cecilia M Jude, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/32/25097/contributors\">",
"     Shahla Modarresi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/32/25097/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/32/25097/contributors\">",
"     William Phillips, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/32/25097/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/32/25097/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/32/25097/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hip is a stable, major weight-bearing joint with significant mobility. In children, common causes of hip pathology include developmental dysplasia of the hip (DDH), transient synovitis, septic arthritis, Legg-Calv&eacute;-Perthes disease, and slipped capital femoral epiphysis. Less common hip disorders include proximal femoral focal deficiency, developmental coxa vara, neuromuscular hip dysplasia, injuries about the hip, arthritides, and tumors. The radiologic evaluation of common and less common hip disorders is discussed below.",
"   </p>",
"   <p>",
"    Accurate diagnosis and treatment of pediatric hip disorders are important because of the potential complications, which may lead to degenerative joint disease in adult life. The history and physical examination, which are necessary to develop a differential diagnosis prior to the selection of imaging tests, and a general review of the imaging tests that are used in the evaluation of bone and joint pain, including the physical principles underlying their usefulness, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=see_link\">",
"     \"Overview of hip pain in childhood\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42057?source=see_link\">",
"     \"Approach to the child with a limp\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3193?source=see_link\">",
"     \"Diagnostic imaging of joint pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25210?source=see_link\">",
"     \"Radiologic evaluation of the painful hip in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF IMAGING STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The modalities available for evaluation of the hip include plain film radiography, computed tomography (CT), magnetic resonance (MR) imaging, radionuclide bone scan, ultrasonography, conventional arthrography, MR arthrography, and CT arthrography (",
"    <a class=\"graphic graphic_table graphicRef74003 \" href=\"UTD.htm?0/53/861\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <strong>",
"     Plain film radiography",
"    </strong>",
"    &ndash; Plain film radiography is used in the initial evaluation of any cause of hip pain or limp. Because the appearance of a child's hips varies with age, strong consideration should be given to ordering antero-posterior (AP) and lateral views of both hips rather than views of a single hip [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/1\">",
"     1",
"    </a>",
"    ]. This allows easy comparison with a \"control\" hip in children with unilateral problems.",
"   </p>",
"   <p>",
"    <strong>",
"     Computed tomography",
"    </strong>",
"    &ndash; In children, computed tomography (CT) may be indicated in the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preoperative assessment and postoperative follow up of developmental dysplasia of the hip",
"     </li>",
"     <li>",
"      Pretreatment evaluation of Legg-Calv&eacute;-Perthes disease",
"     </li>",
"     <li>",
"      Pretreatment evaluation of slipped capital femoral epiphysis",
"     </li>",
"     <li>",
"      Evaluation of tumor matrix and cortical invasion",
"     </li>",
"     <li>",
"      Guidance for biopsy or ablation of certain tumors such as osteoid osteoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Magnetic resonance imaging",
"    </strong>",
"    &ndash; Magnetic resonance imaging (MRI) accurately evaluates the bone marrow, articular and physeal cartilage, subchondral bone, periosteum, synovium, neurovascular structures, and soft tissues. In children, MRI may be indicated in the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Assessment and follow-up of complicated developmental dysplasia of the hip",
"     </li>",
"     <li>",
"      Diagnosis of proximal femoral focal deficiency",
"     </li>",
"     <li>",
"      Preoperative planning of developmental coxa vara",
"     </li>",
"     <li>",
"      Early diagnosis, staging and evaluation of complications of Legg-Calv&eacute;-Perthes disease",
"     </li>",
"     <li>",
"      Early diagnosis of slipped capital femoral epiphysis",
"     </li>",
"     <li>",
"      Early diagnosis of osteomyelitis and exclusion of osteomyelitis in children with septic arthritis",
"     </li>",
"     <li>",
"      Diagnosis of occult traumatic injuries, including soft tissue injuries",
"     </li>",
"     <li>",
"      Early diagnosis of arthritis",
"     </li>",
"     <li>",
"      Tumor staging",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Administration of gadolinium-containing MRI contrast agents should be avoided in patients with severely impaired renal function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Radionuclide bone scan &ndash;",
"    </strong>",
"    Radionuclide bone scan surveys a large area; however, it is often nonspecific. In children, radionuclide bone scan may be useful in the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Early evaluation of osteomyelitis",
"     </li>",
"     <li>",
"      Detection of metastatic disease",
"     </li>",
"     <li>",
"      Early detection of Legg-Calv&eacute;-Perthes disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Ultrasonography",
"    </strong>",
"    &ndash; Ultrasonography (US) has low cost, is readily available, allows dynamic evaluation of the tendons and muscles, and does not involve ionizing radiation; however, it is highly operator dependent. In children, US may be useful in the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diagnosis and follow-up of developmental dysplasia of the hip",
"     </li>",
"     <li>",
"      Diagnosis of hip effusions due to transient synovitis and septic arthritis",
"     </li>",
"     <li>",
"      Detection of bursal or periarticular fluid collections, which may be seen in bursitis, arthritis and infection.",
"     </li>",
"     <li>",
"      Dynamic evaluation of the snapping iliopsoas syndrome",
"     </li>",
"     <li>",
"      Guidance of hip aspiration and injection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Conventional arthrography",
"    </strong>",
"    &ndash; The imaging indications for conventional hip arthrography are limited due to the increased use of magnetic resonance arthrography (MR arthrography), which visualizes joint anatomy as well as bone and surrounding soft tissues. In children, hip arthrography is occasionally used in the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preoperatively and intraoperatively in the treatment of developmental dysplasia of the hip",
"     </li>",
"     <li>",
"      Preoperatively in Legg-Calv&eacute;-Perthes disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     MR arthrography",
"    </strong>",
"    &ndash; MR arthrography with intraarticular gadolinium administration best delineates the joint anatomy, including the acetabular labrum and articular cartilage. MR arthrography is used in cases of hip pain that may involve any of the above-mentioned structures. In children, MR arthrography is indicated mainly in the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Legg-Calv&eacute;-Perthes disease",
"     </li>",
"     <li>",
"      Diagnosis of labral tears",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Administration of gadolinium-containing MRI contrast agents should be avoided in patients with impaired renal function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     CT arthrography",
"    </strong>",
"    &ndash; CT arthrography with intraarticular iodinated contrast is used in cases where MR arthrography is contraindicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     IMAGING STUDIES FOR SPECIFIC CLINICAL SETTINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age of the child generally directs the investigation toward the most likely hip pathology, as outlined below. However, juvenile idiopathic arthritis and bone tumors may occur at any age. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developmental dysplasia of the hip and proximal femoral focal deficiency are the most common pathologic disorders affecting infants. Septic arthritis and osteomyelitis also may occur in infants, but are more common in toddlers and young children. They are discussed below. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Septic arthritis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'Osteomyelitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Developmental dysplasia of the hip",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developmental dysplasia of the hip (DDH) is a relatively common condition that is more prevalent in girls, following breech deliveries or oligohydramnios, in Caucasians, and in the presence of a positive family history. DDH is defined as abnormal position of the femoral head relative to the acetabulum, which results in abnormal growth of both components of the hip. Most cases are detected in the first year of life, but DDH may present later, particularly in children with bilateral disease and no asymmetry on physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Static and dynamic ultrasonography is the imaging modality of choice for diagnosis in neonates and infants up to the age of four months. Plain film radiography is recommended for older infants and children. Characteristic imaging features include abnormal position or shape of the femoral head and delayed ossification of the femoral head. Computed tomography (CT) scanning may be used for preoperative planning, conventional contrast arthrography for intraoperative evaluation, and MRI for postoperative follow-up. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/199?source=see_link\">",
"     \"Epidemiology and pathogenesis of developmental dysplasia of the hip\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27113?source=see_link\">",
"     \"Clinical features and diagnosis of developmental dysplasia of the hip\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21254?source=see_link\">",
"     \"Treatment and outcome of developmental dysplasia of the hip\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ultrasonography &ndash; Ultrasonography (US) is used in the evaluation of the femoral head, which is not ossified and not visible on plain radiographs in the first four months of life. US is the technique of choice for evaluating high-risk infants, patients with equivocal clinical findings, and for monitoring treatment. Due to normal instability of the hip in the first days of life, US should be performed after the first week in patients with clinical suspicion of DDH [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/3\">",
"       3",
"      </a>",
"      ]. In high-risk patients with negative clinical examination, a screening US should be performed at six weeks of age, as hip laxity and mild acetabular dysplasia may resolve spontaneously by four to six weeks of life. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27113?source=see_link&amp;anchor=H23#H23\">",
"       \"Clinical features and diagnosis of developmental dysplasia of the hip\", section on 'Infants with risk factors'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      US is able to directly visualize the cartilaginous components of the hip, determine the position and coverage of the femoral head, depth and morphology of the acetabulum, and evaluate dynamic instability. The main finding is superolateral displacement of the femur from the acetabulum [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/4\">",
"       4",
"      </a>",
"      ]. Diagnosis of DDH on US is made by measuring the alpha angle, formed by the acetabular roof and the vertical cortex of the ilium (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56328 \" href=\"UTD.htm?25/48/26374\">",
"       image 1",
"      </a>",
"      ). The degree of instability can range from mild laxity to subluxation and dislocation of the hip. When instability is present, US determines the reducibility of the femoral head, which is important for management. US also demonstrates the cause of obstruction to hip reduction, such as inverted labrum and soft tissue in the acetabulum.",
"      <br/>",
"      <br/>",
"      US is important in follow-up of patients treated with a Pavlik harness, to demonstrate improvement in the position of the femoral head and the acetabular angle, usually seen after three weeks of treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21254?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment and outcome of developmental dysplasia of the hip\", section on 'Abduction splints'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Plain film radiography &ndash; Plain film radiography is indicated for diagnosis of DDH in patients four months or older (when the ossified femoral head can be visualized) and in follow-up of infants treated for DDH in this age group (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79994 \" href=\"UTD.htm?26/39/27251\">",
"       image 2",
"      </a>",
"      ). The characteristic diagnostic feature is superolateral displacement of the femur from the acetabulum. Other findings are asymmetry of the femoral head ossification center in unilateral cases and delayed ossification of the femoral head.",
"     </li>",
"     <li>",
"      CT &ndash; CT is valuable in the preoperative assessment and postoperative follow-up of DDH. Pediatric protocols that involve reduced doses of radiation should be used. Three-dimensional CT images are particularly useful in the preoperative planning of complex cases and improve the ability to match the proper osteotomy with the specific acetabular deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/5\">",
"       5",
"      </a>",
"      ]. Postreduction CT offers precise information regarding the position and coverage of the femoral head within the acetabulum in the cast and confirms successful reduction. Postreduction CT also has predictive value for development of avascular necrosis by measuring the abduction angle of the hip.",
"     </li>",
"     <li>",
"      Conventional arthrography &ndash; Conventional arthrography is used as a guide intraoperatively to confirm the position of the femoral head and to visualize structures which may block the reduction of the hip.",
"     </li>",
"     <li>",
"      MRI &ndash; MRI is most useful in the preoperative assessment of complicated DDH and in the evaluation of postsurgical reduction and long-term sequelae of partially treated or untreated DDH. Contrast-enhanced MRI shows the position and shape of the cartilaginous femoral head and obstacles to reduction, as well as changes of the acetabulum not demonstrated by ultrasonography (US) or radiography. MRI also gives information about the acetabular labrum, which is important in the preoperative planning. MRI assesses the vascularity of the cartilaginous femoral head and can detect ischemia. Global decrease in perfusion of the femoral head is associated with significantly increased likelihood of avascular necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/6\">",
"       6",
"      </a>",
"      ]. If ossification of the femoral head does not occur by one year of age, avascular necrosis is believed to be present [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H474001009\">",
"    <span class=\"h3\">",
"     Proximal femoral focal deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal femoral focal deficiency (PFFD) is an uncommon congenital condition manifested by hypoplasia of part or all of the proximal femur. PFFD encompasses a spectrum from hypoplasia of the femoral head to congenital absence of all but the distal femoral epiphysis. PFFD is unilateral in 90 percent of cases. PFFD presents in infancy with limb shortening.",
"   </p>",
"   <p>",
"    Plain film radiography demonstrates a short femur with dysmorphic or absent head and neck. There is delayed appearance or non-appearance of the femoral capital ossification center. MRI enables early identification of an incompletely ossified femoral head and whether the intervening segment of femur is absent. MRI shows the cartilage structure of acetabulum and upper femur, therefore assisting in prognosis and treatment planning [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/8\">",
"     8",
"    </a>",
"    ]. MRI is the most accurate modality for determination of the type and prognosis of PFFD, including prediction of leg length discrepancy at maturity, hip joint integrity, and stability of the femoral segment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Toddlers and children up to 10 years of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of hip pain in toddlers and children younger than 10 years of age include transient synovitis, septic arthritis, osteomyelitis, developmental coxa vara, and Legg-Calv&eacute;-Perthes disease. Neuromuscular hip dysplasia may become apparent in toddlers and children younger than 10 years but is usually asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Acute transient synovitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute transient synovitis is a relatively common disorder seen in children 2 to 10 years of age, more commonly in boys, characterized by pain and limitation of motion in the hip, arising without a clear precipitant, and resolving gradually with conservative therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of hip pain in childhood\", section on 'Transient synovitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plain film radiography is used primarily to exclude other disorders involving the bone, while ultrasonography can both detect an effusion and be used to guide joint aspiration. Joint aspiration is the gold standard in differentiating toxic synovitis from septic arthritis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &ndash; Plain film radiography is indicated to exclude osseous abnormalities. Plain film radiography may be normal or may indicate a joint effusion.",
"     </li>",
"     <li>",
"      US &ndash; US is very sensitive for the diagnosis of joint effusion. Some clinicians use ultrasound-guided arthrocentesis therapeutically to reduce the risk of subsequent avascular necrosis.",
"     </li>",
"     <li>",
"      MRI &ndash; MRI demonstrates joint effusion and synovial inflammation and enhancement with intravenous gadolinium administration. MRI findings are nonspecific and do not distinguish between toxic synovitis and septic arthritis in all cases. The presence of bone marrow edema favors septic arthritis, however this finding is not always seen. Decreased perfusion of the femoral epiphysis on contrast-enhanced MRI is seen more often in septic arthritis than in transient synovitis and is valuable in differential diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/11\">",
"       11",
"      </a>",
"      ]. Administration of gadolinium-containing MRI contrast agents should be avoided in patients with severely impaired renal function (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"       \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Septic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septic arthritis in children usually is monoarticular; the hip is the most commonly affected joint. Septic arthritis of the hip is an emergency, as destruction of the femoral head can ensue quickly if treatment is not promptly initiated.",
"   </p>",
"   <p>",
"    Plain film radiography may detect a large effusion, but primarily serves to exclude bone involvement. Ultrasonography may aid both in detection of an effusion and guiding needle aspiration. Joint aspiration is the gold standard in differentiating toxic synovitis from septic arthritis. Arthrocentesis is required for definitive diagnosis. It is also required for joint decompression as joint effusion is a risk factor for avascular necrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=see_link\">",
"     \"Bacterial arthritis: Clinical features and diagnosis in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &ndash; Plain film radiography may demonstrate joint effusion (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81582 \" href=\"UTD.htm?21/53/22352\">",
"       image 3",
"      </a>",
"      ) and soft tissue swelling in the early stage, and cortical destruction, periosteal reaction, and subluxation in advanced cases.",
"     </li>",
"     <li>",
"      US &ndash; US may be used to detect joint effusion and guide aspiration; absence of fluid excludes septic arthritis and eliminates the need for joint aspiration. In patients with signs of sepsis, a sterile effusion may be secondary to osteomyelitis, and a bone scan or MRI must be considered as additional modalities.",
"     </li>",
"     <li>",
"      MRI &ndash; MRI demonstrates joint effusion and synovial inflammation and enhancement with intravenous gadolinium administration (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69485 \" href=\"UTD.htm?10/31/10738\">",
"       image 4",
"      </a>",
"      ). MRI findings are nonspecific and do not distinguish between toxic synovitis and septic arthritis in all cases. The presence of bone marrow edema favors septic arthritis; however this finding is not always seen. Decreased perfusion of the femoral epiphysis on contrast-enhanced MRI is seen more often in septic arthritis than in transient synovitis and is valuable in differential diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/11\">",
"       11",
"      </a>",
"      ]. Bone marrow edema is limited to the periarticular subchondral bone in septic arthritis; more extensive changes raise the suspicion of osteomyelitis.",
"      <br/>",
"      <br/>",
"      Administration of gadolinium-containing MRI contrast agents should be avoided in patients with severely impaired renal function (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"       \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Osteomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute osteomyelitis can occur at any age and is usually caused by hematogenous spread of infection. Osteomyelitis of the hip is uncommon, but can present with hip pain secondary to involvement of the epiphysis. In infants and children younger than 18 months, the epiphysis may be involved secondary to spread of infection from the adjacent metaphysis. In older children, epiphyseal involvement from a septic joint can occur, but is uncommon. Osteomyelitis in the pelvic bones also may cause referred pain in the hip. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=see_link\">",
"     \"Clinical features of hematogenous osteomyelitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation of osteomyelitis is performed with plain radiographs, bone scintigraphy, and MRI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation and diagnosis of hematogenous osteomyelitis in children\", section on 'Imaging'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiographs &ndash; Plain film radiographs are usually normal in the early stage. In advanced cases, bone destruction and joint effusion are demonstrated.",
"     </li>",
"     <li>",
"      MRI &ndash; MRI is indicated when the symptoms are localized to the pelvis and the plain radiographs are normal. MRI demonstrates bone marrow edema and joint effusion.",
"     </li>",
"     <li>",
"      Radionuclide scan &ndash; Bone scintigraphy is used in children with suspected osteomyelitis and normal radiographs. Bone scintigraphy is most useful when symptoms are poorly localized (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61164 \" href=\"UTD.htm?6/45/6879\">",
"       image 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Developmental coxa vara",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coxa vara is defined as an angle of less than 120 degrees between the femoral neck and shaft (",
"    <a class=\"graphic graphic_figure graphicRef59633 \" href=\"UTD.htm?33/2/33828\">",
"     figure 1",
"    </a>",
"    ). Normal femoral neck-shaft angle decreases from 150 degrees in infants to 120 degrees in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/12\">",
"     12",
"    </a>",
"    ]. Coxa vara deformity may be functional (which has a normal femoral neck-shaft angle and is secondary to prior infection, avascular necrosis, or trauma) or true coxa vara. True coxa vara may be secondary to congenital abnormalities or developmental. Developmental coxa vara usually presents at two years of age with an abnormal gait. It is bilateral in 40 percent of cases.",
"   </p>",
"   <p>",
"    Plain film radiography and MRI are the modalities of choice for evaluating coxa vara deformity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &ndash; Radiographic findings in coxa vara include decreased femoral neck-shaft angle, vertical orientation, and widening of the physis with small corner fractures along the medial aspect. In developmental coxa vara, a triangular ossification is seen in the inferomedial femoral neck; secondary changes occur in the femoral head and acetabulum.",
"     </li>",
"     <li>",
"      MRI &ndash; MRI is used in preoperative planning to demonstrate the relationship of the acetabulum, femoral head, neck, and shaft, and to differentiate between cartilaginous and bony components. MRI demonstrates widening of the physis and expansion of the cartilage [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Legg-Calv&eacute;-Perthes disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Legg-Calv&eacute;-Perthes disease is a syndrome of idiopathic avascular necrosis of the femoral epiphysis, possibly due to repeated multiple vascular occlusive episodes that involve the femoral head. It typically presents as hip pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    limp of acute or insidious onset, most commonly in Caucasian boys between the ages of 3 and 12 years, with peak incidence at five to seven years of age. Legg-Calv&eacute;-Perthes is bilateral in 15 percent of patients. The outcome depends upon the age at onset and the extent of femoral head involvement on radiographs. Younger children (&lt;6 years old) have a greater capacity for the acetabulum to remodel to accommodate irregularities in the shape of the femoral head. Onset in children older than eight years and nonspherical femoral head at skeletal maturity are associated with higher incidence of osteoarthritis in adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/12\">",
"     12",
"    </a>",
"    ]. It is estimated that approximately 60 to 70 percent of hips affected heal spontaneously without functional impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of hip pain in childhood\", section on 'Legg-Calv&eacute;-Perthes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Legg-Calv&eacute;-Perthes disease is a diagnosis of exclusion, and other causes of osteonecrosis in children such as trauma; systemic diseases such as leukemia, lymphoma, and systemic lupus erythematosus; hemoglobinopathies; coagulopathies; steroid treatment; epiphyseal dysplasia; and Gaucher&rsquo;s disease must be ruled out [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/13\">",
"     13",
"    </a>",
"    ]. These may present with similar imaging features [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plain film radiography may be normal in early disease, and in such cases, a more sensitive imaging modality, typically MRI where available, or radionuclide bone scanning if MRI is unavailable or contraindicated, is used to detect early osteonecrosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &ndash; Plain film radiography is the mainstay of diagnosis, classification, and follow-up of the disease. The degree of involvement and the shape of the femoral head on the plain film have prognostic value for outcome. Legg-Calv&eacute;-Perthes disease can be radiographically silent during the first three to six months [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/15\">",
"       15",
"      </a>",
"      ]. Early radiographic changes in Legg-Calv&eacute;-Perthes include apparent joint space widening and a subchondral fracture (rope sign). The classic findings of later Legg-Calv&eacute;-Perthes are sclerosis, fragmentation, and subchondral collapse of the ossification center of the femoral head (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52637 \" href=\"UTD.htm?10/43/10943\">",
"       image 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Radionuclide bone scan &ndash; Bone scintigraphy is helpful in the early stages if the plain films are normal. Scintigraphic changes precede radiographic findings by an average of three months. A focal area of decreased uptake is seen in the femoral head, the size of which correlates with the amount of involvement. Increased activity may be seen in the capsule due to synovial inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MRI &ndash; MRI is useful in the diagnosis, staging, and evaluation of complications of Legg-Calv&eacute;-Perthes disease. MRI is more sensitive than radiography for diagnosis (due to early detection of bone marrow edema), for detection of subluxation of the femoral head, and for assessment of femoral head containment [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/12\">",
"       12",
"      </a>",
"      ]. MRI is used to calculate percentage of femoral head involvement, and to predict risk of future collapse [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/13\">",
"       13",
"      </a>",
"      ]. MRI demonstrates the extent of healing of the femoral head, and is recommended for follow up in conjunction with plain radiographs [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/15\">",
"       15",
"      </a>",
"      ]. MRI is able to identify children at risk for early disability due to physeal abnormalities, which may lead to growth arrest [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Contrast-enhanced MRI &ndash; Contrast-enhanced MRI depicts different abnormalities associated with the two phases of Legg-Calv&eacute;-Perthes disease, the avascular phase, and the revascularization and reparative phase. In the avascular phase, absence of bone marrow enhancement in dynamic postcontrast MRI confirms the diagnosis and evaluates the extent of involvement (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63334 \" href=\"UTD.htm?34/51/35632\">",
"       image 7",
"      </a>",
"      ). Other MRI findings of the avascular phase include abnormal signal in the capital femoral epiphysis, metaphysis and, occasionally, the physis, along with thickening of the articular cartilage and synovial proliferation. During the revascularization and reparative phase, the epiphysis may show hyperenhancement. Other findings include articular surface flattening (coxa plana), fragmentation, subluxation, and loss of containment.",
"     </li>",
"     <li>",
"      MR arthrography &ndash; MR arthrography after intraarticular administration of gadolinium may be beneficial for assessment of complications, and allows detailed evaluation of articular cartilage, labrum, and femoral head-acetabular congruency [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/13\">",
"       13",
"      </a>",
"      ]. MRI is comparable to arthrography for demonstrating containment and congruency of the articular surfaces of the hip [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/15\">",
"       15",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Administration of gadolinium-containing MRI contrast agents should be avoided in patients with severely impaired renal function. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"       \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"      </a>",
"      .).",
"     </li>",
"     <li>",
"      CT &ndash; CT allows early diagnosis of bone collapse and three-dimensional reformatted images provide information about the anatomical relationship between femoral head and acetabulum and femoral head deformity. However, the use of CT is limited because of the high radiation dose [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      US &ndash; US can be used as an adjunct to other imaging modalities. Persistent hip effusion should raise the suspicion for early Legg-Calv&eacute;-Perthes disease. Thickening of the synovium and of the articular cartilage of the femoral head and flattening and fragmentation of the femoral head have been described [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Conventional arthrography &ndash; Dynamic arthrography under direct fluoroscopic observation is used in advanced disease to assess whether femoral head containment is possible and to select the best surgical option [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Neuromuscular hip dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who do not walk before the age of five due to cerebral palsy or other neuromuscular disease have a 58 percent prevalence of hip dislocations, which are bilateral in 44 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/16\">",
"     16",
"    </a>",
"    ]; plain film radiography reveals characteristic deformities of the femoral head and the acetabulum. Lack of weight bearing produces a coxa valga deformity. CT scanning may be used for preoperative planning.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &ndash; Simulated standing radiographs demonstrate the valgus deformity, abnormal shape and location of the femoral head, and dysplastic changes in the acetabulum [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CT &ndash; CT is helpful preoperatively to evaluate the shape of the acetabulum and determine femoral anteversion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Children older than 10 years and adolescents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Slipped capital femoral epiphysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slipped capital femoral epiphysis (SCFE) is characterized by displacement of the capital femoral epiphysis from the femoral neck along the plane of the physeal plate. It is one of the most common hip disorders of adolescence and is more frequent in African-American and overweight children. SCFE is caused by the repetitive stress of weight-bearing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=see_link\">",
"     \"Slipped capital femoral epiphysis (SCFE)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SCFE is bilateral at presentation in 10 to 20 percent of the cases, however the opposite side may also become involved later, usually within 24 months of the initial occurrence. SCFE is classified as stable or unstable slip depending on the stability of the physis; the majority of SCFE cases are stable. Complications of SCFE are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=see_link&amp;anchor=H20#H20\">",
"     \"Slipped capital femoral epiphysis (SCFE)\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film &ndash; Plain film radiography is the primary method for the diagnosis of SCFE. The lateral radiograph is more sensitive than the anteroposterior view for detection of mild displacement, therefore a frog-leg or a cross-table lateral view should always be performed. Some authors recommend replacing the frog-leg lateral view with a cross-table lateral view in an acute SCFE, as the frog-leg lateral view may accentuate the displacement. In undisplaced SCFE (also known as pre-slip), anteroposterior and lateral radiographs show widening and irregularity of the capital femoral physis, osteopenia, and increased density of the metaphysis due to healing response. In displaced SCFE (the majority of cases), the capital femoral epiphysis slips posteriorly and medially relative to the femoral metaphysis. Medial displacement is seen on the anteroposterior radiograph, however this finding may be difficult to appreciate in subtle cases. Posterior displacement is appreciated on the frog-leg or cross-table lateral view, which is more sensitive than the anteroposterior radiograph for subtle cases (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59157 \" href=\"UTD.htm?18/50/19235\">",
"       image 8",
"      </a>",
"      ). Radiography is used for staging of the severity of slip [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CT &ndash; CT is useful for treatment planning in advanced stages of SCFE, by demonstrating physeal closure, precluding the need for fixation. CT may also be used postoperatively to determine if the hardware has penetrated the joint surface [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MRI &ndash; MRI is more sensitive than radiography for early diagnosis of SCFE, demonstrating the physeal widening before it is apparent on radiographs. Bone marrow edema and synovitis are inconstant features. [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/4\">",
"       4",
"      </a>",
"      ]. MRI is also used for early detection of avascular necrosis, a common complication of unstable SCFE. Preliminary studies show that contrast-enhanced MRI allows for accurate evaluation of the femoral head vascularization before and after surgical pinning [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H477156315\">",
"    <span class=\"h3\">",
"     Injuries about the hip in adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hip pain in adolescents, particularly physically active, may result from both intra-articular and extra-articular disorders. Extra-articular causes of hip pain include pelvic apophyseal injuries, iliopsoas tendinosis and bursitis, snapping hip syndrome, athletic pubalgia, and stress fractures. Intra-articular causes of hip pain include acetabular labral tears and femoroacetabular impingement [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h4\">",
"     Pelvic apophyseal avulsions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic apophyseal avulsions are sports injuries that occur in adolescents during forceful or repetitive traction from the attached muscles. Before ossification, the apophyseal growth cartilage is the weakest point in the musculotendinous unit, making the apophysis vulnerable to injury (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62834 \" href=\"UTD.htm?39/46/40672\">",
"     image 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/9\">",
"     9",
"    </a>",
"    ]. The apophyses involved are the iliac crest, anterior superior iliac spine (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50052 \" href=\"UTD.htm?1/43/1712\">",
"     image 10",
"    </a>",
"    ), anterior inferior iliac spine, ischial tuberosity, and the greater and lesser trochanters. The most commonly involved apophysis is the ischial tuberosity, followed by anterior inferior iliac spine and anterior superior iliac spine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evaluation is done with plain film radiography and MRI.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &ndash; Plain film radiography demonstrates displacement of the apophyseal center from its normal position, callus formation, and bony reaction.",
"     </li>",
"     <li>",
"      MRI &ndash; MRI is useful in suspected avulsion injuries with negative radiographs [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/21\">",
"       21",
"      </a>",
"      ]. Bone marrow edema and soft tissue injuries such as tendon tear can be seen by MRI at the site of avulsion. Chronic microtrauma to the physis may result in physeal widening, which is difficult to see on radiographs and is diagnosed by MRI. In difficult cases, MRI is valuable in differentiating avulsion from neoplasm. MRI also detects other sites of pelvic injuries, including ilium adjacent to the sacroiliac joint and the pubic ramus, which may not be seen on radiographs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H477156343\">",
"    <span class=\"h4\">",
"     Iliopsoas tendinosis and bursitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iliopsoas tendinosis may be associated with trauma, overuse injury, or arthritis. It is often seen in kicking-related sports. Due to their proximity, inflammatory processes frequently involve the iliopsoas tendon together with the bursa. MRI shows thickening and increased signal within the tendon, with increased synovial fluid or hypertrophy of the bursa, which is located anterior to the hip joint (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79821 \" href=\"UTD.htm?36/15/37110\">",
"     image 11",
"    </a>",
"    ). Ultrasound can show an enlarged bursa, and can guide bursal aspiration and anesthetic-corticosteroid injection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H477156351\">",
"    <span class=\"h4\">",
"     Snapping hip syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The snapping iliopsoas tendon is seen in young athletes who use a wide range of hip motion for activities such as ballet or karate. The &ldquo;snap&rdquo; results from catching of the posterior iliotibial band or anterior portion of the gluteus maximus muscle over the greater trochanter (&ldquo;external snapping hip&rdquo;); from intra-articular lesions such as labral tear or loose body; or from the iliopsoas tendon moving over the lesser trochanter (&ldquo;internal snapping hip&rdquo;). Dynamic sonography can be used to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/19,22\">",
"     19,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=see_link&amp;anchor=H2791029#H2791029\">",
"     \"Overview of running injuries of the lower extremity\", section on 'Labral tear'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=see_link&amp;anchor=H2791036#H2791036\">",
"     \"Overview of running injuries of the lower extremity\", section on 'Iliopsoas tendinopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H477156359\">",
"    <span class=\"h4\">",
"     Athletic pubalgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Athletic pubalgia refers to a group of musculoskeletal processes that occur in and about the pubic symphysis. MRI is the study of choice to evaluate this condition. Numerous muscles attach to the parasymphyseal pubic bone, including anterior abdominal wall muscles and adductor muscles of the thigh. The most frequent pattern identified on MRI is injury to the insertion of the rectus abdominis muscle with or without adductor tendon injury. Another cause of pubalgia is osteitis pubis, which is thought to result from chronic repetitive trauma, as occurs in long distance runners. On radiography, there is sclerosis of the pubic symphysis with symmetric distribution. MRI shows intense edema across the pubic body. Stress fractures of the pubis can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20373?source=see_link\">",
"     \"Sports-related groin pain or 'sports hernia'\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/14/39142?source=see_link\">",
"     \"Osteitis pubis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H477156367\">",
"    <span class=\"h4\">",
"     Stress fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress fractures of the femur are uncommon in children and adolescents, mainly occurring in athletes who engage in repetitive loading of the lower extremities, such as runners. Plain film radiographs detect chronic stress reaction. Plain films may be normal in the early stage. MRI and radionuclide bone scan are sensitive for early detection of stress fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H477156375\">",
"    <span class=\"h4\">",
"     Acetabular labral tear",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acetabular labrum is a dense fibrocartilaginous ring which is attached to the margin of the acetabulum, increasing the depth and stability of the joint. The labrum is poorly vascularized, especially the anterior-superior portion, where most labral tears occur. Acetabular labral tears account for up to 20 percent of hip pain presentations in athletic adolescents. Sport activities that involve pivoting or twisting of the hip can result in injury to the labrum. Other causes of labral tears include developmental dysplasia of the hip and femoroacetabular impingement. Labral tears predispose to early osteoarthritis. Direct MR arthrography with intra-articular injection of contrast is the procedure of choice for diagnosing labral tears, as well as any associated articular cartilage thinning [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H477156383\">",
"    <span class=\"h4\">",
"     Femoroacetabular impingement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Femoroacetabular impingement (FAI) results from abnormal contour of the proximal femur and acetabulum, resulting in abnormal contact, which increases with motion. FAI leads to labral cartilage injury, pain, and osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/23\">",
"     23",
"    </a>",
"    ]. Athletes who perform motions of extreme hip flexion and rotation, such as dancers, are at increased risk for FAI. Other predisposing disorders include developmental dysplasia of the hip, slipped capital femoral epiphysis and Legg-Calv&eacute;-Perthes disease. Plain film radiographs are the first imaging modality in the diagnosis of FAI. Two distinct forms of FAI have been described, cam-type and pincer type. Plain film radiographs of the cam-type FAI demonstrates a non-spherical femoral head or lack of femoral head-neck offset. The pincer type of FAI shows signs resulting from acetabular overcoverage. MRI helps diagnose the type of FAI and respective abnormalities of the femoral head, neck, and acetabulum, and shows associated chondral and labral injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H477156669\">",
"    <span class=\"h3\">",
"     Idiopathic chondrolysis of the hip",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic chondrolysis of the hip is a disorder characterized by extensive loss of articular cartilage of the proximal femoral epiphysis and acetabulum, with resultant joint space narrowing and restriction of motion. It can be seen in association with slipped capital femoral epiphysis (SCFE), trauma, infection, arthritis and immobilization. Girls are affected more than boys and the symptoms are often unilateral. Patients present with a painful, stiff hip.",
"   </p>",
"   <p>",
"    Plain film radiographic abnormalities appear several weeks to months after onset of symptoms. Findings on radiography are joint space narrowing and osteopenia, leading to protrusion acetabuli and premature physeal fusion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62259 \" href=\"UTD.htm?11/49/12049\">",
"     image 12",
"    </a>",
"    ). MRI is more sensitive for early detection of the disease, and shows cartilage loss, geometric abnormal signal in the proximal femoral epiphysis (which may be associated with pin penetration into the joint following repair of SCFE), acetabular bone marrow edema, synovial hypertrophy and enhancement, and minimal joint fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/14,24\">",
"     14,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26823812\">",
"    <span class=\"h2\">",
"     Children of any age",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H477156583\">",
"    <span class=\"h3\">",
"     Juvenile idiopathic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Juvenile idiopathic arthritis is the most common cause of chronic arthritis in childhood. Juvenile idiopathic arthritis (formerly known as juvenile chronic arthritis or juvenile rheumatoid arthritis) comprises a clinically heterogeneous group of arthritides that begin before the age of 16 years and persist for more than six weeks. Clinical features and imaging of JIA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35717?source=see_link\">",
"     \"Classification of juvenile arthritis (JRA/JIA)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=see_link\">",
"     \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=see_link\">",
"     \"Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=see_link\">",
"     \"Pauciarticular onset juvenile idiopathic arthritis\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H477156426\">",
"    <span class=\"h3\">",
"     Tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone tumors and tumor-like lesions of the hip in children are rare. Signs and symptoms are nonspecific, often leading to a delay in diagnosis. In a large retrospective study of tumors and tumor-like lesions of the hip, tumor-like lesions accounted for 43 percent of cases, most commonly simple bone cyst (30 percent of cases), followed by eosinophilic granuloma and aneurysmal bone cyst [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/25\">",
"     25",
"    </a>",
"    ]. In the same study, benign tumors of the hip comprised 45 percent of cases, most commonly osteoid osteoma (30 percent of cases), followed by fibrous dysplasia and exostosis. Malignant tumors made up only 12 percent of cases, including Ewing sarcoma and osteosarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25097/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benign and malignant bone tumors and tumor-like lesions in children and adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link\">",
"     \"Overview of benign bone tumors in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=see_link\">",
"     \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=see_link\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H477156469\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The modalities available for evaluation of the hip include plain film radiography, computed tomography (CT), magnetic resonance (MR) imaging, radionuclide bone scan, ultrasonography, conventional arthrography, MR arthrography, and CT arthrography (",
"      <a class=\"graphic graphic_table graphicRef74003 \" href=\"UTD.htm?0/53/861\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Imaging studies for specific clinical settings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of the various imaging modalities in the evaluation and management of specific hip conditions in infants and children is summarized in the tables (",
"      <a class=\"graphic graphic_table graphicRef53048 graphicRef64344 graphicRef72030 \" href=\"UTD.htm?19/30/19951\">",
"       table 2A-C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/1\">",
"      Gough-Palmer A, McHugh K. Investigating hip pain in a well child. BMJ 2007; 334:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/2\">",
"      Aronsson DD, Goldberg MJ, Kling TF Jr, Roy DR. Developmental dysplasia of the hip. Pediatrics 1994; 94:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/3\">",
"      Harcke HT, Grissom LE. Pediatric hip sonography. Diagnosis and differential diagnosis. Radiol Clin North Am 1999; 37:787.",
"     </a>",
"    </li>",
"    <li>",
"     Donnelly LF. Section 6: Musculoskeletal. In: Diagnostic Imaging: Pediatrics, 1st ed, Amirsys, Salt Lake City, UT 2005. p.98.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/5\">",
"      Murray KA, Crim JR. Radiographic imaging for treatment and follow-up of developmental dysplasia of the hip. Semin Ultrasound CT MR 2001; 22:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/6\">",
"      Tiderius C, Jaramillo D, Connolly S, et al. Post-closed reduction perfusion magnetic resonance imaging as a predictor of avascular necrosis in developmental hip dysplasia: a preliminary report. J Pediatr Orthop 2009; 29:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/7\">",
"      Jaramillo D, Villegas-Medina O, Laor T, et al. Gadolinium-enhanced MR imaging of pediatric patients after reduction of dysplastic hips: assessment of femoral head position, factors impeding reduction, and femoral head ischemia. AJR Am J Roentgenol 1998; 170:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/8\">",
"      Biko DM, Davidson R, Pena A, Jaramillo D. Proximal focal femoral deficiency: evaluation by MR imaging. Pediatr Radiol 2012; 42:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/9\">",
"      Dillon JE, Connolly SA, Connolly LP, et al. MR imaging of congenital/developmental and acquired disorders of the pediatric hip and pelvis. Magn Reson Imaging Clin N Am 2005; 13:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/10\">",
"      Carpineta L, Faingold R, Albuquerque PA, Morales Ramos DA. Magnetic resonance imaging of pelvis and hips in infants, children, and adolescents: a pictorial review. Curr Probl Diagn Radiol 2007; 36:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/11\">",
"      Kwack KS, Cho JH, Lee JH, et al. Septic arthritis versus transient synovitis of the hip: gadolinium-enhanced MRI finding of decreased perfusion at the femoral epiphysis. AJR Am J Roentgenol 2007; 189:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/12\">",
"      Hubbard AM. Imaging of pediatric hip disorders. Radiol Clin North Am 2001; 39:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/13\">",
"      Dillman JR, Hernandez RJ. MRI of Legg-Calve-Perthes disease. AJR Am J Roentgenol 2009; 193:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/14\">",
"      Houghton KM. Review for the generalist: evaluation of pediatric hip pain. Pediatr Rheumatol Online J 2009; 7:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/15\">",
"      Dimeglio A, Canavese F. Imaging in Legg-Calv&eacute;-Perthes disease. Orthop Clin North Am 2011; 42:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/16\">",
"      Scrutton D, Baird G. Surveillance measures of the hips of children with bilateral cerebral palsy. Arch Dis Child 1997; 76:381.",
"     </a>",
"    </li>",
"    <li>",
"     Kay RM. Slipped Capital Femoral Epiphysis. In: Lovell and Winter's Pediatric Orthopaedics, 6th ed, Morrissy RT, Weinstein SL.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1085.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/18\">",
"      Staatz G, Honnef D, Kochs A, et al. Evaluation of femoral head vascularization in slipped capital femoral epiphysis before and after cannulated screw fixation with use of contrast-enhanced MRI: initial results. Eur Radiol 2007; 17:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/19\">",
"      Laor T. Hip and groin pain in adolescents. Pediatr Radiol 2010; 40:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/20\">",
"      Kovacevic D, Mariscalco M, Goodwin RC. Injuries about the hip in the adolescent athlete. Sports Med Arthrosc 2011; 19:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/21\">",
"      Meyers AB, Laor T, Zbojniewicz AM, Anton CG. MRI of radiographically occult ischial apophyseal avulsions. Pediatr Radiol 2012; 42:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/22\">",
"      Cardinal E, Buckwalter KA, Capello WN, Duval N. US of the snapping iliopsoas tendon. Radiology 1996; 198:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/23\">",
"      Bedi A, Kelly BT. Femoroacetabular impingement. J Bone Joint Surg Am 2013; 95:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/24\">",
"      Laor T, Crawford AH. Idiopathic chondrolysis of the hip in children: early MRI findings. AJR Am J Roentgenol 2009; 192:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25097/abstract/25\">",
"      Ruggieri P, Angelini A, Montalti M, et al. Tumours and tumour-like lesions of the hip in the paediatric age: a review of the Rizzoli experience. Hip Int 2009; 19 Suppl 6:S35.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6292 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.22.229.50-C760863B48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_32_25097=[""].join("\n");
var outline_f24_32_25097=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H477156469\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF IMAGING STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IMAGING STUDIES FOR SPECIFIC CLINICAL SETTINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Developmental dysplasia of the hip",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H474001009\">",
"      - Proximal femoral focal deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Toddlers and children up to 10 years of age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Acute transient synovitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Developmental coxa vara",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Legg-Calv&eacute;-Perthes disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Neuromuscular hip dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Children older than 10 years and adolescents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Slipped capital femoral epiphysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H477156315\">",
"      - Injuries about the hip in adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pelvic apophyseal avulsions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H477156343\">",
"      Iliopsoas tendinosis and bursitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H477156351\">",
"      Snapping hip syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H477156359\">",
"      Athletic pubalgia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H477156367\">",
"      Stress fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H477156375\">",
"      Acetabular labral tear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H477156383\">",
"      Femoroacetabular impingement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H477156669\">",
"      - Idiopathic chondrolysis of the hip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26823812\">",
"      Children of any age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H477156583\">",
"      - Juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H477156426\">",
"      - Tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H477156469\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6292\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6292|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/48/26374\" title=\"diagnostic image 1\">",
"      Ultrasound hip dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/39/27251\" title=\"diagnostic image 2\">",
"      Plain film hip dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/53/22352\" title=\"diagnostic image 3\">",
"      Hip effusion plain film",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/31/10738\" title=\"diagnostic image 4\">",
"      Hip effusion MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/45/6879\" title=\"diagnostic image 5\">",
"      Osteomyelitis bone scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/43/10943\" title=\"diagnostic image 6\">",
"      Avascular necrosis hip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/51/35632\" title=\"diagnostic image 7\">",
"      Avascular necrosis hip MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/50/19235\" title=\"diagnostic image 8\">",
"      SCFE radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/46/40672\" title=\"diagnostic image 9\">",
"      Avulsion ischial tuberosity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/43/1712\" title=\"diagnostic image 10\">",
"      Avulsion anterior iliac spine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/15/37110\" title=\"diagnostic image 11\">",
"      Iliopsoas bursitis CT and MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/49/12049\" title=\"diagnostic image 12\">",
"      Idiopathic chondrolysis of the hip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6292|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/2/33828\" title=\"figure 1\">",
"      Coxa vara",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6292|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/53/861\" title=\"table 1\">",
"      Hip imaging indications in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/58/27564\" title=\"table 2A\">",
"      Infant hip imaging overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/11/23741\" title=\"table 2B\">",
"      Young child hip imaging overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/58/35757\" title=\"table 2C\">",
"      Overview hip imaging children older than 10 years",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42057?source=related_link\">",
"      Approach to the child with a limp",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=related_link\">",
"      Bacterial arthritis: Clinical features and diagnosis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35717?source=related_link\">",
"      Classification of juvenile arthritis (JRA/JIA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27113?source=related_link\">",
"      Clinical features and diagnosis of developmental dysplasia of the hip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=related_link\">",
"      Clinical features of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=related_link\">",
"      Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3193?source=related_link\">",
"      Diagnostic imaging of joint pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/12/199?source=related_link\">",
"      Epidemiology and pathogenesis of developmental dysplasia of the hip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=related_link\">",
"      Evaluation and diagnosis of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/14/39142?source=related_link\">",
"      Osteitis pubis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=related_link\">",
"      Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=related_link\">",
"      Overview of hip pain in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=related_link\">",
"      Overview of running injuries of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=related_link\">",
"      Pauciarticular onset juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=related_link\">",
"      Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25210?source=related_link\">",
"      Radiologic evaluation of the painful hip in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=related_link\">",
"      Slipped capital femoral epiphysis (SCFE)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20373?source=related_link\">",
"      Sports-related groin pain or 'sports hernia'",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21254?source=related_link\">",
"      Treatment and outcome of developmental dysplasia of the hip",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_32_25098="General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases";
var content_f24_32_25098=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/32/25098/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/32/25098/contributors\">",
"     Megan B Clowse, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/32/25098/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/32/25098/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/32/25098/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/32/25098/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/32/25098/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/32/25098/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alkylating agents are used in the treatment of a number of inflammatory conditions including systemic vasculitis, systemic lupus erythematosus (SLE), and other disorders.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    (CYC) has emerged as the alkylating agent of choice for most inflammatory disorders.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     Chlorambucil",
"    </a>",
"    is employed in patients who cannot tolerate CYC, particularly in those who develop bladder toxicity when treated with CYC.",
"   </p>",
"   <p>",
"    This topic will provide an overview of the mechanism of action and major toxicities of CYC and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , with a focus on the former. The uses of alkylating agents in individual diseases are discussed separately in the topics that address the treatment of individual disorders.",
"   </p>",
"   <p>",
"    The pharmacology of CYC is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link&amp;anchor=H2#H2\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\", section on 'Pharmacology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORICAL BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alkylating agents were first introduced as a treatment for autoimmune disease in the early 1950s, at approximately the same time as glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . The effectiveness of nitrogen mustard, the agent first such agent employed, was overshadowed by the enthusiasm in that era for glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/1\">",
"     1",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     Chlorambucil",
"    </a>",
"    and CYC emerged in the 1970s as popular therapies for vasculitis and SLE. Because of the greater potential for bone marrow toxicity associated with chlorambucil, CYC is usually preferred for patients whose inflammatory diseases require intensive, broad-based immunosuppression.",
"   </p>",
"   <p>",
"    There is general agreement that alkylating agents are among the most effective medications for treating autoimmune disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/2\">",
"     2",
"    </a>",
"    ]. However, recognition of a variety of toxicities, particularly concerns about the long-term risk of malignancy and gonadal toxicity, often lead clinicians to consider less toxic alternative medications whenever possible [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alkylating agents exert their biologic activity via covalent binding and crosslinking of a variety of macromolecules including deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and proteins. DNA crosslinking, probably the most important biologic action of these drugs, impairs DNA replication and transcription, ultimately leading either to cell death or to altered cellular function [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of inhibition of immune function is dependent upon the dose and duration of therapy. Alkylating agents are cytotoxic. Absolute lymphopenia is frequently seen following their administration, with reductions in the number of B cells and T cells of both CD4+ and CD8+ types [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The ratio of circulating T cells and B cells may also be affected [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These drugs also appear to impair T-cell proliferative responses and other measures of T-cell function, although the nature of the effect is less clear [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. The effect of CYC on T-cell lymphokine production is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An example of the general net decline in immune function is illustrated by the common reduction in anti-double-stranded DNA antibody production following the administration of intravenous pulse CYC in patients with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alkylating agents share a number of important side effects including bone marrow suppression, increased susceptibility to infection, gonadal toxicity, and increased risk of late malignancy.",
"   </p>",
"   <p>",
"    Much of our knowledge about the toxicity of alkylating agents derives from studies of patients treated for malignancies. Cancer chemotherapy protocols use pulsed doses up to five times higher than those used to treat rheumatic disease. Thus, acute hematologic and bladder toxicity may be more common in oncology patients. On the other hand, the duration of therapy (and possibly the cumulative dose) is often greater in patients with rheumatic disease, thereby predisposing patients to significant longer-term risks of malignancy and gonadal toxicity. In addition, autoimmune disease patients frequently are treated with other immunosuppressive agents (particularly glucocorticoids) that may put them at especially high risk of infectious complications.",
"   </p>",
"   <p>",
"    The risk of toxicity from alkylating agents is related to the cumulative dose of the medication. Thus, strategies that reduce the duration of exposure can minimize the long-term risks. One such strategy, intermittent &ldquo;pulse&rdquo; therapy, has been used in rheumatic diseases such as lupus nephritis and granulomatosis with polyangiitis (Wegener&rsquo;s), abbreviated as GPA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link&amp;anchor=H15#H15\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\", section on 'Cyclophosphamide'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H17#H17\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Monthly intravenous cyclophosphamide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cumulative dose with pulse CYC may be as low as one third that with daily oral therapy. Bladder toxicity appears to be substantially reduced with pulse therapy. A 2001 meta-analysis of vasculitis trials compared pulse versus daily oral CYC and concluded that leukopenia and infections were less frequent with pulse dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/12\">",
"     12",
"    </a>",
"    ]. Because the daily and intermittent administrations of CYC are not therapeutically equivalent in many settings, the decision about the route of administration and timing of doses, whenever possible, should be based upon data available for a specific disease.",
"   </p>",
"   <p>",
"    The cumulative dose can be minimized by a strategy of remission induction with CYC followed by a change to another less toxic medication for maintenance. Two illustrative example of such an approach are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of sequential therapy for lupus nephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/13\">",
"       13",
"      </a>",
"      ], patients began with pulse CYC for six months, followed by random assignment to one of three different regimens: continued CYC,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      . By switching from CYC to another drug, the risk for infection decreased from 77 percent to 29 to 32 percent. Prolonged amenorrhea decreased from 32 percent to 6 to 8 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of patients with GPA and microscopic polyangiitis (the CYCAZAREM trial), orally administered CYC (plus glucocorticoids) was given for three to six months for remission induction, and then patients were randomly assigned to discontinue CYC in favor of the less toxic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or to continue CYC [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/14\">",
"       14",
"      </a>",
"      ]. At 18 months, the numbers of disease flares in the two treatment groups did not differ, but those patients in the azathioprine group were spared months of CYC exposure, presumably incurring lower long-term risks of cancer, infertility, and other side effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For CYC, which requires biotransformation from an inactive prodrug to an active alkylating agent, both the clinical efficacy and toxicity depend, to some extent, upon individual variations in the cytochrome P450 enzyme system. As an example, in one study of 62 patients with lupus nephritis, those treated with CYC who were either homozygous or heterozygous for the cytochrome P450 variant 2C19*2 demonstrated a significantly lower risk of ovarian failure (from 80 to 35 percent). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Gonadal toxicity'",
"    </a>",
"    below.) However, these genotypes also correlated with an increased risk of progression to end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/15\">",
"     15",
"    </a>",
"    ]. Assessment of cytochrome P450 variants is not performed routinely in clinical practice. Consequently, further study is needed to determine whether a pharmacogenetic approach will affect management decision-making. These findings, however, emphasize the variability in susceptibility to the effects of alkylating agent therapy. They also underscore the importance of careful monitoring for adverse effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link&amp;anchor=H20#H20\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\", section on 'Use of daily oral cyclophosphamide'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link&amp;anchor=H29#H29\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\", section on 'Intermittent (pulse) cyclophosphamide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hematologic toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most serious short-term side effects of alkylating agents relates to the induction of cytopenias. Hematologic toxicity becomes more common with increasing doses of these medications and is also more likely to occur as the duration of use lengthens. For both CYC and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    administered orally, granulocytes are most likely to be affected first (sometimes within days to a few weeks of treatment), followed by the platelet count and hematocrit. The total white blood cell count, as well as either the absolute neutrophil or the lymphocyte lines, can be affected. The tendency of alkylating agents to cause lymphopenia is enhanced by the concomitant use of high doses of glucocorticoids.",
"   </p>",
"   <p>",
"    In general, granulocytopenia is not a goal of therapy with alkylating agents when used to treat inflammatory disease. Successful outcomes of oral therapies are not predicated upon the induction of granulocytopenia. Although lymphopenia is observed, suppression of the total white blood cell count is not an aim of treatment and should be avoided, with dose adjustments as the total white blood count begins to fall. Even in treating aggressive inflammatory disease, most experts aim to maintain total white blood cell counts greater than",
"    <span class=\"nowrap\">",
"     4000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    and certainly not lower than",
"    <span class=\"nowrap\">",
"     3500/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    In view of the demargination of neutrophils that occurs with high-dose glucocorticoids, this level of white blood cell count is associated with substantial immunosuppression even if the counts remain within normal limits.",
"   </p>",
"   <p>",
"    In order to detect impending and potentially dangerous bone marrow toxicity, patients treated with alkylating agents should have complete blood counts checked no less often than every two weeks for as long as they receive these medications. For patients with histories of hematologic toxicity, with previous immunosuppression, or of advanced age, even more frequent complete blood counts may be prudent until the impact of treatment on bone marrow function can be assessed.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     Chlorambucil",
"    </a>",
"    is even more notorious than CYC for inducing precipitous declines in bone marrow function and is also more likely to cause abrupt thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/16\">",
"     16",
"    </a>",
"    ]. The ultimate duration of alkylating agent therapy may be limited, in some cases, by progressive bone marrow depression or by mild dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Bone marrow suppression with intravenous CYC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving intravenous pulse CYC, usually administered on a monthly basis, develop leukopenic nadirs in a predictable fashion 7 to 14 days after administration. Bone marrow recovery is usually evident by 21 days. In a review of 109 SLE patients treated with intravenous (IV) CYC, five patients (5 percent) suffered severe leukopenic events (defined as white blood cell counts",
"    <span class=\"nowrap\">",
"     &lt;2/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/18\">",
"     18",
"    </a>",
"    ]. By comparison, there was no difference in the number of such events among 103 patients examined in the same study who were treated with oral CYC; seven (7 percent) of those patients suffered severe leukopenia.",
"   </p>",
"   <p>",
"    In the CYCLOPS study that compared oral with intravenous CYC for the treatment of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis, fewer episodes of neutropenia were observed in the intravenous CYC arm [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/19\">",
"     19",
"    </a>",
"    ]. However, this lower rate of neutropenic events was not associated with fewer infectious complications of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alkylating agents can predispose to infection by inducing bone marrow depression, resulting in neutropenia or lymphopenia, and by interfering with normal neutrophil and lymphocyte function even in the absence of count reductions. A variety of different infections can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/5,20-25\">",
"     5,20-25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial infection, including pneumonia, sinusitis, urinary tract infection, abscesses, and septicemia",
"     </li>",
"     <li>",
"      Opportunistic infection, including Pneumocystis, fungal infections, and nocardia",
"     </li>",
"     <li>",
"      Reactivation of dormant Varicella zoster (either shingles or disseminated infections), Mycobacterium tuberculosis, and human papilloma virus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients receiving CYC who are at particular risk for infection are those who become neutropenic (white blood cell count less than",
"    <span class=\"nowrap\">",
"     3000/microL)",
"    </span>",
"    and those who are treated concomitantly (as most are) with high doses of glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/5,25\">",
"     5,25",
"    </a>",
"    ]. One report, for example, evaluated 143 patients with SLE, of whom 100 received CYC and of whom 43 were treated with glucocorticoids alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/25\">",
"     25",
"    </a>",
"    ]. Infection occurred in 45 percent of the CYC-treated patients, as opposed to only 12 percent of those treated with glucocorticoids alone.",
"   </p>",
"   <p>",
"    Major bacterial or fungal infections can occur in the absence of neutropenia. This has been estimated to occur in 5 to 21 percent of patients treated with CYC for granulomatosis with polyangiitis (Wegener&rsquo;s) or lupus nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/5,18,21,22\">",
"     5,18,21,22",
"    </a>",
"    ]. Concomitant use of glucocorticoids is thought to be a major risk factor for infection in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some evidence suggests that reactivation of Varicella zoster is directly induced by CYC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/26\">",
"     26",
"    </a>",
"    ]. The incidence of zoster in different trials of vasculitis and lupus has ranged from 8 to 33 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/5,21,22\">",
"     5,21,22",
"    </a>",
"    ]. In one large trial of GPA, most zoster events did not occur during the periods of most intensive immunosuppression but rather occurred after patients had discontinued CYC and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , suggesting the possibility of an immune reconstitution syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a live-attenuated Varicella",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    may reduce the risk of zoster when given to older immunocompetent adults [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/28\">",
"     28",
"    </a>",
"    ], there is rarely an opportunity to immunize patients once a serious inflammatory disorder is diagnosed. The use of a live-attenuated vaccine in patients who are immunosuppressed is not recommended.",
"   </p>",
"   <p>",
"    In contrast, there is no doubt about the importance of prophylaxis against Pneumocystis (P. jirovecii). One rule of thumb is that Pneumocystis prophylaxis should be employed for any patient treated with the combination of high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and any other immunosuppressive agent. This clearly extends to the combination of alkylating agents and glucocorticoids. The risk of Pneumocystis pneumonia increases dramatically with lymphopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/29\">",
"     29",
"    </a>",
"    ]. Recommendations regarding prophylaxis against Pneumocystis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gonadal toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;All alkylating agents are toxic to both ovaries and testes. The incidence of gonadal dysfunction is dependent upon age, sex, and total dose [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13706?source=see_link\">",
"     \"Effects of cytotoxic agents on gonadal function in adult men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=see_link\">",
"     \"Ovarian failure due to anticancer drugs and radiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Female gonadal toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In females, alkylating agent therapy may lead to premature amenorrhea (premature ovarian failure), ovarian fibrosis, and permanent infertility. Women treated before the age of 25 are at lower risk of infertility than those treated after the age of 30 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/30,32,33\">",
"     30,32,33",
"    </a>",
"    ]. The cumulative total CYC dose is an independent risk factor for ovarian toxicity, regardless of how the medication is administered.",
"   </p>",
"   <p>",
"    The following data illustrate these points:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of women treated for lupus nephritis, ovarian failure occurred in 12 percent of women younger than 26 years, in 27 percent of those aged 26 to 30, and in 62 percent of those older than 30 [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/30\">",
"       30",
"      </a>",
"      ]. Sustained amenorrhea did not occur in any of the 16 patients treated with pulse glucocorticoids alone but did develop in 2 of 16 patients (13 percent) treated with seven monthly pulses of CYC and in 9 of 23 (39 percent) treated with 15 or more monthly pulses of CYC. Amenorrhea began within the first seven months in one-half of those affected and occurred more quickly in women older than 25.",
"     </li>",
"     <li>",
"      A report of 84 women who were menstruating prior to IV CYC administration for lupus or vasculitis also demonstrated the importance of age [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/34\">",
"       34",
"      </a>",
"      ]. Chronic amenorrhea did not develop in any of the 22 women younger than 26 years of age but occurred 14 of the 20 women (70 percent) older than age 35.",
"     </li>",
"     <li>",
"      A study of patients with SLE and diffuse proliferative glomerulonephritis compared one year of monthly pulse",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      with monthly pulse CYC (administered for six months and then quarterly) and combination therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/20\">",
"       20",
"      </a>",
"      ]. Amenorrhea occurred in more than 50 percent of women treated with CYC compared with 10 percent of those treated with methylprednisolone alone.",
"     </li>",
"     <li>",
"      In a study that compared the long-term outcomes of lupus nephritis patients treated with oral or IV CYC, transient amenorrhea and sustained amenorrhea were both more common in patients treated with oral CYC [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/18\">",
"       18",
"      </a>",
"      ]. Transient amenorrhea, defined as lasting longer than two months but ultimately associated with a return of normal menstrual periods, occurred in 33 of 89 patients (37 percent) in the oral CYC group compared with only 20 of 99 patients (20 percent) who received IV CYC. Permanent ovarian failure occurred in 25 (28 percent) and 13 (13 percent) of the orally and intravenously treated patients, respectively.",
"     </li>",
"     <li>",
"      A study of 42 women with granulomatosis with polyangiitis (Wegener&rsquo;s) in the Wegener&rsquo;s Granulomatosis",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      Trial (WGET) demonstrated that women with prior CYC exposure had a higher rate of menstrual cessation and lower levels of anti-mullerian hormone (AMH), compared with women without prior exposure to CYC [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/35\">",
"       35",
"      </a>",
"      ]. AMH is produced by early ovarian follicles and can serve as a marker for ovarian reserve or for the number of ovarian follicles that remain; a low AMH is indicative of diminished ovarian follicles and is a predictor of premature menopause and infertility. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=see_link&amp;anchor=H12#H12\">",
"       \"Evaluation of female infertility\", section on 'Anti-m&uuml;llerian hormone (AMH)'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      At study entry, women without prior CYC exposure had a higher mean AMH level compared with women exposed previously to CYC (2.5 versus 0.6",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      and had a statistically significant lower rate of having experienced premature cessation of menstruation (0 versus 33 percent). Of the 12 women who had an AMH level over 1",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      at study entry, the AMH in the eight who received CYC during the study significantly declined compared with the four women who did not receive CYC during the trial (mean change of -3.6 versus +0.7",
"      <span class=\"nowrap\">",
"       mg/mL).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pregnancy during and after alkylating agent use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are treated successfully with alkylating agents are often able to conceive and deliver healthy children [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/33,34,36\">",
"     33,34,36",
"    </a>",
"    ]. In a study of women who became pregnant during or after IV CYC treatment, nine women became pregnant after completing treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/34\">",
"     34",
"    </a>",
"    ]. The outcomes of 16 pregnancies in these women included 10 healthy babies, three spontaneous miscarriages, and three pregnancy terminations (two for anomalies and one for an SLE flare).",
"   </p>",
"   <p>",
"    Because women may remain fertile during therapy with alkylating agents, steps to avoid pregnancy during treatment are essential. In one review, six women became pregnant between IV pulses of CYC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/34\">",
"     34",
"    </a>",
"    ], despite receiving between 6 and 17 CYC pulses. Three of the pregnancies were terminated electively, and one ended with a spontaneous abortion. Two led to live births.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Male gonadal toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In comparison with the data on women, there are significantly fewer studies of men treated with alkylating agents upon which to base conclusions. There is, however, no reason to believe that the potential impact on fertility in males is any less dire than in females. In males, there are frequent reductions in sperm count and, in severe cases, testicular endocrine dysfunction that result from alkylating drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. A study of men with Beh&ccedil;et&rsquo;s disease showed significant infertility after CYC therapy; severe oligospermia or azoospermia occurred in 13 of 17 men treated with CYC but occurred in none of the 10 men treated without medicines or with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/39\">",
"     39",
"    </a>",
"    ]. Nevertheless, many men have fathered children after alkylating agent therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approximate minimum total dose of CYC at which gonadal toxicity may become a problem may be as little as 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in mature males [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/31\">",
"     31",
"    </a>",
"    ]. For a 70 kg man receiving 150 mg of CYC per day (ie, approximately 2",
"    <span class=\"nowrap\">",
"     mg/kg/day,",
"    </span>",
"    a standard dose for a patient with normal renal function), this threshold would be achieved in fewer than 50 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Prevention of gonadal toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The induction of gonadal quiescence during therapy with alkylating agents may minimize the risk of testicular and ovarian failure. The administration of a gonadotropin-releasing hormone agonist (GnRH-a) such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    has the potential to preserve ovarian function [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]. These agents initially enhance the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary. This transient stimulation is followed by a sustained decrease in the secretion of LH and FSH, leading to reversible amenorrhea.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In women &mdash; A meta-analysis of seven observational studies and two randomized trials, involving a total of 366 patients who were receiving chemotherapy for a rheumatologic disease or malignancy, found a 68 percent increase in the rate of ovarian preservation with GnRH-agonist therapy, compared with no treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/46\">",
"       46",
"      </a>",
"      ]. A significantly higher proportion of women who received GnRH-agonist treatment regained menses (93 versus 48 percent). There was a low rate of pregnancy overall, but more pregnancies occurred in women who received GnRH-agonist therapy (22 versus 14 percent). Thus, menses are often regained following GnRH-agonist therapy, although the data are inadequate to prove that fertility is maintained.",
"      <br/>",
"      <br/>",
"      The following examples illustrate the potential utility of gonadal quiescence in women receiving alkylating chemotherapeutic agents:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A retrospective, uncontrolled study of five women undergoing chemotherapy for Hodgkin lymphoma suggested that gonadal function may be preserved with concomitant birth control pills [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/47\">",
"       47",
"      </a>",
"      ]. All of the women maintained ovarian function after chemotherapy which included nitrogen mustard.",
"     </li>",
"     <li>",
"      In an uncontrolled trial, eight women with SLE or nephrotic syndrome under therapy with CYC or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      were treated with a GnRH-agonist. Their outcomes were compared with those of nine patients not referred for such treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/45\">",
"       45",
"      </a>",
"      ]. In that study, none of the women receiving GnRH-a experienced premature ovarian failure, in contrast to five cases of ovarian failure in the non-treatment group.",
"     </li>",
"     <li>",
"      A series of 62 women received GnRH-a in addition to a variety of gonadotoxic agents for lymphoma, leukemia, or SLE [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/48\">",
"       48",
"      </a>",
"      ]. Their outcomes were compared (in an unrandomized and unblinded fashion) with those of a control group of 55 women treated with similar chemotherapy regimens. Among the surviving patients in the GnRH-a treatment group (the precise number of survivors is not mentioned in the paper), all but one (a 40-year-old) resumed spontaneous ovulation and menses within six months. In contrast, 60 percent of women in the comparison group suffered permanent ovarian failure.",
"     </li>",
"     <li>",
"      In a study that compared 20 female patients with severe SLE with 20 historical controls matched for age and cumulative CYC dose, monthly depot",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"       leuprolide",
"      </a>",
"      (3.75 mg) appeared to protect against premature ovarian failure [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/43\">",
"       43",
"      </a>",
"      ]. Premature ovarian failure occurred in 1 of the 20 patients (5 percent) treated with leuprolide compared with 6 of the 20 controls (30 percent). Following their courses of CYC, more of the women who received leuprolide had successful pregnancies than those who did not receive leuprolide (35 versus 15 percent).",
"     </li>",
"     <li>",
"      A study of 25 women with diffuse proliferative glomerulonephritis from lupus received both IV monthly CYC and 3.75 mg intramuscular (IM)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"       leuprolide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/44\">",
"       44",
"      </a>",
"      ]. All of these women regained their menses after their treatment courses; three eventually became pregnant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In men &mdash; The available evidence suggests that GNRH-agonists are not effective in preserving testicular function in men undergoing therapy with alkylating agents [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/49-51\">",
"       49-51",
"      </a>",
"      ]. In men, therefore, greater attention has focused on the potential role of testosterone in preserving fertility for patients undergoing alkylating agent therapy. Supranormal levels of testosterone in men induce testicular quiescence and may be effective in preserving sperm production.",
"      <br/>",
"      <br/>",
"      A controlled trial of testosterone evaluated 15 men with nephrotic syndrome who were to be treated with CYC for six to eight months [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/52\">",
"       52",
"      </a>",
"      ]. The patients were randomly assigned to receive either daily oral or IV pulse CYC alone or IV pulse CYC plus testosterone (100 mg every 15 days). After six months of therapy, recovery of normal sperm counts occurred in only 1 of 10 of those treated with CYC alone, compared with all five of those receiving testosterone. Serum FSH levels normalized in the latter group but remained elevated in those who had not received testosterone.",
"      <br/>",
"      <br/>",
"      A second study by the same group included 10 men treated with testosterone (250",
"      <span class=\"nowrap\">",
"       mg/dose),",
"      </span>",
"      administered intramuscularly every 15 days, starting 30 days prior to and continuing during",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/53\">",
"       53",
"      </a>",
"      ]. Within 12 months following cessation of both therapies, nine men had a sperm count in the normal range, but the oldest man in the study (age 59) did not have significant recovery of his sperm count. Because of the small number of patients and the short duration of follow-up, the robustness of these observations remains unclear. Larger studies are needed.",
"     </li>",
"     <li>",
"      Gonadal cryopreservation &mdash; Other options for patients considering pregnancy following treatment with CYC are cryopreservation of sperm, oocytes, or embryos [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/54\">",
"       54",
"      </a>",
"      ]. If clinical circumstances permit, the collection of semen prior to treatment with alkylating agents is recommended in men for whom fathering children in the future is a possibility. In contrast to the collection of ova, sperm collection can be performed quickly and does not require a significant delay in therapy.",
"      <br/>",
"      <br/>",
"      The options for cryopreservation for women are more difficult. &ldquo;Emergency in vitro fertilization&rdquo; can be performed but requires significant hormonal manipulation, a three- to five-week delay in therapy, and immediate fertilization of retrieved eggs. For most patients with inflammatory illnesses who require an alkylating agent, a three- to five-week delay is not an option. Cryopreservation of oocytes is not widely available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=see_link\">",
"       \"Ovarian failure due to anticancer drugs and radiation\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Cryopreservation of ovarian tissue for future reimplantation is in the early stages of development. The removal of a single ovary prior to therapy can be performed laparoscopically and, in some centers, within a few days [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/55\">",
"       55",
"      </a>",
"      ]. Very few successful pregnancies have been achieved through this method [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Teratogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;All alkylating agents are teratogenic and are absolutely contraindicated in pregnant women except for life-threatening circumstances in the mother [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/57-60\">",
"     57-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of birth defects is greatest with exposure during the first trimester. Eleven case reports of women who received CYC for cancer or lupus therapy during the first trimester showed a pattern of anomalies labeled &ldquo;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    embryopathy&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. These infants had multiple abnormalities, including growth restriction, ear and facial abnormalities, absence of digits, and hypoplastic limbs. Of the six pregnancies that resulted in surviving children, at least three had severe developmental delay. One twin pregnancy with CYC exposure for acute lymphocytic leukemia resulted in two live infants who were small for dates and who required intubation after delivery. One of these infants recovered fully and developed normally. The other had significant congenital abnormalities, had developmental and cognitive problems, and developed both papillary thyroid cancer and neuroblastoma by the age of 14 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exposure to CYC during the second and third trimester may be associated with low birthweight and with neonatal pancytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .) In a study of women diagnosed with breast cancer during pregnancy, all 24 pregnancies with second- and third-trimester exposure to CYC resulted in live births [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/66\">",
"     66",
"    </a>",
"    ]. When CYC is required mid-pregnancy to treat a life-threatening lupus flare, however, the survival of the fetus is less likely [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/60,67\">",
"     60,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women of child-bearing potential should be counseled on the importance of using adequate birth control while receiving alkylating agent therapy. Pregnancy tests before and periodically during courses of therapy are appropriate. A pregnancy test should be obtained prior to each administration of pulse CYC to avoid inadvertent first trimester exposure.",
"   </p>",
"   <p>",
"    Men should also practice effective birth control to avoid conception during CYC treatment. Although there are no established human data, exposure of male rats to CYC is associated with increased rates of fetal loss and malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, successful pregnancies have been reported in both men and women previously treated with alkylating agents. Chromosomal abnormalities have been noted in patients after CYC exposure, but it is unclear if similar changes occur in eggs or sperm [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/69\">",
"     69",
"    </a>",
"    ]. One man with prior CYC therapy fathered an infant with tetralogy of Fallot and syndactyly of the toes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/70\">",
"     70",
"    </a>",
"    ]. Four pregnancies after CYC therapy for SLE resulted in four live births. One baby was delivered preterm, and another was small for gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/36\">",
"     36",
"    </a>",
"    ]. The risk of congenital anomalies in offspring to parents previously treated with these agents is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with rheumatoid arthritis (RA), systemic lupus erythematosus, and other autoimmune illnesses are at increased risk of developing lymphoma independent of treatment. However, the administration of alkylating agents enhances this risk and may also increase the risk of leukemia, skin cancer, and other malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/5,17,71-73\">",
"     5,17,71-73",
"    </a>",
"    ]. Mechanisms of alkylating agent-induced malignancy include direct chromosomal damage and decreased immune surveillance. The duration of therapy is an important risk factor, with the incidence being greatest in patients treated for more than two to three years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a trial of CYC with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (a soluble tumor necrosis factor [TNF]-alpha receptor-immunoglobulin fusion protein) in patients with GPA, an increased risk for solid malignancies was found in the combination therapy group [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/74\">",
"     74",
"    </a>",
"    ]. Of 89 patients receiving both CYC and etanercept, six developed a malignancy (9.7 percent) over two years of treatment and follow-up. None of the 91 patients receiving CYC alone developed a cancer. This suggests that these two therapies should be used together cautiously, because of the possible synergistic increase in malignancy risk.",
"   </p>",
"   <p>",
"    Patients with previous exposure to CYC are at increased risk for hematologic malignancies. Myelodysplastic syndrome may occur in up to 8 percent of patients with GPA after CYC and in 13 percent of such patients with a cumulative dose over 100 grams [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/75\">",
"     75",
"    </a>",
"    ]. Myeloproliferative disease, including acute leukemia, non-Hodgkin lymphoma, and multiple myeloma, occurred in 5 of 119 patients within the first decade after treatment with CYC, compared with one case of chronic lymphocytic leukemia in 119 RA patients without a history of use of CYC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=see_link\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies of patients treated with alkylating agents for Hodgkin lymphoma and ovarian cancer suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    is more likely than CYC to result in the development of leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/76\">",
"     76",
"    </a>",
"    ]. Estimates of the risk of acute leukemia in chlorambucil-treated rheumatoid arthritis patients range from less than 1 percent to as high as 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bladder toxicity with CYC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both cystitis and bladder cancer are associated with CYC therapy because of exposure of the bladder to the acrolein, a toxic metabolite of CYC. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    is not associated with bladder toxicity. The eventual occurrence of cystitis, which induces microscopic or gross hematuria that is accompanied commonly (but not always) by dysuria, was reported in up to one-half of patients treated in a United States National Institutes of Health (NIH) study that employed daily oral CYC in patients with GPA [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/77\">",
"     77",
"    </a>",
"    ]. Other studies, however, found a substantially lower rate, and the high incidence of cystitis in the NIH study is probably, at least in part, related to the long duration of CYC use. Although the likelihood of CYC-induced cystitis increases with duration of use, some cases develop within a few weeks of CYC initiation.",
"   </p>",
"   <p>",
"    Hemorrhagic cystitis has also been noted in patients with RA, SLE, and non-Hodgkin lymphoma (NHL) treated with oral CYC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/78\">",
"     78",
"    </a>",
"    ]. It was associated with an increased incidence of bladder cancer in the patients with NHL, GPA, and RA, but it is not clear if there is an association in patients with SLE, for which fewer patients have been studied. The risk of cancer was greater when a total dose of more than 100 grams of oral CYC had been given, and the occurrence of cancer may be delayed for more than a decade after CYC administration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemorrhagic cystitis is rare after IV CYC (in patients with lupus nephritis), and the risk of bladder cancer is not significantly increased (OR 1.2, 95% CI 0.7-2.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/78\">",
"     78",
"    </a>",
"    ]. The cumulative dose of CYC in these patients is usually less than 30 grams.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Prevention of bladder toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several approaches to the avoidance of CYC-induced bladder toxicity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limiting the duration of CYC use. For most diseases, shorter courses of CYC (lasting not longer than three to six months) have increasingly become the standard of care for remission induction. Depending upon the disease,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil may be an appropriate choice for maintenance remission.",
"     </li>",
"     <li>",
"      Avoidance of nighttime dosing to prevent overnight exposure of the bladder to acrolein. Assuming that patients do not suffer from excessive nausea, the full daily CYC dose should be taken in the morning.",
"     </li>",
"     <li>",
"      Forced diuresis, with a minimum of eight glasses (240 mL each) of water daily",
"     </li>",
"     <li>",
"      The use of intermittent pulses of CYC rather than daily doses. Monthly intravenous pulse CYC decreases the total CYC dose by up to two-thirds [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/21\">",
"       21",
"      </a>",
"      ]. With monthly CYC pulses, the bladder is exposed to the toxic drug metabolites only one day per month. Consequently, intermittent CYC use is associated with a decreased incidence of drug-induced cystitis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The concurrent administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"       mesna",
"      </a>",
"      (sodium 2-mercaptoethane sulfonate). Mesna inactivates acrolein in the urine, protecting the bladder from its toxic effects. Most [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/79-81\">",
"       79-81",
"      </a>",
"      ] but not all [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/82\">",
"       82",
"      </a>",
"      ] controlled trials of mesna in bone marrow transplant patients have shown that it decreases the incidence of drug-induced cystitis. However, the largest study [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/82\">",
"       82",
"      </a>",
"      ], of 450 bone marrow transplants, failed to demonstrate a protective effect. The American Society of Clinical Oncology does not recommend the use of mesna in patients receiving CYC except when high doses are used (eg, 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or 2",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/78\">",
"       78",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Mesna can be administered intravenously at the time of pulse CYC dosing; a suggested regimen is 300",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      at the time of CYC therapy and 150",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      four hours later. An oral tablet of mesna has become available in the United States. Oral mesna was used in a study of German patients with GPA, and its use was associated with a significant lowering of both drug-induced cystitis and bladder cancer in that study compared with an earlier NIH cohort [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/5,75,83\">",
"       5,75,83",
"      </a>",
"      ]. However, oral mesna has a disagreeable taste, is cumbersome to prepare, and must be taken several times a day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Role of BK virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;BK virus (human polyoma virus 1) has been recognized as playing an important role as a cofactor in many cases of drug-induced cystitis. This virus is present in its latent form in the majority of adults and can be reactivated, usually in the urogenital tract, during immunosuppression. This was illustrated in a study of 95 bone marrow transplant patients who received CYC; BK virus was present in the urine of 50 (53 percent) of patients during follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/84\">",
"     84",
"    </a>",
"    ]. Only three patients had BK virus in their urine prior to transplant. Viral excretion began 2 to 15 weeks after transplantation. Of those with BK virus in more than one urine sample, one-half developed hemorrhagic cystitis that was temporally related to the viruria and that was not influenced by prophylaxis either with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    or with forced diuresis. No hematuria was noted either in the patients who had no evidence of BK infection or reactivation or in the one patient who had a single episode of BK viruria.",
"   </p>",
"   <p>",
"    There is also evidence that BK virus may be associated with malignant transformation of bladder epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=see_link\">",
"     \"Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main approach to management of BK viruria is to decrease immunosuppression. While there are several case reports of the successful use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    to decrease the presence of the virus and to improve hemorrhagic cystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/86\">",
"     86",
"    </a>",
"    ], use of this agent (which has a significant risk of nephrotoxicity) for prophylaxis is not recommended. Additional studies of cidofovir for this indication are required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96055813\">",
"    <span class=\"h3\">",
"     Bladder cancer risk and surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder cancer (also due to contact with acrolein) is the most common tumor associated with daily CYC therapy. Long-term follow-up of 145 patients treated with prolonged oral CYC for GPA has been reported from the NIH [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/77\">",
"     77",
"    </a>",
"    ]. Approximately 65 percent of these patients received total doses of more than 50 grams. At a median follow-up of 8.5 years, there was a 4.8 percent incidence of bladder cancer; at 15 years, the incidence was estimated to be 16 percent. All of the patients who developed bladder cancer had had one or more episodes of microscopic or macroscopic nonglomerular hematuria, and all had been treated for at least 2.7 years. Surveillance for the BK virus was not available at the time of that study. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Role of BK virus'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Bladder cancer has developed as little as seven months after starting CYC therapy and as many as 15 or more years after discontinuing the medication [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/5,72,77\">",
"     5,72,77",
"    </a>",
"    ]. Bladder tumors induced by CYC can be particularly aggressive biologically. As an example, a study of 12 cases, found that all of the tumors were grade 3 or 4 transitional cell carcinomas at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the continued late risk, lifelong surveillance is indicated in patients treated with prolonged CYC (greater than six months of therapy). However, there is inadequate evidence to determine the optimal approach to screening for bladder toxicity after using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . Reliance upon hematuria detected at urinalysis alone is potentially inadequate due to deficiencies both in sensitivity and in specificity. Some patients clearly require further investigation with cystoscopy. However, the risks of repeated and frequent use of cystoscopy, including urosepsis, need to be balanced with the benefits of its use for screening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging of bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We use the following approach, based upon the available data and upon our clinical experience. An urinalysis should be obtained every six months to screen for hematuria and should be repeated within one week if hematuria is detected. Patients with confirmed nonglomerular hematuria should undergo cystoscopy to exclude bladder cancer. For patients with cystoscopic evidence of bladder damage, the procedure should be repeated every 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/77\">",
"     77",
"    </a>",
"    ]. Cytologic examination of the urine may miss low-grade lesions and is not useful. No studies have been performed to evaluate the utility of urine cytology screening at different intervals in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging of bladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hyponatremia due to SIADH",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-dose intravenous CYC can induce hyponatremia due to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Marked water retention and potentially fatal hyponatremia can occur, because patients receiving this regimen are treated with intravenous fluids to prevent drug-induced cystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/88\">",
"     88",
"    </a>",
"    ]. SIADH has been described primarily with doses in the range of 30 to 50",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    typical of those used to treat cancer. SIADH can also occur with the somewhat lower doses (10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    used to treat inflammatory disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\", section on 'Drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyponatremia can be minimized in this setting by using isotonic saline rather than free water to maintain a high urine output. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Therapies to raise the serum sodium'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Miscellaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other side effects can also be induced by alkylating agent therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nausea is common, especially with intravenous CYC [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/91\">",
"       91",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link&amp;anchor=H29#H29\">",
"       \"General principles of the use of cyclophosphamide in rheumatic and renal disease\", section on 'Intermittent (pulse) cyclophosphamide'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hair loss is common, although it is generally not as severe as that seen with cancer chemotherapy. The most common pattern is diffuse thinning. Patients can be told that, although they may note hair thinning that ranges from mild to substantial, all of their hair will not fall out (in contrast to patients treated with cancer chemotherapy doses of alkylating agents). This is particularly true if circumscribed courses (three to six months) of alkylating agents are used.",
"      <br/>",
"      <br/>",
"      Hair loss associated with alkylating agent use is generally reversible upon discontinuation of the drug. However, alopecia is also a potential side effect of immunosuppressive agents used following CYC or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Pulmonary fibrosis is an uncommon complication of alkylating agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41380?source=see_link\">",
"       \"Chlorambucil-induced pulmonary injury\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21990?source=see_link\">",
"       \"Cyclophosphamide pulmonary toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac toxicity is a major problem in oncology patients treated with higher dose regimens. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link&amp;anchor=H20#H20\">",
"       \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\", section on 'Cyclophosphamide'",
"      </a>",
"      .) For patients with inflammatory diseases treated with CYC, doses may need to be attenuated, and heart function may need to be followed closely if there is decreased myocardial contractility at baseline.",
"     </li>",
"     <li>",
"      Both hepatotoxicity and anaphylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/32/25098/abstract/92\">",
"       92",
"      </a>",
"      ] due to CYC are rare. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44074?source=see_link&amp;anchor=H13#H13\">",
"       \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Cyclophosphamide'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The alkylating agents",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (CYC) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      exert their biologic activity via covalent binding and crosslinking of a variety of macromolecules including DNA, RNA, and proteins. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of toxicity from alkylating agents is related to the cumulative dose of the medication. Therefore, strategies that reduce the duration of exposure can minimize the long-term risks. The standard of care for most inflammatory diseases is to induce remission with courses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      lasting not longer than six months and then to switch to a less toxic medication for remission maintenance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"       \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=see_link\">",
"       \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The principal toxicities of alkylating agents relate to their effects on bone marrow, reproductive organs, and bladder. Long-term concerns relate to the induction of malignancy of many different types. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific forms of alkylating agent toxicity include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hematologic toxicity (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Hematologic toxicity'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Infection (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Infection'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Infertility (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Female gonadal toxicity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Male gonadal toxicity'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Adverse effects on pregnancy (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Pregnancy during and after alkylating agent use'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Teratogenicity'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Malignancy induction (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Malignancy'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In women, the administration of a gonadotropin-releasing hormone agonist (GnRH-a) such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"       leuprolide",
"      </a>",
"      has the potential to preserve ovarian function. We suggest leuprolide 3.75 mg IM monthly (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In men, limited data suggest that testosterone may be useful in preserving testicular function. One approach with anecdotal success from a small case series used testosterone 100 mg IM every 15 days. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Prevention of gonadal toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Limiting the duration of CYC use and avoiding of nighttime dosing are both strategies for avoiding CYC-induced cystitis. In addition, for patients on daily CYC, we suggest inducing a forced diuresis with eight glasses (240 mL each) of water daily (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Prevention of bladder toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients treated with intermittent CYC, we suggest the concurrent administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"       mesna",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). One approach is to administer 300",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV at the time of CYC administration and 150",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV four hours later. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Prevention of bladder toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      BK virus (human polyoma virus 1) is an important cofactor in the development of drug-induced cystitis in many patients. We do NOT suggest use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"       cidofovir",
"      </a>",
"      prophylaxis against hemorrhagic cystitis from BK virus (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The optimal approach to the treatment of BK virus is to decrease the level of immunosuppression. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Role of BK virus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients treated with more than six months of CYC, we suggest screening for hematuria every 6 to 12 months with a urinalysis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients with new-onset nonglomerular hematuria should undergo cystoscopy. For patients with cystoscopic evidence of bladder damage, the procedure should be repeated every 6 to 12 months. (See",
"      <a class=\"local\" href=\"#H96055813\">",
"       'Bladder cancer risk and surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/1\">",
"      JIMENEZ DIAZ C. Treatment of dysreaction diseases with nitrogen mustards. Ann Rheum Dis 1951; 10:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/2\">",
"      Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994; 330:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/3\">",
"      Csuka M, Carrera GF, McCarty DJ. Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine. A follow-up study. JAMA 1986; 255:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/4\">",
"      Thorpe P. Rheumatoid arthritis treated with chlorambucil: a five-year follow-up. Med J Aust 1976; 2:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/5\">",
"      Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/6\">",
"      Hall AG, Tilby MJ. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev 1992; 6:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/7\">",
"      Clements PJ, Yu DT, Levy J, et al. Effects of cyclophosphamide on B- and T-lymphocytes in rheumatoid arthritis. Arthritis Rheum 1974; 17:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/8\">",
"      McCune WJ, Golbus J, Zeldes W, et al. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988; 318:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/9\">",
"      Cupps TR, Edgar LC, Fauci AS. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 1982; 128:2453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/10\">",
"      Varkila K, Hurme M. The effect of cyclophosphamide on cytotoxic T-lymphocyte responses: inhibition of helper T-cell induction in vitro. Immunology 1983; 48:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/11\">",
"      Fox DA, McCune WJ. Immunosuppressive drug therapy of systemic lupus erythematosus. Rheum Dis Clin North Am 1994; 20:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/12\">",
"      de Groot K, Adu D, Savage CO, EUVAS (European vasculitis study group). The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001; 16:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/13\">",
"      Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/14\">",
"      Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/15\">",
"      Takada K, Arefayene M, Desta Z, et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 2004; 50:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/16\">",
"      Cannon GW, Jackson CG, Samuelson CO Jr, et al. Chlorambucil therapy in rheumatoid arthritis: clinical experience in 28 patients and literature review. Semin Arthritis Rheum 1985; 15:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/17\">",
"      Lohrmann HP. The problem of permanent bone marrow damage after cytotoxic drug treatment. Oncology 1984; 41:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/18\">",
"      Mok CC, Ying KY, Ng WL, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006; 119:355.e25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/19\">",
"      de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/20\">",
"      Gourley MF, Austin HA 3rd, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/21\">",
"      Boumpas DT, Austin HA 3rd, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/22\">",
"      Austin HA 3rd, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/23\">",
"      Huynh-Do U, Gantenbein H, Binswanger U. Pneumocystis carinii pneumonia during immunosuppressive therapy for antineutrophil cytoplasmic autoantibody-positive vasculitis. Arch Intern Med 1995; 155:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/24\">",
"      Jarrousse B, Guillevin L, Bindi P, et al. Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis. Clin Exp Rheumatol 1993; 11:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/25\">",
"      Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 1996; 39:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/26\">",
"      Cupps TR, Silverman GJ, Fauci AS. Herpes zoster in patients with treated Wegener's granulomatosis. A possible role for cyclophosphamide. Am J Med 1980; 69:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/27\">",
"      Wung PK, Holbrook JT, Hoffman GS, et al. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med 2005; 118:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/28\">",
"      Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/29\">",
"      Sowden E, Carmichael AJ. Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC Infect Dis 2004; 4:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/30\">",
"      Boumpas DT, Austin HA 3rd, Vaughan EM, et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/31\">",
"      Rivkees SA, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 1988; 259:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/32\">",
"      Watson AR, Taylor J, Rance CP, Bain J. Gonadal function in women treated with cyclophosphamide for childhood nephrotic syndrome: a long-term follow-up study. Fertil Steril 1986; 46:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/33\">",
"      Wang CL, Wang F, Bosco JJ. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 1995; 4:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/34\">",
"      Huong DL, Amoura Z, Duhaut P, et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 2002; 29:2571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/35\">",
"      Clowse ME, Copland SC, Hsieh TC, et al. Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken) 2011; 63:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/36\">",
"      Ramsey-Goldman R, Mientus JM, Kutzer JE, et al. Pregnancy outcome in women with systemic lupus erythematosus treated with immunosuppressive drugs. J Rheumatol 1993; 20:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/37\">",
"      Watson AR, Rance CP, Bain J. Long term effects of cyclophosphamide on testicular function. Br Med J (Clin Res Ed) 1985; 291:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/38\">",
"      Guesry P, Lenoir G, Broyer M. Gonadal effects of chlorambucil given to prepubertal and pubertal boys for nephrotic syndrome. J Pediatr 1978; 92:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/39\">",
"      Fukutani K, Ishida H, Shinohara M, et al. Suppression of spermatogenesis in patients with Beh&ccedil;et's disease treated with cyclophosphamide and colchicine. Fertil Steril 1981; 36:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/40\">",
"      Bogdanovi R, Banievi M, Cvori A. Testicular function following cyclophosphamide treatment for childhood nephrotic syndrome: long-term follow-up study. Pediatr Nephrol 1990; 4:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/41\">",
"      Hoorweg-Nijman JJ, Delemarre-van de Waal HA, de Waal FC, Behrendt H. Cyclophosphamide-induced disturbance of gonadotropin secretion manifesting testicular damage. Acta Endocrinol (Copenh) 1992; 126:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/42\">",
"      Montz FJ, Wolff AJ, Gambone JC. Gonadal protection and fecundity rates in cyclophosphamide-treated rats. Cancer Res 1991; 51:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/43\">",
"      Somers EC, Marder W, Christman GM, et al. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005; 52:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/44\">",
"      Dooley MA, Patterson CC, Hogan SL, et al. Preservation of ovarian function using depot leuprolide acetate during cyclophosphamide therapy for severe lupus nephritis (abstract). Arthritis Rheum 2000; 43(Suppl):2858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/45\">",
"      Blumenfeld Z, Shapiro D, Shteinberg M, et al. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000; 9:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/46\">",
"      Clowse ME, Behera MA, Anders CK, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 2009; 18:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/47\">",
"      Chapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. Blood 1981; 58:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/48\">",
"      Blumenfeld Z. Ovarian rescue/protection from chemotherapeutic agents. J Soc Gynecol Investig 2001; 8:S60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/49\">",
"      Johnson DH, Linde R, Hainsworth JD, et al. Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations. Blood 1985; 65:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/50\">",
"      Waxman JH, Ahmed R, Smith D, et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 1987; 19:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/51\">",
"      Kreuser ED, Hetzel WD, Hautmann R, Pfeiffer EF. Reproductive toxicity with and without LHRHA administration during adjuvant chemotherapy in patients with germ cell tumors. Horm Metab Res 1990; 22:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/52\">",
"      Masala A, Faedda R, Alagna S, et al. Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med 1997; 126:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/53\">",
"      Cigni A, Faedda R, Atzeni MM, et al. Hormonal strategies for fertility preservation in patients receiving cyclophosphamide to treat glomerulonephritis: a nonrandomized trial and review of the literature. Am J Kidney Dis 2008; 52:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/54\">",
"      Slater CA, Liang MH, McCune JW, et al. Preserving ovarian function in patients receiving cyclophosphamide. Lupus 1999; 8:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/55\">",
"      Schmidt KL, Andersen CY, Loft A, et al. Follow-up of ovarian function post-chemotherapy following ovarian cryopreservation and transplantation. Hum Reprod 2005; 20:3539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/56\">",
"      Rosendahl M, Loft A, Byskov AG, et al. Biochemical pregnancy after fertilization of an oocyte aspirated from a heterotopic autotransplant of cryopreserved ovarian tissue: case report. Hum Reprod 2006; 21:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/57\">",
"      Kirshon B, Wasserstrum N, Willis R, et al. Teratogenic effects of first-trimester cyclophosphamide therapy. Obstet Gynecol 1988; 72:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/58\">",
"      Murray CL, Reichert JA, Anderson J, Twiggs LB. Multimodal cancer therapy for breast cancer in the first trimester of pregnancy. A case report. JAMA 1984; 252:2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/59\">",
"      Wiebe VJ, Sipila PE. Pharmacology of antineoplastic agents in pregnancy. Crit Rev Oncol Hematol 1994; 16:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/60\">",
"      Clowse ME, Magder L, Petri M. Cyclophosphamide for lupus during pregnancy. Lupus 2005; 14:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/61\">",
"      Enns GM, Roeder E, Chan RT, et al. Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype? Am J Med Genet 1999; 86:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/62\">",
"      Vaux KK, Kahole NC, Jones KL. Cyclophosphamide, methotrexate, and cytarabine embropathy: is apoptosis the common pathway? Birth Defects Res A Clin Mol Teratol 2003; 67:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/63\">",
"      Paladini D, Vassallo M, D'Armiento MR, et al. Prenatal detection of multiple fetal anomalies following inadvertent exposure to cyclophosphamide in the first trimester of pregnancy. Birth Defects Res A Clin Mol Teratol 2004; 70:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/64\">",
"      Paskulin GA, Gazzola Zen PR, de Camargo Pinto LL, et al. Combined chemotherapy and teratogenicity. Birth Defects Res A Clin Mol Teratol 2005; 73:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/65\">",
"      Zemlickis D, Lishner M, Erlich R, Koren G. Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide. Teratog Carcinog Mutagen 1993; 13:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/66\">",
"      Berry DL, Theriault RL, Holmes FA, et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 1999; 17:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/67\">",
"      Kart K&ouml;seoglu H, Y&uuml;cel AE, K&uuml;nefeci G, et al. Cyclophosphamide therapy in a serious case of lupus nephritis during pregnancy. Lupus 2001; 10:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/68\">",
"      Trasler JM, Hales BF, Robaire B. Paternal cyclophosphamide treatment of rats causes fetal loss and malformations without affecting male fertility. Nature 1985; 316:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/69\">",
"      Tolchin SF, Winkelstein A, Rodnan GP, et al. Chromosome abnormalities from cyclophosphamide therapy in rheumatoid arthritis and progressive systemic sclerosis (scleroderma). Arthritis Rheum 1974; 17:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/70\">",
"      Russell JA, Powles RL, Oliver RT. Conception and congenital abnormalities after chemotherapy of acute myelogenous leukaemia in two men. Br Med J 1976; 1:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/71\">",
"      Vasquez S, Kavanaugh AF, Schneider NR, et al. Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents. J Rheumatol 1992; 19:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/72\">",
"      Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995; 38:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/73\">",
"      Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 2008; 168:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/74\">",
"      Stone JH, Holbrook JT, Marriott MA, et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006; 54:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/75\">",
"      Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/76\">",
"      Kaldor JM, Day NE, Pettersson F, et al. Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990; 322:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/77\">",
"      Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/78\">",
"      Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum 2010; 62:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/79\">",
"      Hows JM, Mehta A, Ward L, et al. Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study. Br J Cancer 1984; 50:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/80\">",
"      Shepherd JD, Pringle LE, Barnett MJ, et al. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 1991; 9:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/81\">",
"      Luce JK, Simons JA. Efficacy of mesna in preventing further cyclophosphamide-induced hemorrhagic cystitis. Med Pediatr Oncol 1988; 16:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/82\">",
"      Tsuboi K, Kishi K, Ohmachi K, et al. Multivariate analysis of risk factors for hemorrhagic cystitis after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 32:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/83\">",
"      Hellmich B, Kausch I, Doehn C, et al. Urinary bladder cancer in Wegener's granulomatosis: is it more than cyclophosphamide? Ann Rheum Dis 2004; 63:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/84\">",
"      Bedi A, Miller CB, Hanson JL, et al. Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. J Clin Oncol 1995; 13:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/85\">",
"      Geetha D, Tong BC, Racusen L, et al. Bladder carcinoma in a transplant recipient: evidence to implicate the BK human polyomavirus as a causal transforming agent. Transplantation 2002; 73:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/86\">",
"      Kwak EJ, Vilchez RA, Randhawa P, et al. Pathogenesis and management of polyomavirus infection in transplant recipients. Clin Infect Dis 2002; 35:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/87\">",
"      Fernandes ET, Manivel JC, Reddy PK, Ercole CJ. Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases. J Urol 1996; 156:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/88\">",
"      Bressler RB, Huston DP. Water intoxication following moderate-dose intravenous cyclophosphamide. Arch Intern Med 1985; 145:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/89\">",
"      Salido M, Macarron P, Hern&aacute;ndez-Garc&iacute;a C, et al. Water intoxication induced by low-dose cyclophosphamide in two patients with systemic lupus erythematosus. Lupus 2003; 12:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/90\">",
"      Spital A, Ristow S. Cyclophosphamide induced water intoxication in a woman with Sj&ouml;gren's syndrome. J Rheumatol 1997; 24:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/91\">",
"      Singh G, Fries JF, Williams CA, et al. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991; 18:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/32/25098/abstract/92\">",
"      Garas G, Crawford GP, Cain M. Anaphylactic reaction to intravenous cyclophosphamide. Aust N Z J Med 1995; 25:59.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7987 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-42E0F5FCD1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_32_25098=[""].join("\n");
var outline_f24_32_25098=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORICAL BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hematologic toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Bone marrow suppression with intravenous CYC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gonadal toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Female gonadal toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pregnancy during and after alkylating agent use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Male gonadal toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Prevention of gonadal toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Teratogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bladder toxicity with CYC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Prevention of bladder toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Role of BK virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H96055813\">",
"      - Bladder cancer risk and surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hyponatremia due to SIADH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Miscellaneous",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41380?source=related_link\">",
"      Chlorambucil-induced pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=related_link\">",
"      Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21990?source=related_link\">",
"      Cyclophosphamide pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13706?source=related_link\">",
"      Effects of cytotoxic agents on gonadal function in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=related_link\">",
"      Evaluation of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=related_link\">",
"      Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=related_link\">",
"      Ovarian failure due to anticancer drugs and radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=related_link\">",
"      Therapy of diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=related_link\">",
"      Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_32_25099="Risk stratification of myeloma";
var content_f24_32_25099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk stratification of myeloma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        High risk",
"       </td>",
"       <td class=\"subtitle1\">",
"        Intermediate risk",
"       </td>",
"       <td class=\"subtitle1\">",
"        Standard risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         17p deletion",
"        </p>",
"        <p>",
"         t (14;16)",
"        </p>",
"        <p>",
"         t (14;20)",
"        </p>",
"        <p>",
"         High risk gene expression profiling signature",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         t (4;14)",
"        </p>",
"        <p>",
"         Deletion 13 or hypodiploidy by conventional karyotyping",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Trisomies (hyperdiploidy)",
"        </p>",
"        <p>",
"         t (11;14)",
"        </p>",
"        <p>",
"         t (6;14)",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Myeloma patients are risk-stratified at initial diagnosis based on fluorescence in situ hybridization (FISH) studies on the bone marrow for t(11;14), t(4;14), t(6;14), t(14;16), t(14;20), del17p13, and trisomies of odd numbered chromosomes. If FISH is unavailable, conventional cytogenetics can be used as an alternative, but is much less sensitive.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 26:479.",
"      </li>",
"      <li>",
"       Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012; 87:78.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_32_25099=[""].join("\n");
var outline_f24_32_25099=null;
var title_f24_32_25100="Pulm tox neoplastic agents";
var content_f24_32_25100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical syndromes of pulmonary toxicity caused by antineoplastic agents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Syndromes",
"      </td>",
"      <td class=\"subtitle1\">",
"       Description",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute bronchoconstriction",
"      </td>",
"      <td>",
"       Evidence of airflow limitation (eg, wheezing, prolonged expiratory phase, reduced FEV1)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Infusion reaction",
"      </td>",
"      <td>",
"       <p>",
"        Acute onset of symptoms/signs (eg, angioedema, flushing, itching, urticaria, arthralgias, bronchoconstriction, dyspnea, hypotension, hypoxemia, nausea, or back pain) during or shortly after infusion",
"       </p>",
"       <p>",
"        May be caused by mast cell/basophil activation or cytokine release in a systemic inflammatory reaction",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alveolar hemorrhage",
"      </td>",
"      <td>",
"       Dyspnea, sometimes hemoptysis, diffuse radiographic opacities, hypoxemia, BAL fluid with evidence of hemorrhage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Eosinophilic pneumonia",
"      </td>",
"      <td>",
"       Dyspnea, diffuse radiographic pulmonary opacities, hypoxemia, and BAL fluid eosinophilia (&gt;20 percent eosinophils), sometimes with peripheral eosinophilia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypersensitivity pneumonitis",
"      </td>",
"      <td>",
"       <p>",
"        Dyspnea and radiographic pulmonary opacities developing within hours to days of treatment due to a cell-mediated (Type IV) delayed hypersensitivity reaction",
"       </p>",
"       <p>",
"        May be associated with pulmonary eosinophilia",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Interstitial pneumonitis (includes nonspecific interstitial pneumonia, usual interstitial pneumonia, and organizing pneumonia)",
"      </td>",
"      <td>",
"       Dyspnea, cough, sometimes fever, diffuse or focal radiographic opacities (eg, septal thickening, ground glass opacities, consolidation) and nonspecific BAL findings",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Radiation recall lung injury",
"      </td>",
"      <td>",
"       <p>",
"        Appearance of radiographic opacities in areas of prior irradiation in response to treatment with a cytotoxic agent",
"       </p>",
"       <p>",
"        Often associated with cough and dyspnea",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Noncardiogenic pulmonary edema",
"      </td>",
"      <td>",
"       Pulmonary edema without evidence of heart failure or increase in left atrial pressure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Capillary leak syndrome",
"      </td>",
"      <td>",
"       Noncardiogenic pulmonary edema associated with diffuse peripheral edema and sometimes intravascular hypovolemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute lung injury/ARDS",
"      </td>",
"      <td>",
"       Noncardiogenic pulmonary edema PLUS evidence of acute inflammation (eg, fever, elevated neutrophils in BAL fluid)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FEV1: forced expiratory volume in one second; BAL: bronchoalveolar lavage; ARDS: acute respiratory distress syndrome.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_32_25100=[""].join("\n");
var outline_f24_32_25100=null;
var title_f24_32_25101="ADHD drugs comparison";
var content_f24_32_25101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of drugs used to treat attention deficit hyperactivity disorder in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Short-acting stimulants",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Extensive data efficacy and safety",
"        </p>",
"        Generic formulations available",
"       </td>",
"       <td>",
"        Must be taken 2 to 3 times per day if full-day coverage is desired",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Long-acting stimulants",
"        </strong>",
"       </td>",
"       <td>",
"        Can be dosed once per day (can avoid administration at school)",
"       </td>",
"       <td>",
"        <p>",
"         Side effects may extend later in the day",
"        </p>",
"        <p>",
"         Increased cost",
"        </p>",
"        Fewer generic options",
"       </td>",
"       <td>",
"        Short-acting stimulant can be added in PM for afternoon boost when needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Single-pulse sustained release (eg, Ritalin SR&reg;, Metadate ER&reg;, Methylin ER&reg;)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Must be swallowed whole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sustained release bead preparations (eg, Dexedrine&reg; Spansule&reg;, Ritalin LA&reg;, Focalin XR&reg;, Adderall XR&reg;, Metadate CD&reg;)",
"       </td>",
"       <td>",
"        <p>",
"         Approximates a twice-per-day dosing schedule",
"        </p>",
"        Can be sprinkled into soft foods for children who have difficulty swallowing pills",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         The beads should not be chewed",
"        </p>",
"        <p>",
"         Should not be taken with antacids or other drugs that decrease gastric acidity",
"        </p>",
"        Ingestion with a high-fat meal may delay time of onset and increase peak concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Osmotic release (eg, Concerta&reg;)",
"       </td>",
"       <td>",
"        Approximates a three-times-per-day dosing schedule",
"       </td>",
"       <td>",
"        Children with decreased GI absorption or intestinal resection may not receive the full benefit",
"       </td>",
"       <td>",
"        <p>",
"         Capsule should not be opened or chewed",
"        </p>",
"        Capsule is passed through the GI tract and into the stool intact",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patch (Daytrana&reg;)",
"       </td>",
"       <td>",
"        Can be used for patients who cannot take oral medications",
"       </td>",
"       <td>",
"        Patch must be applied 2 hours before needed effect",
"       </td>",
"       <td>",
"        Early removal of the patch permits controlled duration (effects last approximately 2 to 3 hours after patch is removed)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Prodrug (Lisdexamfetamine)",
"       </td>",
"       <td>",
"        <p>",
"         May have lower risk for abuse",
"        </p>",
"        Capsules can be opened and mixed with water for children who have difficulty swallowing capsules",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Atomoxetine",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Can be dosed once per day",
"        </p>",
"        <p>",
"         Lower potential for abuse than stimulants",
"        </p>",
"        Not a controlled substance",
"       </td>",
"       <td>",
"        <p>",
"         May be less efficacious than stimulants",
"        </p>",
"        <p>",
"         Potential increased risk of suicidal ideation",
"        </p>",
"        <p>",
"         More time to steady state (up to 2 weeks for initial response; up to 8 weeks for maximal effect)",
"        </p>",
"        \"Drug holidays\" are not an option",
"       </td>",
"       <td>",
"        <p>",
"         Taking with food may prevent nausea",
"        </p>",
"        Requires dosing adjustment if administered with agents that inhibit the cytochrome P450 2D6 (CYP2D6) enzyme",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Extended release alpha-2-adrenergic agonists",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Not a controlled substance",
"        </p>",
"        May also treat coexisting conditions (eg, sleep disorders, tic disorders)",
"       </td>",
"       <td>",
"        <p>",
"         May be less efficacious than stimulants",
"        </p>",
"        <p>",
"         More time to steady state (up to 2 weeks for initial response)",
"        </p>",
"        \"Drug holidays\" are not an option",
"       </td>",
"       <td>",
"        <p>",
"         Must be swallowed whole, not crushed or chewed",
"        </p>",
"        May lead to hypotension and orthostasis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GI: gastrointestinal.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Daughton JM, Kratochvil CJ. Review of ADHD pharmacotherapies: Advantages, disadvantages, and clinical pearls. J Am Acad Child Adolesc Psychiatry 2009; 48:240.",
"      </li>",
"      <li>",
"       Harpin VA. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006. Arch Dis Child Educ Pract Ed 2008; 93:58.",
"      </li>",
"      <li>",
"       Drugs for treatment of ADHD. Treat Guidel Med Lett 2006; 4:77.",
"      </li>",
"      <li>",
"       Wigal SB. Efficacy and safety limitations of attention deficit hyperactivity disorder pharmacotherapy in pediatric patients. J Pediatr 2009; 154:S13.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_32_25101=[""].join("\n");
var outline_f24_32_25101=null;
var title_f24_32_25102="Ankle mortise widening";
var content_f24_32_25102=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F74769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F74769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Wide mortise associated with tibiofibular syndesmosis tear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEATYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5auDmVvrUdST/AOsb61HQJbBRRRQMKKKKAAU8U0UooEPXrXT+HsBl45rmE610+gdVoRhW2Og3EyYODXTaJzbk561y44mxnqea6jRMCEjrj9OK0RwT2OF8Sn/iby+1UV61c8Rf8hmf61SQZqDpj8KLKV2XgGPMszHjoK42P867/wABR4gdiMZaqjuZVXodpMcRKCOBWc/X/DvV+4I2454FZrfK+4+mRVnMQTYB5GcdsVTuMAgHkValOXJ5PFQS4OQew79KQ0Zs2HOM8iqbY8raB1PSrc/DElT1xiqrqdoYAHrQWiRE+VnPXtxWppp2zKy9QwAJ/KsmM5bB4K8n8BWhpzZCljgb8/WgTJfiRH5uhzNgfdrwx6+gPGcQm0KQjnKd/pXgEgwSKie514V6MipDSmkNSdg2ig0UDCkopaACiiigBaWkpaAFpRTRThSESJRQlFBJDL98/WmU+T75plMtBRRRQMKKKKAFFKKQU4UCHL1rp9C4I9ua5lByK6bRjhRQjGtsbYOZM9eK6zQceQ5HY8+9chG3732rrfD5zbyd+cVaOCa0OE8Rf8hq59mqmgzxVvxH/wAhy67DdVZOxxxUnTH4UTxY4Nel+CYQmnxn15rzaBeQBXq/hWLy7CLPQCriYVjSuj8x2njp9KpPyT1arE7FjwRwTVcL+9AzwMj8KZgQOAHJPTbVOX07/WrsvzHGM8VSkIVm4z+PWgaKFwDnnoGz9KrMMqUB4NWZlDEktjjmogFG0juDjNIshH3nKnJx0zV2xfaSoGQoB/Gs8J8jvnOQcVdtSI2x/CACff8AzmgGjoNUTztBcEchcEn6V8/3ibLiVfRiP1r6EiHn6VKPrXguuR+Xqtyp/vmlM3wujaMw00080w1mdyENJSmkpjCiiigAoopaAClpBSikAtKKSnCgQ9aKFooJIZPvGmU5+pptMtBRRS0DEpaKKAAU4UgpwoEPT7wrpdK+WPPPSuaj+8K6ayO22oRhV2NGAkzkE+1dp4fH7h81xdlkzZP0rtPD/wDx7n8jVxOOocH4k/5D13/vf0qrFjFW/EnGvXfpu/pVSGpN18KNCwj8y5jUY5YV63pS+VZL64rzHw7CZb1Cex/WvU4R5dqP930q47HNVepEQdxzzzwfWo3A249M5IpwbKZ5JI7UowEZSOOePxpmZVlID56cf0qlMowCB8wq9NjeTjIIwDVGZSf6cdaBmbcJ95j1amc7xuxnbxVm6XpkYAqqwIYbcccnjikUiMkbtvPXkdKlRzhywJ/+uf8A61RRn5yWXJpUcsr4U46deaBnUaMd8Lp13LkV4z42g8nxDcjGM817BoJzKOCBgAZrzT4n2/la6HxwwP8AOiWxph3adjiWphqR6YayPQQ2m040hpjEopaKACiiigApaAMg+lAoAUU4U0U4UhEi0ULRQIrt1NJSt1pKZQUUUUDCiiigBRThTRThQIlhGZFroYB/o6/WuftxmUV0MfywKO9BjUNS0HIIycA12WgcK/oRxXH2IxIPWuw0DgMO+K0Rx1DiPFC7deufcg/pVKGtLxaP+J3KfUA81nQDt3qDZfCjrfCEAaYE9zXoMpKw8fSuP8GwbUV2HHvXYSjEec8k1otjlm7siQcDj6dqcRhSMDPPNNQD5gT/ABcVI2Qi7fm5ORigkqOMJnH0qlIMMv8AMVfn6bRnOBnFVJgcfKfwoAoXajnkcke1UWXaBxkkE/hV+6UYwTkDr7VSkXIGR8oXHNIpELnBcAfNjqBSLuG056HP1pQAfvZyTwB6U4ofKb6AGgZpaTPi4T+7jn865v4s22fs1wBgdK27Zwk+TngE4Bx+FM+I0AufDXmgcqAR+FD2HTdppnjT1GamcVEazPSQykpxpKChKKKKACiiloAKKKWgAFOFJSikIkSihaKBFdutJTjSUyxKKKKAClFFFACinCkFOFAie1H70V0KjcIx6VhWK5lH1rooI8sCfahHPUepo2fByPzrrtC+4xPXvXLW0e77p6enrXU6L8rbSB0rRHJM5Dxev/E4Yg9VFULGPzJkTGcmtbxio/tNcf3ai8PxbrgEjpU9TVS9w7zw9H5UIJHbpW2RvRQBzwazbD5ItvpyO9aoPGTkgYGPWtDle5EiAE8dPSnSZy/+yAfrUyqQByQQTz1oYYyQc5FAFKZCFAOMn0qrIFJHqD1q/djYQF9T1qoynnd05NIDPvIlJJbgAdaqSbthbBB2jntWhcg8+n16mqzrnhgcMBnB4NA0ZuAh3YGM49M80pP3t3Pzcds+lPuISV+XJAPp79ajC/u8dcdKRZI2FZZM4yCTjseK0dUh+2aDdwH5iFJH9azXAwy5weMVr6cwlEkZYc7lPtTE+54TKpVip6jioTWt4htjaaxdxEYw5I+h5rKYVkelF3VyM0lONJQWNopaKAEpaKKAClpKWgBRSikFOFIQ9aKFooEQHrSUp60lMsKKKKAClFJTqAACnjrTRT1oJZe04fvMntXQxDMsZ61g6auSTXR2aj5O5xTRz1DRtEO8Af3hmul03KsO3SsSwAaXoM57+1b9ohUA56Y/CrRyzZzXjCP/AEyMn3qTw1Hhg3HWp/GUeZIMeuKs+HIV8shh7ZpLcd/cOptslFyOvWtRVAwOCD6Vn6chLRlugOT7+lair90Ejrk1ZiyUD93x07CowvTP0NWNnzKqgjHJ49qXy+MdsdPegDPuEU7QPm5JNU5YwCRzn0H1rWkhyeSPw4qlcDac9unHekBl3MeVz1zjn0qvtO3A7ACtKVTIDgY471CyHy1x6ZyOlAzIuY2RWCYIwcEjrzTFjJjfoWB7+1XHTBwwzlTx75zUUcR8vqT1JI780DuULlG+Vzznn8hV3T2KXDMOgIJH1pjAHaWyevHtxSxD97Jx3xj0HagZw3xKtPJ1kTKMCVQa4tq9T+IVsbrSo5wMtHxmvLnFZyWp20JXiRGmmntTDSNxKKKKBhRRRQACloFFACinCmilFICRaKFooEQHrRQetFMoKSlooAKWkpwoEKBT1FNFSoOaBM1LBcQsxrpLBB5UbYGWFYFumIEX1PNdHBHsiULz0Apo5ahpacgEnPY10NtwFUHv6Vj6YpBU9vpW3a7mkxjIPP41ojmkZfia3MjRNjOCPxqbR0K7UGMDGceprS12IC2z3HeqelHMq9unPrSFfQ6PT1O4BunbP8617ePzHUhRgAVk2QO7AHPT175rorRNsJOOTVEEONm4sMZOBmhQWB7VYCk53dB196QRggkD+InigClMgUDHI7+tVZolIK5wT1wK05EO73HaqbIWzuBySTmgDMuYmcbsBcdqimQMi7M9MVflQM2GOAO571FIem1cHaSDmgDIbBZxzuBwMcCmovBAwSeD9atyoq5C9B/P6VEqhTnJyMk0hlCcDzUAOO/seQOaj25ZVcbWAzVi4+ZegJBz+n+NVc8lvmGAF5oGR3sYubG4tyv3icY6V47eRGGeRGGCpIxXsPmoMhuRnIPrmvO/Gdn5GomVVwkgzxUSOnDuzscw1NNSNTDUnYhppKWkoGKOtFJS0AFFFFAC04U2lFICRaKFooEQmig9aKZQUUUUAApwpAKcBQIcoqxAu5wKhUVf0+PdISegoJbsjVs490iDHANb1qmSpz8uec1mWifdB9e1blkvO0cc9Pwqkck2bNko2gKMf/qrZs4gsitj7wA6d6zdPi3S4xyeRxXQwJgqemKtHNIra2gaxywzt5wKoWEYG3AIBrXuohJA45z6VTtoVUruJIPFAja0yMsVzwvBrfQfu1GOMZxn2rN0tAIkAzWwwG4AAcAUxDCnBwuD0/CmlR0JIz1xVjAydyjoSKi2hi3Xr3oArsmD9wZGef5VBKqg5+6MVcdThgeAeM/Wq04BBx97GOPTpQBnzoQNrHPue4qCVV2rjHHpzVxiXDDacAjg/lVebLlQAcdMe1AyhPH2BwxGcduagAyykkHJ7dzV2cNu3DqDkdsVTl4k4IGO2O+DSAoygbyCf4c5rOuMbWKdySRjrkVqXKkk4BGOMisuVSxbOcZ4+mKBop3J/dFRmsbxFANR0vfjMsY3f0IrTuWYOwP15NZwl8syI2drdalmsdHdHnMi4Yg9RURFa2t23k3TMB8rVlNUHfF3VxhopTSUFBRRRQAUtJS0AApwptOFIB60ULRQIiNJSmkplBS0UUAKKcopAKeooEPUVs2Mfl24J6sazbSPzJlUDqa34VUuo/gFCMZvoXbVcRqx5PvW3YgLsGPm9RWPb5crkAAdhXQafGpdB0weatHLM39MAJQ469DW6UCg4yfT2rKtE28gY/HtW4V3RgjgHBBFUYMrBR5Tk89e9VbaMHGM5A9elX5BkHHc8D1qpbIwZgC2fSgR0ulxgwKc5GcHtWhtJxgY96qaMh8llI79/pWmq8d8imBCULA5YjHajZzkZPPQDirnlcjLD8qUQYOVfuBmgDOcDPIyue9V3jzvyPwrVeHn5ipz04qGSPBPy9fegDGaIru4OM1WmiCIvPTitiTDOzbBx0GPeoJudoEaleR0oGZLQ9x3NVpo04G3kH8q2JVRoztBB7AdqoXaMgOwneBkZoAy5FAyBx7ZrJmUMhbb0zzWvdHauMDIGOhGTWVcMuG3HkDaQOKQzKv4yCxH0yR7VgXwIw2M59v0rdvWGN33g2eh9KxLttzkrkj0IqWaxMDWYRNAcD5l6Vy7D17V2F2wzkjg1zGow+VOcfdPIqGddJ9CkaSnGkNBsJRRRQAUtJS0gAU4UgpRQA9aKFooERUUGimUFLRSigQoqRRTBUqDJFAjU0mLGX7ngVtQxFQDjrxVXTIc4QdABzWqU+Yc8AY/CnY5py1H2cZJAK5zXQ2KfMOBz3HSs20UJjkGt6wZDt4GW6GqRzzZtWUBcLtOenWtu1jIQhumCcnpVLTlyFx29q3HZEt2AHOOTVmJnTIAQvvx71DbRbtxXHXIxTpZfkYtxjoelLaP8wPTFIZ0OmxlEznOR2rTWIlRgGs2wvItu2YKeeoretTE6rtkA+ppiGKpBIIOMHrTlXJPBA4NXFhLMCCDxjrSCP5vmFMCnIgYgjPtVaSDIO0ZwOxrUZF+9zgUwqqnkHJ70gMGS2Iz1zzj3pi2p5XGBnGa3mRCScfnTfLUZ6rz60DOYmtpCoxkjIIwKzL+1kz8iZUjHXtXcfZVZh2JGKRtOVweAR+NAHmF1EAxHGD19RWRcJgZJ5zjNesXmhwygloxk965XUvD3khigJGc0mho83vlk2qNvQk5HqayrjcZcrguOMZxmuu1WwKE9AO4PX3rlr+MpgYIH06VLNYsxbyMDPcE8f4VjapF5luWH3k5+oro7pC0RLbdwPT0rKZQzFG5DDnipZvB2OWYU01PcRmKV0PVTioTUnUJRRRTGFFFFIQopRSClFAEi0ULRQBDRS0UxhThSUooEPUVatFzKD6c1WWr9iuSaCZPQ6TR48KzAH5etaUcWTgDPHIqHRIy0MoUcMQM+ladtCTNg4AJ5NWjik9Qt4XJG3OD0wPzrf023YJuIO0dcAUWFo4k+UAkHhutblvAkUZRgWOcnvTsYtl3TwQmCOnfpWi6743U9CM1FZRrjtu9K0oIQ8y8AjvmqJOcNu0067iVjx90dTWpBp8TLjDA+ual8ktcuR90EjFX7eIg8Aj/AAoAgj05wRsdSPQipfKuIsblbA5yK04EDAY4NXUj4oC5k217NGeGY89+1aMOqEcOanNurD50U/zqGSyiK9Sn0NAiYX0b8Z59DT2uoSp3Y596zpbL5TtkB9yKrS2lwgyjbgPegZrG8tF/iJ+hqKXVbVBkDn3zWA9pespO0g4wORVdtNvJDyyjPqaAN99dhBwHUEe1QTa/F0MwJ9AawJtFuShHmx88nr1rmtcsryxQyOpZMcMpyB9aVxo7dtfO7Acn05q9bX0V+mwjDHgDsa8WXVLu3k3O25e4NdFomuGRxsbHPQmhMbjY6rWtPjYnjD87SR1rz3W7FgWBU57nFenXMqXtmkhGcjH41yOsW29c8jnBxn86GCdjzW6j2sykc8jFZlwm3BHPPWuo1e2KMc5zxyO9YdxFuUjqc9ahm8WcpraAXQcfxCsw1sa4pV1zWQ1SdkNhhopaSgoKBRS0hhThTRThQIetFC0UARUUtFMBRSikFOFAD0Famnr0x9azUFbOmp8w4yaEZz2Ou0VGRCV4HPPvityztiG3MOTjOe9UNGhDx7d2M4NdBY/eAIyM4IrRHBJmlZQAAfIBg8gZrXgiTJwu1FPOefwqrYDKjdkeuDVkuhcqh+Ud8ZpmZo220JlcbTxitS1TEW4cZ/lWVbbQmASffNbNpkRqAO3fvTAiigxMcjAq8sGTgZ5pYYgTketaKQ/KMYz64piKqQ+mQB2qxEhABz7c1MExgYzn2qQR+goAjK9iPpTPK6nHFW1A65xmnKoxz6UAZzw5Xr9R603yeuRWiyZIAyc803YCOn1oAoeT0znimmIc8fjWiYx15Oe9N8sAdqQzLkgyQT34qpdafHNEyyJlGGCD3rb8sdgBzmmSR5U4xj1oA8E8R6d/Z+oz2+OFb5fpWLbTta3IfPGeR6133xHttutFgBh4lI/lXAXKjkioZrHVHpmiXpNiFY7lPQ+lF8gZGJbAPf3rE8MSh9PjAYEgAEE4P1rf8hnh5yCB171RBxWsxlnHHy44rnZYv3hGOnGK7jVbMsuByc8/41gXlkIkaRs4QE5pMuLPNvEjD7SqjsKxGrR1ibz76Vx0zgVnms2ehBWSGUUUUigoooFMApwpBS0gHrRSrRQIiooopjFFPWminrQBLGOa6DSUzg4rCiHNdLoShlHT0poxqbHa6DGQAw4wP8iuiig2yAKDjOeR61i6FGFTJ69667T4g6AsAMdj6VocEnqIuETaeo60225k5JOfX+VFwB52ADg9wKsWce4jjk9OeaCTTththGf5Vq2snmAKBxnBNc5Ncl7kQxZIHBIPeuo0q2KwJkDpmmBpW6ECtGJDgetRW0JIGelX0UDHPamIiWIfjUgj9fSpxHk+9O8vCmkBW2duuTT9g9MZqbyzzx9KcyfLwOKAKm0lifXgUm0ZqaQcZFIwxyetAEJXI+lNKgc9elSjnII70x/4ufwoGRFQXxxkHFT+SrRnjnriozwfYVZi/wBVz2zTA8j+JEYeWCUAchkP4Ef415rdrgnpur1rxxbmTT5SBloZcn6Hj/CvLr1ODgc1DNIFDTb+Wyu1KthCeRXbWmsOAqlyw9688uRtGe4Oa09Pv90aqTyOKEypRvqdPqGsGNMhAx9elcl4n1tv7Kl2hV3gKMGrl/Mrxdc5rh/ElyJHSFD8q5JpNlUoXZz0hyTmojUr1Eag7hppKU0lIYUtJRQAopRSU4UAPWilWigCGloopgKKkTrTFqRKALEI5re0OXypQCOOtYkI6Vo2pII9RTRlPVHqOgMswG3nuRiusidYIskqGxgDNeTabdXCBRHMy/Q10dnfSkAyncemc81dzhlCx13mEsS2OO2KdJc7VIjPzkYz6CsWO4eUDqO3Fbuj2PnSK0uSvXFMzNDw1pr3NyGcYiXqT3rvYIUUdOR2rN05BHFsjUDgdugrXhQ7c1Qi0n+yPoKsque3NRQxFmH9avxxDFIBijJGRTiuf/r1OIx1xTggxxQMrBT1oYce1WGWmsgx/nigCoVpjL8vvVpo8kmmlO569KAKDA5PfvUcgxnPpxVxojk49ahmTGPb3oAqs+D7AZzUsMh8r1FQuvBHtTY22KRnqOMdc0wMDXrdJXnifhLhMZ/z7149q1s8E0sUgIdCVI9xXtGuDEanA3KMfhXB+KdP+2Rm4gH+kKuHA/jA7/WpY4s8uvF5OazPOMLevetrUU2MfY1iTpkk1DOmJDe6jMyEIxBPU1gz5YknrWncLgc1myipZtBWKTiomqeQYNQNQbDDSUppKQwpaSloABThTacKAJEooSigCKig0CmA4VKnWohU0dAi3BWlbr0qhbjoa1LVeRTMpmxp64AroLFRkADNYliuSAa6LTY89O1UjlmbenRbpFX174rttKiEaqdvXHHpXL6QoWRcg11tjncuMkVaMGb9iu5+e1bVvFuIXFULCEpGjFcFulb1qgVQT1NMRLFFtwDwasqAMcVDHkg9KsoBmgaHD6fpTsA84oC1JigojZBTCg61Pjn0pCmc4oArGOmNHx15qztppHXigLFJwAMn8qqyrljnpmtGROaqzxfNk9OtBJmSKSzDFUmJUjHqc1pTAI3r7f1qjcdQAuBnsKAMzVv3lg7kfMpOBXEXM7ovzAq3r6V2d0xCOzkEHjmuG1f95JIVI5zikwRxvieKJy0sY2OxyV7H3rkJcqTiun1lvNuHGcgfKPwrm7oc1DN4GdcPuHzAVkXAG47TWtcDGRWVOOSag6IFCUVA1WZarPQbojNJSmkpDClpKWgYU4UgpRQIkSilSigCKiiimA4VNHUIqaPrQJl+2FbNkuSM1k2ozW9YR7itNGFRmrp6nOPWum0+MqRjrWNp8PzDNdLZoNqk4q0ck2aunAiVcDgV2mhRieVI+x5NcjYqTx+AxXbeFY/9Idh2T9apGbOntkDSHBGBxWmowRjoB0qrZRgLuI57VcjGWNMRPEOKnUcVGg46VOn86ChVFSLimjpSjk5oGOIoApc0tAxjKBTCOKmI4phGaAK0qnBxVWXIyOtXpBkGqs0Z4xziglmXKFBLf5xWZcSbh9DitaWPPXis6aHG/jqOKBHJ6zdFVKJ8qJnOep4rlLsn5cgH3rpdRi3SSLjg5PtXP6hDyqg8gDmkBwN6jb5MjvzWFcrgmuy1a2G5mAwD1+tcxdw43HFQzaLMG6WsmYVu3ScGse4XBNSzogzMmFVXq5OOtVHpG6ITSUrUlBQUtIKWkAopwpopRQBKlFEdFAEVFJS0wHCp4uoqBanh6igTNaxXJFdJpkeSoxWDpq8j0rqtNTpgVSOWozbsYPmBNb9nEcZI47Vn2CYwB6Vv2cR5PbHNWcjLVlHgA8V3XhSP9xJIB1YCuRtI8kAd69A8NQCOzjGOWO6qEzZiX5AP5VajXOCPSowMkY6ZqeMZ7UAiSMdKmFMUU8daBjhTl600U7igY4U6kHalHrQMX6UxhUg6U0jmmBA4zTCnHNWGA61GwxSEVJFHbrVKdcntWkwqtNHkdKBM4fVrMF2YA4yciuX1OAry3GBk/SvRb62yXzyDXKajZtvOQDgfjSEee3sRYEHG481yl5GAWx1zXoGoWMgc/Ketctfae5lc4wCfSky4uxxF0p3n3rIvI8ZP511Gp2jRNyOKwb1OMDvUM6IMwZxVGStG4HX1rPlHJqTpiV2pKVutJSNApRSUtMQtKKbThSAlSiiOigCKikpaYCirMH3hVZatW/3hQJnQ6WmSK7DSo8hcYxXLaQmSK7TS0+XjrVo4qrN2wi6ZBNb1nGQox1rLsU4zxW/aJwAOtWcxqaTbCS4UN90ctXf6YgEa8YA6cVzmiWXlgM4wW5+grrrWMKgpiJ40qwmKiWpRQUSKBT9tMWpBQAmMUoFPHNKAO1A7CAU7iilpjFFNNOpvagY01GakPWmNQIiaonHWp2qJ+RSAzrhMk5HSsG9hU5+XFdFcjCEcc1k3UYbPfFBJyWoRRqWPGfp0rmNTtlk5HHfJPSuz1SDcp2nIHWuVvxtRmPGSByP50hHC65bgqR0XHTOa4O9XazA9jivT9Stg52ADBHb3rzzWIfLupF64NQzamzl7lcbqzJhg1rXY5NZVx1NQdsCq3Wm05utJQaAKKKKBiinCminDrSESpRQlFMCKkpaKAFFWrb74qqKs233xQJnX6ImcV2ulrjbxXIaCuVXFdzpqfKprRHBV3OgsVyoz3re05A0yZHGRWNp4G3vXQ6cuJUOM81SMTtLBcyAZ4ABrcjPFZGlr+7J/AVqx8KM0xE4POamU4FQAipVNAyZTUqmoVqQHpQMeD1pwNMB4pwoGOFPpgpwpjF7UnalpKAGNTGFSNTD0oAjPrUT8/wCNSuetVpDSEVp+c1mXXBOBzWpICwyeBVK4TPTk0EmDcx87c8HnPvXNaqqsjZX5cmusvosAkcEnv2rltS3AHA7ZoA4m+Xa7dQcYrjfE1vkeeq4/vD3rvNTAZc45B5+lczqKCRXST7rZB9iahlRdmeYXow5rIuOtb2qxmOV0bqpxWDcdTWZ3wZUbrSUrdaSg1CiiigBRThTRThSAmjopI6KYEVFFFACr1qzbffFVh1q1a/fFAmdv4eGVUc13mnjha4fw2M7a72wXaFxz71qjz6m5uWYxjpjPNdDYL8wxn1rCsBkgdq6XTY8sAOM8fSmZHaaWN0EeeMjNaArP0z5Y1HtWkRhc0wHD+tTr0qJV5ziplXigaJFqRelMUVIBQMcKcKaAaeo46Uxi04dKAKKBhSGg+1JQA1ulRtmntTD3oERsPWoXx2qZ6jYUAVZM49Kpztj+Yq9KPlOKzZwTn270iTNvSDuNcvqiAqygE/Lgc1101uWU/wAqw9Ts2OePrQI4G/XaXyBn+lc7fJuOccd66zVYSjOCMY4wTXKapKLdHkYZGMkYqWUjzfxIQb2XHY1zFx1re1eQyTO56scnFYE/U1mzvp7FVutJTjTaRqJS0UUDFFOFNFOFAiaPvRRFRSEQ0tFFMYCrVp99aKKaE9jvvDX3RXeaccgDtiiitFscFTc6bTkAPGa6XSx8/wCY/SiiqMjp7ViCuK2oBlOaKKARIowRUqmiigpEqciniiimMeO1OTpRRQA8UhoooGJSDmiigBrUxvSiimBG3UiozzxRRSEVbn7pqo6jH1GaKKCWQScJmqM6htwPNFFIRx/iSJFZCFHOa8o8ayFGKJgKc5AoopMuO55vqJO81izdTRRWTO6BXNNNFFI0EpaKKBiinLRRQIniGc0UUUgP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anteroposterior radiograph of the ankle shows widening of the ankle mortise. Note the increased space between the medial malleolus and the adjacent talus. This appearance strongly suggests a tear of the distal tibiofibular syndesmosis, an injury that is referred to as a syndesmotic sprain or, in layman's terms, as a high ankle sprain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl B Fields, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_32_25102=[""].join("\n");
var outline_f24_32_25102=null;
var title_f24_32_25103="Mucous membrane lesions in SLE";
var content_f24_32_25103=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F63605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F63605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oral ulcers in lupus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 179px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erosive lesions of the mucous membrane in lupus, causing oral ulcers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Samuel Moschella, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_32_25103=[""].join("\n");
var outline_f24_32_25103=null;
